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CHAPTER I 
1.1. Epidemiology 
1.1.1. lllcidellce alld mortality 
Ovarian cancer contributes significantly to the consumption of health care resources in the Netherlands. As in the industrialized countries of the western 
world, ovarian cancer represents the fourth most frequent type of cancer among 
females, with approximately 1.500 new cases each year in the Netherlands. The risk 
of developing ovarian cancer in a woman's lifetime is estimated to be approximately I 
in 70. The incidence of ovarian cancer increases with age and peaks in the eighth 
decade. According to data of the Dutch Cancer Registration, collected between 1991 
and 1995, the rate increases with age, from 11.8 per 100.000 in the 40 to 44 age group 
to a peak rate of 59.6 per 100.000 in the 76 to 79 age group. 1.2 
Ovarian cancer is the leading cause of death from gynecological cancer in the 
western world. It has a high frequency of metastasis, yet generally remains 
localized within the peritoneal cavity. Although multimodality treatment regimens, 
including cytoreductive surgery and cisplatin containing combination chemotherapy 
have usefully prolonged survival, the overall cure rate of the disease has not changed 
dramatically. A significant factor contributing to the poor prognosis of ovarian cancer 
patients is that, because of the absence of early symptoms, approximately two-thirds 
of the patients will have disease that has already spread beyond the ovaries at the time 
of diagnosis. Extensive intra abdominal disease is difficult to eradicate completely by 
surgery, and many patients have only a paI1ial response to postoperative 
chemotherapy. The development of chemotherapy resistance is also an important 
factor contributing to the poor prognosis of ovarian cancer patients. The 5-year 
survival for patients with localized disease is approximately 80% whereas only 20% 
of the patients diagnosed with disease that has spread outside the pelvis are alive after 
5 years.3-5 Interval debulking surgelY has resulted in a slight improvement in survival 
rates for patients with advanced ovarian cancer6 but still survival rates are poor. To 
design new treatment modalities in order to improve survival rates for ovarian cancer 
it is important to understand more about the biology of ovarian cancer. 
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1.1.2. Risk/acio!'s 
The cause of ovarian cancer is unknown. Several reproductive factors are thought 
to influence the risk of developing ovarian cancer. Endocrine factors are thought to 
play an important role in the development of ovarian cancer.' Epidemiological studies 
have demonstrated that (multi)parity and oral contraceptive use are associated with a 
decreased risk of ovarian cancer.S-IO A histOlY of breastfeeding, late menarche and 
early menopause have also been hypothesized to decrease the risk, but these fmdings 
have been inconclusive. These observations have led to the incessant ovulation 
I I · 1112 E I I' . I' C lYpot leSIS.' ae 1 OVU at IOn causes a nUllor trauma to t le ovanan SUl'laCe 
epithelium by the formation of inclusion cysts. Aberrations in the repair mechanism 
might lead to unrestrained proliferation and neoplasia. The risk of ovarian cancer has 
also been related to gonadotropin stimulation. '.13 High levels of gonadotropins in 
women in the early postmenopause have been suggested to play a role in the 
development of ovarian neoplasms. In addition, risk of ovarian cancer may be 
increased by factors associated with excess androgenic stimulation of ovarian 
epithelial cells. 13 Interestingly, exposure to fertility dl1lgs and hormone replacement 
therapy have been suggested to be associated with an increased risk of ovarian cancer 
but the findings have been inconsistent. 14-21 Epidemiologic studies suggest 
environmental factors to play an important role in ovarian carcinogenesis but 
unambiguous associations with industrial exposure to carcinogens or to diagnostic and 
therapeutic radiation have not been established. There have been conflicting reports 
regarding the association of the use of talcum powder and the development of ovarian 
cancer.22-26 Exposure to talc particulates could lead to passage of these materials 
through the vaginal reproductive tract to the ovaries. One of the strongest risk factors 
found in epidemiologic studies is a positive family histOlY of breast cancer. 2' 
Compared to the sporadic form, familial ovarian cancer is unconunOIl, accounting for 
approximately 5-10% of ovarian cancers. Three distinct genotypes of hereditary 
ovarian cancer have been identified:28 hereditmy breast and ovarian cancer, hereditmy 
site-specific ovarian cancer (HOC), and the Lynch type II cancer family syndrome, 
which is characterized by the inheritance of non-polyposis colorectal cancer 
(HNPCC), endometrial, breast and ovarian cancer. 
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1.2. Pathology 
Cancer of the ovary is a collection of diverse pathologic entities that can be 
broadly characterized as epithelial, germ cell, or stromal in origin. This thesis focuses 
on tumors of epithelial differentiation. The common malignant epithelial tumors 
account for more than 90% of all ovarian cancers. Epithelial tumors are thought to 
arise from the surface epithelium, or serosa, of the ovary and its inclusion cysts?9,30 
During embryonic life, the coelomic cavity forms and is lined by mesothelial cells of 
mesodermal origin (coelomic epithelium). The pluripotential coelomic epithelium 
becomes specialized to form the serosal epithelium covering the gonadal ridge. By a 
process of invagination, the coelomic epithelium also gives rise to the mullerian ducts, 
from which the fallopian tubes, uterus and vagina arise. As the ovary develops, the 
surface epithelium extends into the ovarian stroma to form inclusion glands and 
cysts,)! In becoming malignant, the ovarian surface epithelium can exhibit a variety of 
mullerian-type diffcrentiations (in order of decreasing frequency): serous (resembling 
the fallopian tube), mucinous (resembling the endocervix), endometrioid (resembling 
endometrium), and clear cell (glycogen-rich cells resembling endometrial glands in 
pregnancy) tumors,) 
The nomenclature of ovarian tumors not only reflects cell type (histologic 
classification) but also the degree of biological malignancy, Ovarian epithelial 
neoplasms can be divided into three biological subtypes: benign tumors, tumors of 
low malignant potential (borderline) and malignant tumors:3 
Benign epithelial tumors most frequently develop in women between the ages of 
20 and 60. They are frequently large in size and are typically cystic, hence the term 
cystadenoma. Benign tumors almost always have a serous or mucinous histology. 
Furthermore, benign serous tumors are more commonly bilateral than the other 
epithelial benign tumors. 
The borderline tumor or ovarian tumor of low malignant potential (LMP) is a 
clinically distinct, form of epithelial tumor that is intermediate between benign 
adenomas and malignant carcinomas. These tumors retain an overall cellular and 
nuclear architecture similar to invasive carcinomas and have the ability to metastasize, 
but lack the invasive histologic properties of their fully malignant counterparts. 
Sometimes malignant tumors are misdiagnosed as borderline. The distinction between 
a borderline tumor and malignant tumor is difficult, especially when the decision must 
be made on the architectural basis of invasion. The distinction between a pushing 
II 
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border versus destructive infiltrative growth is often the only feature that differentiates 
a borderline tumor from one that is fully malignant. Patients with borderline tumors 
are usually older than patients with benign tumors and younger than women with 
malignant tumors. Patients have an excellent prognosis. Even if the borderline tumor 
has spread to the pelvis or abdomen, about 90% of patients are alive after S years. 
However, fatalities from the tumor present later and after 20 years 10-20% of the 
patients will have died as a result of the disease. 
Malignant tumors are characterized by infiltrative destl1lctive growth. They often 
present as solid masses with areas of necrosis. These tumors are uncommon in 
younger women under age 3S. Symptoms often present when the tumor has already 
spread beyond the OVaty and seeded the peritoneum. Since reported survival rates for 
these advanced stages are poor (S-year survival: 20%), ovarian cancer is sometimes is 
regarded as a "silent killer". Advanced stage serous adenocarcinomas are often 
bilateral and it is thought that the multiple tumors are monoclonal in origin.32.J4 
1.3. Genetic alterations 
It is widely accepted that the pathway leading to formation of a tumor is a 
multistep process involving the accumulation of genetic alterations. Several types of 
genetic alterations have been identified, including losses or gains of whole 
chromosomes, chromosomal translocations (fusions of different chromosomes or of 
nonnally non-contiguous segments of a single chromosome), gene mutation (base 
substitutions, deletions or insel1ions of a few nucleotides) and gene amplifications 
(multiple copies of an amplicon). Epigenetic alterations like methylation may also be 
involved in tumorigenesis. 
Genes involved in development and other normal physiologic cellular processes 
have been implicated in cancer. These include genes involved in signal transduction, 
celi cycle control, DNA repair, cell growth and differentiation (growth factors and 
their receptors), transcriptional regulation, senescence and apoptosis. Apart from 
these, genes involved in angiogenesis, immune regulation, cellular responses to stress, 
motility, adhesion and invasion are also involved.J5 
The genetic damage in cancer cells is often found in genes termed proto-oncogenes 
and tumor suppressor genes. A single mutation in a proto-oncogene may be sufficient 
to activate it to an oncogene. The oncogene product wili push cells toward the 
cancerous state by contributing to the abnormal growth of cells. In contrast, tumor 
12 
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suppressor genes are involved in the suppression of tumor growth. According to 
Knudson's two hit hypothesis, inactivation of a tumor suppressor gene involves two 
independent mutational events. The first hit usually involves a mutation in one of the 
alleles of the gene whereas the second hit may occur by a variety of mechanisms, of 
which deletion appears to be the most common. Thus, mutations in proto-oncogenes 
result in a gain of function that acts in a dominant fashion to the wild type allele 
whereas mutations in tumor suppressor genes result in a loss of function and so act in 
a recessive fashion to wild-type. 
The minimum number of defined genetic events required for tumor formation is 
not known. Recent iI/-vitro experiments have shown that tumor formation can be 
mimicked in the laboratory by interfering with at least four distinct pathways.J6 
Normal human epithelial and fibroblast cells were converted to tumorigenic cells by 
delivering the catalytic hTERT subunit of telomerase (which maintains telomere 
length), combined with SV40 large T-antigen (which inactivates both the TP53 and 
retinoblastoma "pathways") and an activated RAS oncogene (which induces 
transformation to a cancerous state, allowing cells to grow indefinitely in the absence 
of growth factors). However, iI/-vivo, cancer relies on the tumor's ability to evade the 
immune system, to attract its own blood vessels and to spread around the body. Tumor 
formation iI/-vivo likely requires more genetic alterations. 
1.4. Genetic alterations in ovarian cancer 
The past few years there has been an expansion of the knowledge concerning the 
molecular biology of cancer and many oncogenes and tumor suppressor genes have 
been discovered. Only few of these have been studied in some detail in ovarian 
cancer. Moreover, most studies have been small and inconclusive and often no 
mutations have been found in candidate genes. In the next paragraphs some of the 
most intensively studied or most promising oncogenes and tumor suppressor genes 
that may be involved in ovarian cancer will be discussed. 
1.4.1. Ol/cogel/es 
Several proto-oncogenes have been extensively studied and found to be altered in 
ovarian carcinomas (Table I). The role of HER-2/neu in ovarian cancer has received 
much attention. The HER-21I/eu gene, also known as c-ERBB2, codes for an epidermal 
13 
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growth factor (EGF) receptor-like protein. This gene was found to be amplified and 
overexpressed in breast cancer and to be associated with a poor prognosis.37,38 The 
role of HER-2/neu protein overexpression or gene amplification in ovarian cancer is, 
however, less clear. Some have reported overexpression or amplification of HER-
2!lle/{. However, the frequency of these observed changes varies widely (8_40%).39.42 
Consequently, overexpression or amplification of HER-2Ine/{ has correlated with a 
poor survival in some studies43.46 but not in others.4t ,47.5o Furthermore, 
overexpression of HER-2/neu has been associated with a poor response to platitl-
containing chemotherapy in ovarian cancer.45,46 Interestingly, an antibody to the 
HER-2/neu receptor was shown to mediate an increased sensitivity to cisplatin in 
dl1lg-resistant ovarian carcinoma cells containing multiple copies of HER-21Ile/{? In 
metastatic breast cancer, combination therapy with the anti-HER-2/neu antibody 
trastuzumab (Herceptin) and cisplatin has resulted in better response rates.52 
Another proto-oncogene that has been found overexpressed in 57-100% of ovarian 
cancers is cFMS, which encodes the receptor for CSF- I (macrophage colony-
stimulating factor I), a growth factor required for the growth and differentiation of 
monoeytes.53.55 Overexpression of cFMS has been found to be associated with 
advanced stage disease and high grade. 56 Furthermore, cFMS overexpression in 
metastases of ovarian cancer patients appears to be a strong independent poor 
prognostic factor for outcome.57 Ovarian cancer cells express not only c-FMS but also 
its ligand CSF_1.53 The presence of both receptor and ligand suggests the presence of 
an autocrine mechanism that may modulate cellular proliferation of ovarian cancer 
cells. Based on its emblyologic role in throphoblast implantation, CSF- I may be 
involved in invasion andlor metastasis.58 Interestingly, during macrophage activation, 
CSF-l promotes activity of urokinase-type plasminogen activator (uP A), which in 
several malignancies (e.g. lung, breast, colon, prostate) is significantly correlated with 
the ability to invade. 59 Expression of uPA and also expression of its inhibitor PAI-I 
have also been found increased in advanced stages of ovarian cancer and in ascites but 
I . "'fi" . . I 60·63 t lett' prognoshc Slglll lcance 111 ovarian cancer IS controversIa . 
The K-RAS gene encodes a signal transduction protein. Although overexpression 
and amplification of the K-RAS oncogenc has been described in several studies, it 
appears to be a rare evcnt in ovarian cancer.64 ,65 Nevertheless, some have reported a 
relationship between p21-RAS expression and shorter surviva1.66,67 Distinct K-RAS 
mutations have also been detected in ovarian carcinomas, although these show a wide 
variation, fluctuating from 4_30%.68.70 Interestingly, K-RAS mutations have been 
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Table 1: Putative oucogenes and tumor suppressor genes investigated in ovarian cancer 
Gene 
c-FMS 
cMYC 
K-RAS 
HER-2!neu 
AKT2 
FHIT 
APC 
CDKN2!MTSI 
PTEN 
WTI 
ATM 
p2 7"'PI 
TEL 
RBI 
TP53 
OVCAI&2 
NFl 
NM23 
BRCAI 
Chromosome 
location 
Function % altered Spectrum of mutations 
ONCOGENES 
5q33.3-q34 receptor-like tyrosine kinase 57-100% overexpression 
8q24 transcription factor 30% amplification, overexpression 
12p12 signal transduction 4-30% simple (codon 12,13 and codon 61) 
17q21-q22 receptor-like tyrosine kinase 8-40% amplification,overexpression 
19q 13.1-q 13.2 serine-threonine protein kinase 10-15% amplification., overexpression 
TUMOR SUPPRESSOR GENES 
3p14.2 Unlmown 4-8% altered transcripts 
5q21 binds 0.- and ~-catenin: involved in rare multiple mutations 
adhesion 
9p21 eyelin-dependent kinase inhibitor rare multiple mutations 
IOq23.3 phosphatase rare multiple mutations 
llp13 transcription factor none mutations 
llq22-q23 protein kinase none mutations 
12p13 cydin-dependent kinase inhibitor 30-50% loss of expression 
none mutations 
12p13 transcription factor none mutations 
13q14 cell cycle regulator rare multiple mutations and loss of 
expression 
17p13.1 cell cycle regulator; DNA repair and 50% multiple mutations and 
apoptosis overexpression 
17p13.3 lliiknOwn ? loss of expression 
17ql1.2 downregulates the active form ofRAS none mutation 
17q21.3 nucleoside diphosphate kinase rare mutation 
70% enhanced expression 
17q21 transcription factor rare multiple mutations 
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detected more frequently (up to 48%) in ovarian tumors of borderline malignancy.69.71 
Based on these findings it has been suggested that borderline tumors may represent a 
separate biological entity69 
AKT2, a gene encoding a serine-threonine protein kinase related to protein kinase 
C, has been found amplified and overexpressed in several ovarian carcinoma cell 
Iinesn and amplified in 10-15% of ovarian carcinomas.72,73 AKT2 is activated by a 
variety of growth factors via phosphatidylinositol 3-kinase (PI3-kinase) but its normal 
cellular role is not well understood. Recently, the PIK3CA gene, which encodes the 
p II 0 alpha catalytic subunit of PI3-kinase, has been found frequently increased in 
copy number in ovarian cancers, suggesting that PIK3CA may be implicated as an 
.. 74 
oncogene Il1 ovanan cancer. 
The nuclear transcription factor cMYC, which is involved in transition from the 
GO to the G I phase of the cell cycle, has been reported to be amplified and 
overexpressed in approximately 30% of ovarian tumor specimens39,75.77 but 
chromosomal rearrangements have not been observed?9,78 Since abnormality of 
cMYC is often associated with more aggressive tumors, cMYC may playa role in 
disease progression 76 Nevertheless, in ovarian cancer there seems to be no correlation 
between cMYC amplification and clinical outcome.77,79 
Other proto-oncogenes have been examined in small numbers of ovarian cancer 
biopsy specimens and cell lines including LMYC, NMYC, cMYB, cMOS, cSIS, NRAS, 
cABL, cFES, VEGF and INT2.8o However, no amplification, deletion, rearrangements, 
or point mutations have been observed in these genes. 
1.4,2. Till/lOr wppressor gel/es 
In general, tumor suppressor gene studies have received far more attention than 
oncogene studies in ovarian cancer. However, much of the work has focused on 
identifying possible locations where tumor suppressor genes may reside in the genome 
rather than the actual study of known tumor suppressor genes. The most popular 
approach to identify where tumor suppressor genes may reside in the cancer cell 
genome is by examination for loss of heterozygosity (LOH). LOH is determined using 
polymorphic markers, which are scattered at high density throughout the genome and 
it is often stated that a frequency of LOH of approximately 30% suggests that this 
region of the genome may comprise a tumor suppressor gene. Many allelic losses have 
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been identified in ovarian cancer, including losses on chromosomes 3, 5, 6, 7, 9, II, 
12,17, 18 and 22.80.86 
Several regions of LOR on chromosome 3p have been identified in ovarian 
cancer, including 3p 12-13, 3p21.1-22, 3p23-24.2 and 3p24-25 but the most interesting 
region has been 3pI4.2.87-90 Since loss at chromosome 3p14.2 occurs within the 
FRA3B aphidicolin-inducible fragile site, the FHIT (fragile histidine triad) gene 
spanning FRA3B has been suggested as a promising candidate tumor suppressor gene. 
The FHIT gene belongs to the histidine triad superfamily of nucleotide-binding 
proteins, members of which bind and cleave diadenosine polyphosphates but the 
function of FRIT remains unknown. Aberrant FHIT gene transcripts have been 
detected in esophageal, gastric, lung and head and neck cancer but abnormal 
transcripts and lack of normal FHIT in ovarian tumor cell lines or in ovarian tumors 
seems to be rare. 91 .94 
A high percentage (30-50%) of LOR on chromosome 5q has been 
rep0l1ed.86.95.96 The adenomatous polyposis coli (APC) gene, which is located at 
5q21-22, has been suggested as a good candidate tumor supprcssor gene. Germ-line 
mutations in the APC gene are responsible for familial adenomatosis polyposisl. 
Mutation analysis, however, showed that APC was not mutated in ovarian tUlllors.95 
Interestingly, another exploratory study showed an association between 5q LOH and 
TP53 mutation with 78% (l8/23) of tumors with LOH on 5q also harboring a TP53 
mutation.96 
Detailed deletion mapping of chromosome 6q sequences have implicated several 
broad regions in ovarian cancer involving 6q21-22.3, 6q23.2-q23.3, 6q25.I-q25.2, 
6q26 and the telomeric portion in band 6q27.97.101 The estrogen receptor is located at 
6q25.1 but no rearrangements in this receptor have been identified. 102 Furthermore, 
screening of the AF-6 (ALL-I fusion partner from chromosome 6) gene on 6q27, 
which has been identified as a gene involved in acute myeloid leukemia with 
t(6;11)(q27;q23) translocations lOJ and has been shown to be a target for RAS, 
revealed no mutations.97 
With respect to chromosome 7, several studies showed common deleted regions 
on chromosome 7q31.1 and 7q31.3 in 50-75% of ovarian tumors, suggesting the 
existence of a putative tumor suppressor gene in this region. 104·106 LOH at this region 
J Familial adenomatosis polyposis is characterized by the development of hundreds of colonic 
polyps in early life, which can lead to colorectal cancer in untreated patients. 
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has been observed more frequently in advanced stages of ovarian cancer. IOS As yet, 
the candidate gene remains unknown. The observation that a high frequency of LOH 
occurs within the FRA 7G region, an aphidicolin-inducible common fragile site at 
7q31.2, may help in the identification of the candidate locus. 107 
On chromosome 9 LOH at several loci has been reported, including 9p21, 9q31 
and 9q32_34.83.108-111 With respect to 9p21, the p16INK4a or cyclin-dependent kinase 
inhibitor 2 (CDKN2) gene has been suggested as a candidate gene. It plays an 
important role in regulation of the G I/S phase cell cycle checkpoint. Despite the 
identification of frequent homozygous deletions in ovarian cancer cell lines I 12, neither 
mutations nor abnormal expression have been found in ovarian tumor tissues (see also 
chapter 2), suggesting that p161NK4a does not play an important role in the 
pathogenesis of ovarian tumors. A surprising discovery of recent years has been the 
realization that the INK 4a locus contains an overlapping gene named p 14ARF• By 
interfering with the breakdown of TP53, the product of this gene can also induce cell 
cycle arrest following an oncogenic stimulus (see next sections). The role of pl4ARF 
inactivation in ovarian cancer has not been studied yet. 
LOH on chromosome 10 has mainly been reported in relation to the PTEN/MMAC 
(phosphatase and tens in homolog deleted on chromosome ten/mutated in multiple 
advanced cancers) gene locus on chromosome IOq23.3. 113•114 The PTEN gene 
encodes a protein tyrosine phosphatase with homology to tensin and the ill-vi1'o 
function of PTEN appears to be dephosphorylation of phosphotidylinositol 3,4,5-
triphosphate. Germ-line mutations in PTEN have been reported to be responsible for 
Cowden' disease. 115 PTEN mutations have been observed frequently in endometrial 
. 116 M . I I b d . Ii I' " carclI1omas. utatlons lave, lOwever, eell reporte 111 requent y 111 ovarian 
tumorsI14.117.118, but interestingly they have been observed more frequently in 
d . "d . 113119 . I PTEN I I' I en ometnol -type ovanan tumors . ,suggestlllg t lat may p ay a ro e III t Ie 
etiology of this subtype. 
Allele imbalance on chromosome 11 loci is a frequent event and three major 
regions of LOH have been identified: IlpI5.1_15.5120-122 including the HRAS locus 
and the Ilq12-q22 and Ilq23.3-q24.1 regions. 123-126 The Wilms' tumor suppressor 
2 Cowden disease is a rare autosomal dominant syndrome characterized by hamartomas in 
multiple sites, including the skin, thyroid, breast, oral mucosa and intestine. About one third of 
patients have macrocephaly. Patients are at increased risk to develop thyroid carcinoma, 
meningiomas and breast cancer. 
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gene (WT1), which is involved in the development ofWilms,3 tumor, maps to 111'13 
and encodes a transcription factor. 127 In ovarian cancer mutations in WTl have not 
been observed. 128.129 Furthermore, the progesterone receptor (PR) gene maps to IIq22 
and LOH at this locus has been shown to conciate with low PR expression. 130 Finally, 
the ATM gene, which causes ataxia telangiectasia4, maps to IIq23 but so far no 
somatic aIterations oflhe ATM gene were found in ovarian tumors. 126 
With respect to chromosome 12, two commonly deleted regions at 121'12.3-13.1 
and 12q23-ter have been identified. l31 The region of LOH at 12pI2.3-13.1 includes 
the genes that code for the ETS-family transcriptional factor, known as TEL, and the 
cyclin-dependent kinase inhibitor p27Kipl • Mutational analysis of both TEL and p27K1pl 
showed no abnormalities, suggesting that neither of these genes are the target for 
inactivation within this region. l31 Interestingly, loss of p27Kipi expression has been 
reported in 30-50% of ovarian tumors and a relation between p27KiPI staining and 
. d' I d 132 1JJ Improve SlUVlva was suggeste. ' 
The retinoblastomaS susceptibility (RB) tumor suppressor gene is located at 
chromosome 13q14 and LOH at this locus has been reported in 30-50% of ovarian 
cancer patienls. I34,13S However, LOH at the RB locus does not coincide with loss of 
RB expression 1J5,136 and, moreover, mutations of RB have not been observed, 
Loss of heterozygosity studies have indicated that chromosome 17 plays the most 
significant role in ovarian tumor development. On the short ann, LOH at 
171'13.1 86,137.139 as well as LOH at a more distal locus, 171'13.3139.141, has been 
observed in high percentages of tumors. The TP53 tumor suppressor gene maps to 
171'13.1. Mutation of TP53 is the most conunon genetic aIteration thus lar in ovarian 
cancer, mutations being present in approximately 50% of advanced stage ovarian 
carcinomas (see next section for function of TP53), With respect to chromosome 
171'13.3, two novel candidate tumor suppressor genes, OVCAl and OVCA2, with an 
.3 Wilms' tumor is a childhood kidney tumor associated with severe gonadal dysplasia and life-
threatening hypertension. 
4 Ataxia telangiectasia is a multisystem recessive disease characterized clinically by cerebellar 
ataxia, oculocutaneous telangiectasias, immunodeficiency, higher sensitivity to radiomimetic 
agents and an increased predisposition to cancer. 
S Retinoblastoma is a rare hereditaty disease, occurring in children, affecting retina cell 
precursors. Patients are also susceptible for tumors in mesenchymal tissues, often 
osteosarcomas or son tissue sarcomas 
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as yet unknown function have been identified within this region. 142 Recently, 
expression of OVCAI was shown to be reduced in ovarian tumor cell lines and in 
ovarian tumor tissues compared to normal ovarian tissues. 143 Moreover, 
overexpression of OVCAI in the ovarian cancer cell line A2780 was shown to 
suppress clonal outgrowth in a colony formation assay.143 Interestingly, 
hypennethylation at chromosome 17p13.3 has also been reported in approximately 
one third of ovarian tumors and it was suggested that hypermethylation precedes 
chromosome 17 loss.144 
On the long arm of chromosome 17, loss of 17q12-q21 has frequently been 
observed. 138,139,145,146 The breast and ovarian cancer susceptibility gene BRCAl, 
which localizes to this region (17q21), has been cloned in 1994147 and has since been 
the centcr of attention (see chapter 6A for a review), Germ-line mutations in BRCAl 
are responsible for approximately 50% of families that have a predisposition to breast 
cancer and up to 80% of those in which multiple cases of both breast and ovarian 
148 H ' lb' 0 • d' r cancer occur. owevel', mutatIOns lave proven to e Bllrequent In spora Ie lorms 
of ovarian cancer.149.152 In addition to the BRCA I locus, two other regions of common 
loss have been identified on chromosome 17, one at chromosome band 17q 11.2 (NFl 
locus) and the other at 17q23-24 (NM23 and prohibitin).139,153.155 The observed LOH 
at the NFl locus suggests that inactivation of the NFl gene, which codes for 
neurofibromin, may playa role in the pathogenesis of ovarian cancer. The NFl gene 
contains a GTPase-activating protein-related domain that accelerates hydrolysis of 
RAS-bound GTP to GDP, thereby conveliing RAS from its active to inactive form. 
Germ-line mutations in the NFl gene are responsible for neurofibromatosis I', 
which is highly associated with the development of neurofibromas. Somatic NFl 
mutations have also been observed in tumors other than neurofibroma l56 but in 
ovarian tumors no NFl mutations have been detected,157 Thc NM23-1 (non-
metastatic) or NMEl (non-metastatic cells expressed) gene has several functions 
including nucleoside diphosphate kinase activity, serine autophosphorylation and 
protein-histidine kinase activity, Mutation of the NM23-1 gene is a rare event70 but 
6 Neurofibromatosis I, also known as von Recklinghausen disease is characterized by increased 
incidence of benign peripheral nerve sheath tumors (neurofibromas), which can progress to 
malignancy, Patients develop a broad range of nonspecific cognitive impainnents, including 
low IQ, learning disabilities and behavorial difficulties. 
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enhanced expression of NM23-1 as well as the isoform NM23-2 has been detected in 
ovarian carcinomas, correlating with enhanced expression of HER-2. 158 An inverse 
relationship was observed between metastatic potential and expression of NM23-1 in 
ovarian cancer, expression being higher in lymph node-negative tumors than in lymph 
node-positive cases158.160 and an independent prognostic role was attributed to NM23-
I expression. 160 Interestingly, an increased sensitivity to cisplatin has been observed 
in NM23-transfected breast (MDA-MB-435) and ovarian carcinoma (OVCAR-3) cell 
lines 161 but expression of NM23 could not predict response to platinum-containing 
therapy.162 Finally, many studies have suggested that loss of the entire chromosome 
17 may be a relatively frequent event in ovarian tumors, thus deleting TP53, BRCAI 
d I . I . . I t 163·166 an ot leI' potentia tumor suppressor genes m a Slllg e even. 
Allelic loss at chromosome 18q23 has also been reported in ovarian tumors. 167,168 
The DCC (deleted in colorectal carcinoma) gene, which is involved in the 
development of colorectal cancer, has been proposed as a candidate gene but the 
region of loss does not always include this locus. 167 Moreover, SMAD4 (DPC4) also 
maps to 18q21 but mutations in this gene are rare. 168 
The neurofibromatosis type 2 (NF2) gene has been prqposed as a plausible 
candidate for rep0l1ed losses on chromosome 22q but detailed LOH studies have 
shown that the conunon loss region lies distal to NF2.169.170 
1.5. TP53 pathway 
Abnormalities of the TP53 (tumor protein 53) tumor suppressor gene are among 
the most frequent molecular events in human neoplasia. Such abnOlmalities probably 
facilitate carcinogenesis primarily through abrogating the tumor suppressor activities 
of the wild type TP53 protein, although at least some forms of tumor-associated 
mutant proteins may also contribute ove11 oncogenic activities. The current view of 
the normal function of TP53 is that it is a transcription factor, which after a certain 
stimulus can induce both cell cycle arrest and apoptosis. The biological effect ofTP53 
following DNA damage has been most intensively studied. The rapid induction of 
TP53 activity in response to genomic damage serves to ensure that cells canying such 
damage are effectively taken care off. In addition, TP53 may also contribute directly 
. 01' indirectly to particular DNA repair processes. The pivotal role of TP53 in 
maintaining genomic integrity has earned it the nickname "guardian of the 
genome,,171 and in 1994 it was chosen as "molecule of the year". Besides cell cycle 
21 
INTRODUCTION 
arrest, DNA repair and apoptosis the TP53 gene has also been implicated in 
senescence, cell differentiation and angiogenesis. It is however beyond the scope of 
this thesis to go into detail regarding those functions. The following sections will 
discuss the role TP53 plays in the regulation of the cellular stress response as well as 
the signals and mechanisms that regulate TP53 activity. Since TP53 is one of the most 
studied proteins in the whole of contemporary biology with more than 17.000 papers 
so far written, it is inevitable that this Introduction will not be fully comprehensive. 
Therefore, some useful www-links relating to TP53 are shown below. 
www-links relating to TP53: 
http://perso.curic . fr/Th ierry .Soussil 
Thierry Soussi's TP53 mutation database 
httQ:llmclnlab.ullc.cdu/dnam/mailmage.hlllll 
Neal Cariello's TP53 mutation database and software 
http://www.jure.fr/p53/homepage ,hIm 
Mutation database, introduction, links 
!.illp:l!n53. genome. ad. j p/ 
Mutation database and data analysis 
http://bioinlorlllutics.weizmanll.ac.il/hotllloiccbnsc/cntrics/p53.htm 
Variolls information, gene card for TP53 and other useful links 
http://www3.llcbi.nlm.nih.gov:SO/hlhin-post/Omim/dispmiIll? 191170 
OMIM TP53 site- links to other TP53 infomlation on the WEB 
htlp:llwww.pds.mcd.umich.cdu/users/frankilogo.htmI 
TP53 stl1lcture 
1.5.1. TP53 gelle strllctllre 
The 20 kb gene consists of II exons, the first of which is noncoding. The TP53 
gene encodes a 393 amino acid phosphoprotein with a molecular weight of 53 kD. 
The TP53 protein has several functional domains (Figure I). The highly charged 
acidic amino-terminal region is involved in transcriptional activation. m.m This 
domain allows the TP53 protein, in the context of its specific binding to a target DNA 
sequence, to recruit the basal t!'anscriptional machinelY and thereby activate the 
expression of target genes. In addition, this domain is also critically involved in 
regulating the stability and activity of TP53. The central part of the molecule confers 
sequence-specific DNA_binding.174.175 Interestingly, four of the five highly 
evolutionaty conserved domains map to this central region of the protein. 176 This 
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region is also the most conunon target for mutational inactivation ofTP53. The DNA-
binding domain is separated from the transcriptional activation domain by a region 
containing a series of repeated proline residues, which is typical for a polypeptide that 
can interact with signal transduction molecules that contain an SH3 binding 
domain,l77 Furthermore, the carboxy-terminal region contains an oligomerisation 
regionl78.18o for the formation of stable tetramers, the form in which TP53 is 
predominantly found. The adjacent region is enriched in basic amino acids and can 
bind to single-stranded DNA and RNA. This region may be involved in the 
recognition of damaged DNA and its subsequent repair.181.183 In addition, post-
translational modifications of this region may confer key regulatOlY properties. 
Finally, the carboxy-terminal region contains three nuclear localization signals, which 
are necessalY for directing the protein to the nucleus. 184 
Activatioll 
domain 
I II 
SHJ binding 
domain 
100 
Sequence spedne DNA 
binding domain 
II I I I I II 
II III IV v 
Figllre I: Strllctllre of the TP53 proteill. 
Tctrameriz:~lion 
domain 
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There are several jimctioJlal domains ill TP53, including Gil N-Ierminal acidic domain 
which is reqllired for trallscriplional aclivalioll (alllillo acids 20-42), all SH3 dOlllaill, a 
seqllellce-specific DNA billdillg domaill (alllillo acids 100-293), a leiralllerizalioll dOlllaill 
Ileal' the C-Ierminal elld (alii ilia acids 319-360) alld a highly charged basic regioll allhe 
carboxy lerlllillllS which illlel'(lcis direclly with sillgle slrallded DNA. Boxes illdicale Ihe 
evolutiOlUUJI conserved regiolls, 
1.5.2. Reglllatioll ofTP53 
Under normal conditions, TP53 is latent and does not interfere with normal 
cellular transactions. Moreover, the TP53 protein is very labile with a half-life of only 
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a few minutes. 185 However, in cells containing wild type TP53 genes, TP53 is 
markedly stabilized and its activity is induced by a variety of stimuli, including 
I I · 'd . I' 186 I'd d I . 187 d c lemot lerapeullc agents, OXI alIve stress, lypoxla ,nuc eoll e ep etron an 
oncogene expression (Figure 2). It is generally accepted that the rapid stabilization 
and activation of TP53 protein in response to stress occurs mainly through post-
translational mechanisms (reviewed by Prives and Hall)188 although changes in the 
rate of transcription or translation may also playa minor role. The post-translational 
activation of TP53 involves covalent modifications, particularly protein 
phosphorylation. In response to various types of stress TP53 becomes phosphorylated 
on multiple sites. A number of kinases have been implicated in this process ill-vi/I'o, 
including casein kinase I (serines 6 and 9), DNA-PK (serines 15 and 37), ATM and 
ATR (serine 15), CAK (serine 33), cdk2 and cdc2 (serine 315), protein kinase c 
(serine 378) and CKII (casein kinase II) (serine 392). Interestingly, phosphatases may 
playa role as well in the stabilization and activation ofTP53. lonogenic radiation, for 
example, appears to result in both de novo phosphOlylation of serine 15 and 
dephospholylation of serine 376. Phosphorylation of TP53 may affect its interaction 
with other proteins, including MDM2 (see below), as well as its ability to bind to 
DNA. Finally, TP53 may also be subjected to other types of modifications, including 
acetYlation and glycosylationl 89, which both may lead to increased DNA binding. The 
histone acetylases p300/CBP and PCAF have been shown to directly acetylate TP53 
at Iysines 382 and 320 respectively (in the regulatory region of its carboxy-terminal 
d .) lb' . I b' d' .. fTP53190191 omall1 I t lere y actlvatmg t Ie 111 mg actiVIty 0 .' 
In addition to the covalent modifications described above, protein-protein 
interactions also play a role in regulating TP53 (reviewed by layaraman and 
Prives).I92 A key player in the regulation of TP53 is the MDM2 (mouse double 
minute) protein (in humans also referred to as HDM2). TP53 binds to the MDM2 gene 
and activates its transcription. 193,194 On the other hand MDM2 protein binds to TP53 
within the TP53 transactivation domain and hereby blocks the transcriptional activity 
of TP53. 195,196 Thus an autoregulatOlY loop exists l94, which probably serves to keep 
TP53 under tight control and to terminate the signal once the triggering stress has 
been effectively dealt with (Figure 3). Furthermore, MDM2 promotes ubiquitination 
of TP53, probably by functioning as an E3 ubiquitin protein ligase, which covalently 
attaches ubiquitin groups to TP53. 197 The ubiquitinated TP53 is subsequently 
degraded by the proteasome. 198 Other mechanisms for TP53 ubiquitination and 
degradation also exist, e.g. JNK (c-lun N-terminal kinase). 199 The importance of the 
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TP53-MDM2 interaction is underscored by the finding that IIIdlll2 nullizygous mouse 
embryo's are not viable unless tp53 is likewise deleted.200.201 Since degradation of 
TP53 requires the binding of MDM2, phosphOlylation of residues positioned within 
the binding site for MDM2 may interfere with binding and lead to TP53 
stabilization?02 Otherwise MDM2 may become phosphOlylated in a manner that 
dismpts its interaction with TP5320J or alternatively MDM2 may retain DNA binding 
but become impaired with regard to its ubiquitination activity.204 
Cellular stress: 
DNA damage 
/genotoxicity 
Oncogene activation 
Hypoxia 
Heat shock 
Nitric oxide 
Ribonucleotide 
depletion 
Olher 
Figure 2: Sigllals tilat activate TP53. 
Adaptive 
responses: 
CD Growth arrest 
CD Apoptosis 
• Repair 
.Olher 
Activation results in increased levels of TP53 protein as well as ill increased activity. 
Adaptive respol/ses iI/elude but are I/ot restricted to growth arrest, apoptosis alld DNA 
repair. Respol/se lIIay be il/jluel/ced by cell al/d tissue-type. 
In addition to covalent modifications, the ability of MDM2 to promote TP53 
ubiquitination can also be modulated by binding of other regulatOlY proteins. The 
pl4ARF (alternative reading frame) protein (also know'l as pl9ARF in mice), for 
example, binds to MDM2 and to a lesser extent to TP53 and this binding prevents 
MDM2-mediated TP53 proteolysis, apparently by blocking the ubiquitination activity 
of MDM2. 205-209 The ARF protein arises through translation of an alternative reading 
frame derived from the p16INK4a tumor suppressor gene. The manner by which a single 
genetic locus encodes two proteins is unprecedented in mammals. p 16'NK4, is encoded 
by three closely linked exons (I a, 2 and 3). An alternative first exon (I P), which maps 
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upstream in the human genome, is spliced to exon 2, yielding a p-transcript that is 
almost identical in size to the a-transcript that encodes pI6INK4,. Since the initiator 
codon in exon Ip is not in frame with sequences encoding p161NK4' in exon2, the p-
transcript encodes the novel polypeptide pI4ARF. Overexpression of both proteins 
induces cell cycle arrest through distinct mechanisms: p 161NK4, directly inhibits the D-
type cyclin-dependent kinases CDK4 and CDK6 whereas p 14ARF induces the 
stabilization of TP53. Signals known to induce signaling via the ARF-TP53 pathway 
include MYC210,2II, EIA212,2\3, RAS214,215 and p-catenin?lG The pI4ARF_TP53 
pathway thus serves as a cellular defense mechanism against abnormal growth 
promoting signals. 
Biochemical modifications: 
ATMIATR, DNA-PK 
l §§ 
§§ 
Increase in the 
amount and I 
activity ofTP53 '" 
Transcriptional 
activation of target 
genes 
Figlll'e 3: Tlte TP53-MDM2 alllol'egnialol'), loop. 
Target TP53 for 
degradation 
77,e TP53 pl'otein binds 10 tire MDM2 gene and activates its tl'anscription. TIre I'esultant 
MDM2 protein binds 10 TP53 and blocks lire activity ofTP53. In addilion, MDM2 tal'gets 
TP53 fol' ubiqllitin-lIIedialed degradation. 
26 
CHAPTER I 
INK4a locus 
pl61NK4n / ~ pl4ARF 
cyclinfcdk4 1 active cyclin-cdk4 / 1 ----I~~ complex Induction of 
1 
~TP53 degradation 
Other mitogenic ~ ::~~,alS: 7e, RAS, 153~ MDM2 
~ Rb-P + E2F Stress I 
+ 
Growth arr.est 
signals &apoptosls 
RbJE2F 
[ proliferation I 
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The JNK4a 10cI/s ell codes pI6INK4", which call illd/lce cell cycle arresl, alld pI4ARF, which 
call prevell! TP53 ji-Olll breakdowli. 
1.5.3, TP53 jill/clioll 
Following a stress signal TP53 becomes activated and can induce either a cell 
cycle all'est or apoptotic cell death (reviewed by Amundson et al).217 These activities 
are for the greater part due to the ability of TP53 to form homotetramers that bind to 
specific DNA sequences and activate transcription. 174 The importance of TP53 
binding is underscored by the fact that many of the TP53 residues that directly contact 
DNA are mutational hotspots in human cancer.218 
Growth arrest 
With respect to growth arrest, many TP53 target genes have been identified. Two 
well-known cell cycle control genes include p21, also known as WAFI (wild type 
TP53 activated fragment 1)219, CJPI (cdk-interacting protein 1)220 or SDII (senescent 
cell-derived inhibitor I) and 14-3-3<1.221 The induction of p21 is responsible for GI 
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arrest whereas the induction of 14-3-3", mediates G2 arrest. These checkpoints 
prevent cells with damaged genomes from undergoing DNA replication or mitosis. 
p21 mediates G I arrest by inhibiting the activity of cyclin-dependent kinases (CDKs), 
which phosphOlylate the retinoblastoma (RB) gene product.22o In its 
hypophosphOlylated form, RB sequesters the E2F transcription factor, thereby 
preventing transition from G I to S phase (Figure 5). The RB-E2F complex actively 
represses the expression of E2F target genes required for the transition from the G I to 
S-phase. In addition, RB recruits histone deacetylase (HDACI), which blocks 
transcription by promoting nucleosome compaction.222 p21 also promotes cell cycle 
arrest by preventing PCNA (proliferating cell nuclear antigen) from activating DNA 
polymerase 0, which is essential for DNA replication. In addition, TP53 
transcriptionally activates GADD45 (growth arrest and DNA damage inducible), 
which codes for a protein that binds to PCNA.22J GADD45 has also been implicated 
in DNA repair. 
--8----p21-PCNA ~ /' 1. ~ ~ I t 14-3-3", t t p21 I 
replication I CAK GADD45 t .J... 
arrest .J... / ~ cdc25C-P-+ ct25C 
cyclinD/cdk4/6 
cychnA,E/cdk2 I DNA repair I cyclinB/cdc2-P-+cyclinB/cdc2 
Rb/E2F -1 Rb-P + E2F ~ ~ t t I G2 arrest I M phase 
I G I arrest I S-phase 
apoptosis 
Figllre 5: [lIdllClioll o/growlh arresl by TP53 (ada pled ill revised/arm/rom Siollov alld 
HaIlPI).224 
Activatioll o/TP53 il/dl/ces p2I. which plays a celllral role ill Ihe il/dl/cliol/ o/GI arresl, 
alld 14-3-3u, which prall/ales G2 arresl, 
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TP53 can also trigger growth arrest in a p21-independent way. TP53 can bind to 
cyclin Hand p36Matl, thereby inhibiting the protein kinase complex that activates the 
CDK2/cyclin A complex required for G liS transition.225 In addition to G I arrest, 
TP53 can also induce an efficient G2 arrest. The product of the J 4-3-3<5 gene 
sequesters the phosphorylated form of cdc25C, a phosphatase of the cyclinB/cdc2 
complex that is essential for the G2/M transitionn6•227 TP53 can also inhibit the 
cyclinB/cdc2 complex through the induction of GADD45, which disrupts this 
complex, probably via a direct interaction with cdc2. 
Apoptosis 
TP53 mediates multiple apoptotic pathways and both sequence specific 
transactivation dependent and independent pathways have been identified (Figure 6). 
With respect to sequence specific transactivation, an increasing number of 
TP53-reponsive genes are being associated with apoptotic pathways. By inducing 
proteins acting at the receptor signaling level, TP53 may sensitize cells to apoptosis. 
The insulin-like growth factor-I binding protein 3 (IGF-BP3) induces apoptosis by 
blocking the survival signaling by IGF-I.228 In addition, TP53 also represses the 
IGF-I receptor229 and hereby assures an efficient block of this suvival pathway. The 
death reccptor Fas/Apo-I/CD95, which is upregulated by TPS3, is another mediator 
acting at the level of receptor signaling for apoptosis. Fas/Apo-1 is a membrane 
receptor protein from the tumor necrosis factor receptor (TNFR) family. Binding of 
the Fas ligand to Fas/ Apo-I activates a cascade of signaling events resulting in 
activation of the ICE-like proteases (caspases) culminating in apoptosis. In addition, 
TP53 may facilitate the transpol1 of Fas from the Golgi complex to the cell 
membrane.23o TP53 also induces the death receptor KILLERlDRS, which is another 
member of the TNFR family.23t Interaction with its ligand TRAIL, also called Ap02L, 
activates the cytoplasmic death domain of KILLER/DR5, which subsequently 
. t h d I .. . 232 acttva es t e caspase casca e resu ttng m apoptoslS. 
In addition to proteins acting at the level of receptor signaling for apoptosis, TP53 
can also transcriptionally activate genes, which encode proteins that act downstream 
by activating apoptotic effector proteins. For example, BAX (BCL-2 associated 
~rotein X) is a TP53-induced member of the BCL-2 family.233 The BAX protein 
promotes apoptosis by facilitating the release of cytochrome C fi'om the mitochondria, 
which in tum activates the caspase cascade.234 BAX has been shown to homodimerize 
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as well as heterodimerize with BCL-2, which plays a role in promoting cell survival 
and inhibiting apoptosis. The ratio of those two proteins detennines cell survival or 
death in a stressed cell. 235 In addition to up-regulation of BAX expression, TP53 can 
either directly or indirectly transcriptionally down-regulate the expression of the 
BCL-2 gene. 236 Moreover, overexpression of BCL-2 was shown to increase the half-
life of BAX, suggesting a feedback mechanism that may help to maintain the ratio of 
BCL-2 to BAX protein in physiologically appropriate ranges. 237 
An alternative route by which TP53 may signal to the mitochondria is through the 
elevation of the levels of reactive oxygen radicals. 238 In this view several TP53-
induced genes (PIGl-14) have been identified with a potential to induce oxidative 
stress.239 For example, PIG3 shares homology with an NAPDH-quinone 
oxidoreductase, which generates reactive oxygen radicals?39 Other TP53-induced 
genes have also been identified, including PAG608, which encodes a zinc finger 
protein whose overexpression can promote apoptosis in tumor cell Iines.240 However, 
further study will be required to determine the mechanism by which these latter genes 
contribute to the control of apoptosis. Furthermore, it is important that although 
several TP53-induced target genes can promote apoptosis, the expression of each 
alone is usually insufficient to cause significant cell death. The apoptotic target genes 
may therefore need to act in concert by activating parallel apoptotic pathways in order 
to mount a full apoptotic response. 
DNA repair 
TP53 has also been implicated in DNA repair processes. 241 ,242 The C-terminus of 
the TP53 has been shown to bind directly to sites of DNA damage, including 
mismatches l82 , single-stranded DNA243 and irradiated DNA. IS3 TP53 may thus serve 
as a damage detector, either alone or as part of a larger recognition complex. 
Moreover, a number of DNA repair proteins have been identified that interact with or 
regulate TP53, presumably through its C-terminus. These include the XP-B and XP-D 
components of TFIlH and RAD51,244 With respect to the latter protein, an interesting 
interaction has been observed between BRCA I, RAD51 and TP53 and this is further 
discussed in chapter 6A, The redox/repair protein Ref-I was discovered to be a potent 
activator of TP53 DNA-binding and transactivation,245 TP53 and its downstream 
effector genes have also been shown to playa direct role in DNA repair. As already 
discussed, the GADD45 (growth arrest and DNA damage inducible) gene, for 
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example, is upregulated by TPS3 in response to DNA damage. GADD45 can stimulate 
DNA excision repair and, in addition, binds to PCNA. 
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Figllre 6: IlIdllClioll of apoplosis by TP53 (adapled ill revised form from Siollov allfi 
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TP53 medialed apoptosis through direct sequellce specific trallsaclivlltioll depelldellt 
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1.5.4. TP53 gellefamily 
Many critical cellular regulators are members of gene families with overlapping 
and often complementary functions (e.g. retinoblastoma gene family consisting of 
RB-I, pl07 and pI30). For many years TPS3 was not thought to be part ofa family. 
Recently however, two mammalian TPS3 homologues, p73 and pSI (also known as 
p40, p63, KET or p73L), have been identified (reviewed by Kaelin).252.246-251 Both 
p73 and pSI can, at least when overproduced, mimic the ability of TP53 to bind to 
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DNA, activate transcription and induce apoptosis. The p73 gene maps to chromosome 
I p36, a region that is frequently deleted in neuroblastoma and a variety of other 
human cancers246 whereas p5I maps to chromosome 3q27 -8, which is deleted in some 
bladder cancers. As a result of alternative splicing cells produce multiple isoforms of 
p73 (p73o: and 13) and pSI (pSIA and B). Moreover, unlike TP53, which is 
ubiquitously expressed, expression of p73 and pSI appears to be restricted to certain 
tissues. Although pSI and p73 transcripts have been detected in a variety of human 
tissues, their expression has not been reported in ovaries.248-251 Moreover, neither p 73 
nor p5I appear to be frequently mutated in human cancers.246,253-255 These 
observations are, however, based on limited studies reported to date and additional 
studies are clearly indicated. Furthermore, it has been suggested that p73 is 
monoallelically expressed and that loss of the transcribed allele is associated with 
tumorigenesis.246 However, biallelic expression of p73 has been observed in tumor 
specimens and it has been demonstrated that p73 mRNA levels are increased rather 
th d d · t . I' t d' I' 254256257 an eCl"eaSe m timor tissue re atlve 0 surroun IIlg norma tissue. ' , 
Furthermore, in contrast to tp53-deficient mice, those lackingp?3 show no increased 
susceptibility to spontaneous tumorigenesis. 258 Unlike TP53, p73 is not induced by 
DNA-damaging agents. The normal filllctions ofp51 and p73 remain to be elucidated. 
1.5,5, Role ofTP53 ill callcel' 
Mutations in the tumor suppressor gene TP53 occur in about SO% of all human 
tumors, making it the most frequent target for genetic alterations (general reviews259-
261 and for updates see websites). Mutation is often accompanied by loss of 
heterozygosity. Neve11heless, mutation without LOH may also be disadvantageous 
since some TP53 mutants can inactivate wild type TP53 through hetero-
oligomerization. Moreover, some TP53 mutants can enhance transformation when 
introduced into TP53 nullizygous cells suggesting that prope11ies other than hetero-
ologimerization with TPS3 must contribute to their ability to promote transformation. 
In addition to l'P53 mutation, altered degradation or neutralization of TPS3 otherwise 
may also promote cancer without a need to alter the l'P53 gene itself. For example, 
the development of cervical and angogenital cancers has been linked to degradation of 
TP53 by the human papilloma virus E6 protein,262-264 Otherwise, excessive MDM2 
expression achieved through MDM2 gene amplification or other mechanisms can lead 
to neutralization and degradation of TPS3. Sarcomas for example often overproduce 
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MDM2 as a result of amplification?6S,266 Elevated MDM2 levels as the result of 
enhanced translation have also been observed in choriocarcinoma cell Iines.267 A 
change in the subcellular localization may be another way to inhibit TP53's activities, 
For example, TP53 mutations are rare in neuroblastomas but the TP53 protein is 
seemingly sequestered in the cytoplasm. Thus, neutralization of TP53 function is a 
common and possibly requisite step in human cancer. 
1.6. Prognostic factors 
The overall 5-year survival rate for women with ovarian carcinoma is on the order 
of 30%. Current routinely used prognostic factors are based on clinico-pathological 
criteria, which are subject of inter- and intraobserver differences, More quantitative 
approaches to identify new biologic factors associated with clinical prognostic 
significance may decrease the subjectivity frequently associated with prognostic 
factors. Numerous molecular genetic lesions have been identified which may be useful 
for prognostic characterization of ovarian cancer patients. However, afier 20 years of 
intensive research there are still significant gaps in our knowledge concerning ovarian 
cancer etiology, development and treatment. Understanding genetic events that lead to 
initiation and progression of ovarian cancer remains an important challenge in 
gynecological research. Although several genes involved in ovarian cancer have been 
identified, many more genes remain to be discovered and the clinical significance of 
the cancer genes already known is still in its infancy. With respect to the classical 
prognostic factors, some of these are discussed below. 
FIGO stage 
The most impoliant determinant of clinical outcome is the surgicopathologic stage 
at the initial time of diagnosis. The staging system defined by the International 
Federation of Gynecologic Oncologists (FIGO) is shown in Table 2, For patients with 
stage I disease survival rates have been reported over 90%.268 Patients with stage III 
disease, in which the disease has spread outside the pelvis into the abdominal cavities, 
have a 5-year survival rate of approximately 20% whereas patients with stage IV 
disease have a survival rate of less than 5%,3,269 Subdividing each stage stage shows 
marked differences in patient sUl'vival for the substages. l -S For example, for patients 
with stage IlIA disease a 5-year survival of 39.3% has been reported compared to 17% 
for stage I1IC. S 
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Tumor volume aud residual tumor rest 
The initial volume of tumor mass at the time of diagnosis has been shown to 
provide significant prognostic infonnation.27o However, since complete tUnlor cell kill 
by chemotherapy is more likely with small tumor volumes than with large tumors, the 
extent of residual disease after primalY surgery is of greater imp0l1ance. Patients with 
residual tumor nodes smaller than either I or 2 cm after debulking surgery have a 
better prognosis than patients in whom such resection is not ca!Tied ouI.6,271.277 The 
number of residual masses may be a prognostic factor as well. 278 
Table 2: FIGO staging system for epithelial ovarian cancer of the ovary 
FICO 
Stage I 
IA 
IB 
Ie 
Siage II 
- IIA 
liB 
lie 
Siage III 
IliA 
IIIB 
lIIe 
Siage IV 
Definition 
hnllor limited to the ovaries 
one ovary, no ascites, intact capsule 
both ovaries, no ascites, intact capsule 
n1ptured capsule, capsular involvement, positive peritoneal washings Of malignant 
ascites 
ovarian tumor with pelvic extension 
pelvic extension to ulcl1IS or tubes 
pelvic extension to other pelvic organs (bladder, rectum, or vagina) 
pelvic extension plus findings indicated for Ie 
tumor outside the pelvis or with positive nodes 
microscopic seeding outside the true pelvis 
gross deposits ~ 2 em 
gross deposits >2 em or positive nodes 
distant organ development, including liver parenchyma or pleural space 
Reproduced from Cannistra 4 
Histology and grade 
The descriptive histologic classification of the World Health Organization (WHO) 
has found widespread acceptance but there is a high degree of subjectivity (both 
interobserver and intraobserver variability) in assigning histologic type and grade?79-
281 There is no consensus on the prognostic relevance of the various histologic 
types275, except that the clear cell histology may be associated with an adverse 
. 3 272 282-284 Fl' I b d I . 'tl prognosIs." Uli lennore, It las een reporte t lat serous carCll10mas Wi 1 a 
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high number of psanunoma bodies have a better prognosis than patients whose tumors 
demonstrate no or a low psammoma body content. 285 While histologic typing of 
epithelial ovarian cancer according to the WHO classification is in wide use, there is 
no universally accepted grading system. Most commonly, ovarian carcinomas are 
graded in architectural terms as well, moderately or poorly differentiated. However, 
other grading systems, as for example the Broders' system that assesses the 
percentage of differentiated cells, are also used by different pathologists. Histologic 
grade appears to be a patiicularly important prognostic factor in patients with early 
stage disease. Stage I patients with well or moderately differentiated tumors have a 
significantly better survival compared with poorly differentiated tumors.3•S,268 
However, in advanced stage patients, treated with cisplatin, most studies have failed 
to demonstrate a significant correlation between grade and survival. In the last few 
decades the introduction of quantitative techniques have allowed for a more objective 
and consistent approach to the grading of ovarian carcinomas. Tumor aneuploidy as 
demonstrated by DNA flow cytometty, has been shown to be an independent adverse 
prognostic factor. 27o,286,287 In addition, quantitative pathologic (morphometrical) 
features, including mitotic activity 
percentage of epithelium have 
impOliance.270,286,288 
Age and performance status 
index, the mean nuclear 
also been shown to 
area and volume 
have prognostic 
Patient characteristics including patient age and performance status (Karnofsky 
score) have also been shown to correlate with patient outcome.274 ,289-291 However, 
performance status suffers from problems with subjectivity. 
1.7. Aim of the study and outline of the thesis 
In ovarian tumorigenesis multiple genetic and epigenetic alterations must occur 
before a clinically malignant ovarian tumor manifests. The most likely way to develop 
new, effective therapies for epithelial ovarian cancer patients is to improve our 
undcrstanding of and ability to identify the genetic changes leading to initiation and 
progression of ovarian Cancer and to sensitivity and resistance to chemotherapy. The 
aims of this study were to gain more insight into the genetic events that lead to 
initiation and progression of ovarian cancer and to assess the added value of currently 
available molecular markers in ovarian cancer. 
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Initial studies on cell lines have shown that the multiple tumor suppressor gene I 
(MTSI/CDKN2/p/6h1k4a) is homozygously deleted or mutated in many human cancer 
cell lines. It was therefore assumed to be an important player in a variety of human 
cancers including ovarian cancel'. In chapter 2 the prevalence and relevance of 
p16lNK4a alterations in ovarian carcinomas and in ovarian cancer cell lines is 
described. 
There is clear experimental evidence that aberrations in the TP53 tumor suppressor 
gene playa critical role in the development and progression of ovarian cancel'. The 
TP53 gene is mutated andlor overexpressed in up to 50% of ovarian tumors. However, 
the prognostic and predictive significance of TP53 aberrations (i.e. overexpression 
and gene mutation) is still under debate. Tumor heterogeneity, small numbers of 
tumors, different therapies and different techniques used for studying TP53 may be 
responsible for the reported inconsistencies about the prognostic value of TP53. With 
respect to techniques, most studies have utilized an immunohistochemical approach to 
study TP53 status. Since generally only missense mutations are associated with a 
relative overexpression of the protein, studying TP53 alteration by means of 
immunohistochemistlY is not adequate to detect all abelTations. Chapter 3 describes a 
high prevalence of TP53 non-missense mutations in ovarian carcinoma. Since these 
mutations were not accompanied by protein accumulation, the impoliance of 
performing both mutational and immunohistochemical analysis is discussed. 
Subsequently, chapter 4 describes the prognostic significance of both TP53 
mutation and TP53 protein expression, and also of the combination of these data. 
Since it is not known how and to what extent TP53 mutations affect the function of 
the protein, more insight could come from the study of "downstream genes" ofTP53. 
In addition to the clinical value of TP53, chapter 4 describes the expression of celia in 
TP53 downstream genes, including the cell cycle inhibitor p21 and the apoptosis-
related BAX and BCL-2, in relation to clinico-pathological parameters, clinical 
outcome and response to platinum-based chemotherapy. 
Although the TP53 gene is frequently altered 01' overexpressed in malignant 
ovarian tumors, chapter 5 describes that TP53 alterations are not often observed in 
borderline tumors. It is not kno,,:n whether these borderline tumors are precursors of 
malignant carcinomas 01' whether they represent a distinct class of tumors. Some data 
have indicated that mutations in the proto-oncogene K-RAS are more frequent in 
borderline tumors compared to carcinomas, suppoliing the latter hypothesis. Chapter 5 
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also describes the prevalence of K-RAS mutations in borderline tumors and discusses 
the results in relation to this theory. 
Chapter 6A covers a review on the breast cancer susceptibility gene I (SRCAI). 
Germ-line mutations in this gene are responsible for up to 80% of families with both 
breast and ovarian cancer. It is proposed that TP53 dysfunction may be required for 
BRCA I-associated ovarian tumorigenesis. In addition to this hypothesis, chapter 6B 
includes our own findings with respect to the presence of TP53 alterations in BRCAl-
associated ovarian tumors. 
Finally, cliapter 7 critically discusses the results of the studies described in this 
thesis and gives new perspectives. 
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Summary 
The cell cycle regulatOlY proteins p 16 and p21 cause cell cycle an'est at the Gl 
checkpoint by inhibiting activity of cyclin D-CDK4 complexes. The TP53 gene, 
regulating the p21 protein, is mutated at high fi'equency in ovarian cancer. The CDKN2 
gene, encoding the p 16 protein, has been mapped to chromosome 9p21 and encompasses 
three exons. To establish the fl-equency of CDKN2 gene abn0l11lalities in ovarian tumour 
specimens, we have studied this gene in five ovarian cancer cell lines and in 32 primary 
and five metastatic ovarian adenocarcinomas. Using polymerase chain reaction-single 
strand conformation polymorphism (PCR-SSCP) and sequencing techniques both exons I 
and 2 of the CDKN2 gene, encompassing 97% of the coding sequence, were analysed. In 
addition, the TP53 gene was studied for the presence of mutations. The cell line HOC-7 
showed a 16 bp deletion in exon 2 of the CDKN2 gene, resulting in a stop codon, whereas 
in cell line SK-OV-3 this gene was found to be homozygously deleted. Nine primaty 
tumour specimens showed a migration shift on SSCP. Sequencing revealed a common 
polYl11Olphism (Ala 148Thr) in seven of these ovarian tumour specimens. The two other 
tumour samples were found to contain silent mutations, one at codon 23 (GGT -7GGA) 
and the other at codon 67 (GGC-7GGT). Mutations in the TP53 gene were observed in 
46% of the ovarian tumour specimens. We conclude that CDKN2 gene alterations are rare 
events in human ovarian cancer. The low prevalence of these alterations do not allow for 
analysis of an association of this gene with prognosis. 
Introduction 
Cyclins, cyclin dependent kinases (CDKs) and cyclin-dependent kinase inhibitors 
(CKls) playa key role in cell cycle control. To achieve an orderly progression through 
the cell cycle, different cyclin-CDK complexes need to be activated and deactivated at 
appropriate times. Cyclin D-CDK4 is one of the complexes that promotes cell passage 
through the G 1 phase of the cell cycle. It increases the phosphorylation state of the 
retinoblastoma protein which then releases transcription factors (e.g. E2F) essential 
for progression into the S-phase (reviewed by Sherr, Hartwell and Kastan, and Hunter 
and Pines).!') Changes in the amount or composition ofCDKs or their inhibitors may 
lead to loss of cell cycle control and thus to uncontrolled cell growth. 
One of the inhibitors of cyclin D-CDK4 as well as of other cyclin-CDK complexes 
tluoughout the whole cell cycle is the p21 protein, encoded by the WAF 1 (CIP l/SDIl) 
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gene.4•6 Upon genotoxic damage, expression of p21 is induced through the transcriptional 
activation by TP53",.7 The TP53 gene is located on chromosome 17p13.1 and mutation of 
this gene is the most conunon genetic abnormality yet found in human cancers. The 
prevalence of TP53 mutations varies among tumour types with roughly 44% of ovarian 
tumours being mutated (reviewed by Greenblatt et af).8 
Another negative regulator of cyclin 0-COK4/6 activity is the pl6 protein, encoded 
by the CDKN2 (MTSlIp16"Ik4/CDK4I) gene9 ,IO The CDKN2 gene, which has been 
mapped to chromosome 9p21, was found to be deleted or mutated in a wide variety of 
tumour cell lines, including nearly 30% of ovarian cancer cell lines. " Interestingly, loss 
of heterozygosity (LOH) at 9p has been reported in 31 % (49 out of 157) of human 
epithelial ovarian tumours (reviewed by Shelling et af).12 
To detennine whether alterations of the CDKN2 gene are involved in ovarian 
carcinogenesis, we have studied this gene in 32 primary and five metastatic human 
epithelial ovarian tumour specimens and in an additional five ovarian cancer cell lines. To 
this end, exons I and 2, constituting 97% of the coding sequence, were examined using 
PCR-SSCP and sequencing techniques. Our results suggest that alterations of the CDKN2 
gene play no major role in the initiation or progression of ovarian cancer. 
Materials and Methods 
Cel/lilles 
The human ovarian cancer cell lines used in this study were SK-OV-3 (HTB-77), 
SK-OV-6, 2780, 2774, HOC-7 (a gift from Dr. GUnther Oaxenbichler, Innsbruck, 
Austria). The SK-OV-3 and HOC-7 cell lines originated from ascites whereas the 
other cell lines were derived from (adeno)carcinomas (ATCC). 
Tllmollr sampies 
Thirty-two primary and five metastatic ovarian adenocarcinomas were included in this 
study. One patient had bilateral adenocarcinoma of the same histological type. A sample 
of both locations was investigated. The mean age as well as the median age of the patients 
with ovarian tumours was 56 years (range, 26-85 years). Following the WHO 
classification 13 the primmy and metastatic carcinomas were subtyped into serous (/I = 14 
primalY, /I = 5 metastatic), mucinous (/I = 4), endometrioid (/I = 7), clear-cell (/I = 2), 
mixed (/I = 3), poorly differentiated (/I = I) and unknown (/I = I). To estimate the 
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percentage of tumour cells, frozen sections were made from a representative pm1 of each 
tumour and stained with haematoxylin and eosin. The percentages of tumour cells in the 
primary tumour specimens were: below 25% (n ~ 8), between 25% and 50% (n ~ 3), 
between 50% and 75% (n ~ 8) and above 75% (n ~ 12). With respect to the metsatatic 
tumour specimens, the percentages of tumour cells were: between 50% and 75% (/I ~ 3) 
and above 75% (/I ~ 2). In general, 68% of these tumours contained over 50% of tumour 
cells. 
DNA extractioll, polymerase cllaill reactioll (PCR), sillgle stralld cOlljol'll/atioll 
polymOlphislll (SSCP) allalysis alld seqllellce allalysis 
Tumour specimens were stored in liquid nitrogen. Genomic DNA was extracted from 
fi'Ozen tumour tissues or cell lines according to standard procedures. 14 Exons I (150 bp) 
and 2 (307 bp) of the CDKN2 genel5 as well as exons 5, 6, 7 and 8 of the TP53 gene were 
studied by PCR-SSCP analysis. 16 Locations and sequences of PCR-primers for exon 115 
and for exon 217 of the CDKN2 gene are shown in Figure I and Table I respectively. 
Briefly, exon I was amplified by PCR using intronic primer pairs l5 as shown in Table 
I. Exon 2 was amplified using primer pair M2-UIM2-D, generating a 522 bp fi'ab~uent. 
To enhance specificity and to generate smaller fragments, two nested PCRs were carried 
out using primer pairs A1IA2 and BIIM2-D. About 200 ng genomic DNA was used for 
PCR. Amplification was performed in the presence of 10% dimethyl sulphoxide (DMSO) 
and [a32PjdATP using a DNA thermal cycler-480 (Perkin Eimer/Cetus, Norwalk, CT, 
USA). To improve specific annealing, a touchdown PCR procedure was used. Cycling 
parameters are listed in Table I. Genomic input DNA and PCR product ratios were 
compared on ethidium bromide-stained agarose gels (1.3 %) following the first 30 cycles 
of PCR. The breast cancer cell lines, MCF7 and MDA-MB-23I, which have a 
homozygous deletion of the CDKN2 genel7, were taken as a control. 
The exons 5-8 of the TP53 gene were amplified using commercially available primers 
(Clontech, Palo Alto, CA, USA). To obtain a false negative rate below 10%, products of 
less then 200 bp were generated. IS To this end, the TP53 PCR products were digested 
with HinJl (exon 5), HaeIII (exon 6) and BsrI (exon 8). Exon I of the CDKN2 gene was 
digested with BSI'I and exon 2 (fragment BIIM2-D) was digested with Kpnl. For SSCP 
analysis 32P-labelled PCR products were heat denatured and applied to a non-denaturing 
8% polyaclylamide gel containing 10% (v/v) glycerol and electrophoresis was pelfonned 
at 30 W for 6 h at room temperature. PCR products showing an altered electrophoretic 
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mobility were analysed again and then subcloned into a TA cloning vector (PCRII; 
Invitrogen, San Diego, CA, USA). At least ten individual clones were pooled and 
sequenced by double-stranded sequencing (T7 sequencing kit; Pharmacia, Uppsala, 
Sweden) using a 6% denaturing polyacrylamide gel containing 8 M urea. 
Table 1: Primer sequences and cycling parameters for amplification 
of exon 1 and exon 2 of the CDKN2 gene 
Exon Primer sequences 
MI-U: 5'-CGGAGAGGGGGAGAGCAG-3' 
MI-D: 5'-TCCCCTTTITCCGGAGAATCG-3' 
2 M2-U: 5'-GAGAACTCAAGAAGGAAATTGG-3' 
M2-D: 5'-TCTGAGCTITGGAAGCTCTCA-3' 
Nested primers 
AI: 5'-AGCTTCCTITCCGTCATGC-3' 
A2: 5'-ACCACCAGCGTGTCCAGGAAG-3' 
8 I: 5'-ACTCTCACCCGACCCGTG-3' 
M2-D: 5'-TCTGAGCTITGGAAGCTCTCA-3' 
Results 
Cycling parameters 
50 s 92 'C, 30 s 60 'C, 
2 min 72 'C, 30 cycles 
50 s 92 'C, 50 s 57 'C, 
2 min 72 'C, 30 cycles 
50 s 92 oe, 50 s 57 oe, 
2 min 72 oe, 20 cycles 
50 s 92 'C, 50 s 57 'C, 
2 min 72 °e. 20 cycles 
We have studied alterations in exons I and 2 of the CDKN2 gene in 32 primary and 
five metastatic ovarian adenocarcinomas and in five ovarian cancer cell lines using PCR-
SSCP and sequencing techniques. 
Two celi lines, SK-OV-3 and HOC-7, showed alterations in the CDKN2 gene. No 
PCR products for exon I and 2 could be generated using the cell line SK-OV-3, 
indicating that the CDKN2 gene is homozygously deleted in this cell line. The integrity of 
the DNA was confirmed by a successful amplification of TP53 (exons 5-8). The cell line 
HOC-7 was found to have a 16 bp deletion in exon 2 of the CDKN2 gene. This deletion 
removes nucleotides at positions 163-178, thereby placing the sequence in a different 
reading Ii'ame and introducing a stop codon 256 bp downstream li'Om the deletion. In 
addition, this cell line also has a mutation (T---7A) 36 bp downstream ofthis deletion. 
Among the 32 primaty tumours examined a total of nine (28%) altered migration 
patterns were detected (Figure I and Table 2). Two mobility shifts cOiTelated with silent 
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mutations in exon I (codon 23:GGT---)GGA) and exon 2 (codon 67:GGC---)GGT; Figure 
2). The remaining seven (22%) mobility shifts represented a common polymolphism 
(GCG---)ACG; Figure 2), substituting a threonine for an alanine at codon 148. The 
metastatic tumour specimens, however, revealed no mobility shifts by SSCP. 
Primer Locations 
Ml-U 
-
A 
123 4 5 6 
• 
Ml-D 
.... 
o 
o 
o 
o 
NO 
B 
'2 
+-., 
-
1 2 3 4 6 6 
• 
o 
o 
o 
M2-D 
-
M2-D 
.... 
c 
1 234 6 6 
• 
Figllre 1: Top: Primer localiolls for ampiijical/oll of exoll 1 alld eXOII 2 of Ihe CDKN2 
gelle (as described in Ihe Materials alld /IIelhads seclian). Dol/om: Examples of PCR-SSCP 
allalyses ofCDKN2fragmellls. (a) A /IIigralion sh(fl in exall 1. (b and c) Migralioll sh(fls in 
exoll 2. The corresponding sequence analyses are shown ill Figure 2. The asterisks indicate 
Ihe altered /IIigratian paUel'lls. D: denatlll'ed, ND: not dellatllred. 
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Table 2: Genetic alterations of the CDKN2 and TP53 genes in primary 
and metastatic ovarian adenocarcinomas. 
TP53 CDKN2 alteration 
Sample Histology Tumour alteration 
cells (%) Exon Exon Codon Nucleotide Amino acid 
change change 
Primary 
591 serous 525 6 2 67 GGC-->GGT Gly-->Gly 
615 serous 525 7 
602 serous 525 
638 mucinous 525 2 148 GCG-->ACG Ala-->Thr 
580 mucinous 525 
623 endomctrioid 525 2 148 GCG-->ACG Ala-->Thr 
624 mixed 525 
604 unknown s 25 2 148 GCG-->ACG Ala--> Thr 
582 serous 25 - 50 7 2 148 GCG-->ACG Ala--> Thr 
603 serous 25 - 50 
657 mucinolls 25 - 50 5 
601 serous 50 -75 8 
616 serous 50 -75 6 
626 serous 50 -75 8 
585 serous 50 -75 
618 serous 50 -75 
459 poorly diff. 50 -75 6 
545 mixed 50-75 
649 mixed 50 -75 
553 serous ? 75 7 
562 serous ? 75 
621 serous ? 75 
565 mucinous ? 75 2 148 GCG-->ACG Ala-->Thr 
620 endometrioid ? 75 5 
622 endometrioid ? 75 6 
564 endometrioid ? 75 6 2 148 GCG-->ACG Ala--> Thr 
605 endometrioid ? 75 7 2 148 GCG-->ACG Ala--> Thr 
595 endometrioid ? 75 
612 endometrioid ? 75 
625 clear cell ? 75 23 GGT-->GGA Gly-->Gly 
586 clear cell ? 75 
596 serous n.d. 
Metastatic 
583 serous 50-75 5 
617 serous 50-75 8 
540 serous 50-75 
547 serous ? 75 7 
574 serous > 75 5 
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With respect to TP53 gene alterations, 13 out of32 (41%) primaty tumour specimens 
and four out of five (80%) metastatic tumour specimens showed altered migration 
pattems on SSCP. Of the seven tumours having a polymorphism in the CDKN2 gene 
three tumour specimens showed an alteration in the TP53 gene. DNA sequencing analysis 
showed that two mutations occurred in exon 7 (Arg248Trp & Arg248Leu), whereas the 
third mutation was found in exon 6 (lie I 95Thr; Table 2). Of the two tumours having a 
silent CDKN2 gene mutation, one also showed a mutation in exon 6 (Arg213stop) of the 
TP53 gene. 
A B c 
TGGA TGGA T G G A 
~ codon 148 codon 67 codon 23 GGG GGT GGG 
V V \; 
GGA GGT AGG 
Flgllre 2: Seqllellce flllalysis ojille CDKN2 gelle III IIl1l11all ovariall callcer. 
PCR products IVith altered migratioll pallel'lls were allalysed. (a alld b) Silellt IIlll/atiolls ill 
codoll 23 (exoll 1) alld 67 (exoll 2). (c) A COlIlllIOIl polYlllorph/slll ill codoll 148 (e.roll 2). The 
asterisks illdicate the base challges. Seqllences are read ji'01ll bollolll to top ill the 5' __ 3' 
direction. 
DisclIssion 
To determine whether alterations of the CDKN2 gene may be critical in the fonnation 
of ovarian cancer, we have analysed primary and metastatic ovarian adenocarcinomas and 
ovarian cancer cell lines for the presence of CDKN2 gene alterations. One of the five cell 
lines tested, SK-OV-3, was found to be homozygously deleted for the CDKN2 gene, 
whereas another cell line, HOC-7, showed a partial deletion of 16 bp in exon 2, resulting 
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in a frameshift and a premature stop codon. Okamoto el ails and Schultz et al19 also found 
a homozygous deletion in the cell line SK-OV-3. Homozygous deletions have been 
repolied in nearly 30% (two out of seven) of ovarian cancer cell lines. II Our solid ovarian 
tumour specimens, however, were not indicative of homozygous deletions. Among the 32 
primaIy ovarian adenocarcinomas studied, only two silent mutations were found in one 
out of 14 serous and one out of two clear cell tumour specimens. The common 
polymorphism Alal48Thr, previously described as Alal40Thr by Cairns et apo, was 
observed in seven ovarian adenocarcinomas (one out of 14 serous, two out of foul' 
mucinous, three out of seven endometrioid and one out one unknown). We observed no 
CDKN2 alterations in five metastatic tumour samples. Campbell el aPI and Schultz et al19 
observed no mutations in 67 primary and five out of 40 ovarian tumours showing LOH on 
9p respectively. In addition, the latter author reported homozygous deletions of the 
CDKN2 gene in 14% (16 out of liS) of ovarian neoplasms using comparative multiplex 
PCR. However, SO% of the tumours used in their study were cOllUnon epithelial tumours, 
whereas the other SO% were of different histopathological subtype, mainly benign 
tumours. 
The low prevalence of CDKN2 gene alterations obselved by us may also be explained 
by technical difficulties associated with primaty tumour studies. Data on analyses of 
mutations or other genetic abnonnalities in tumours where the material studied contains 
less than SO% tumour cells should be interpreted with caution. For example, the presence 
of homozygous deletions in tumours may be masked by a considerable non-neoplastic cell 
content. Although in the present study the majority of the tumours contained over SO% of 
tumour cells, we were not able to obselve major differences in signal intensities when 
comparing genomic input DNA and PCR product ratios (after 30 cycles). In addition, 
with respect to mutations concern may also exist. However, Table 2 shows that CDKN2 
and TP53 gene mutations are equally prevalent in tumour samples with either a smaller or 
a higher percentage of tumour cells. A possible underestimation of mutations andJor 
deletions in tumour tissues could be excluded by dissecting tumour cells from 
sllll'ounding normal tissue. Another explanation for the low prevalence of CDKN2 gene 
mutations may be the sensitivity of the SSCP teclmique. To reduce the false-negative rate 
below 10%, we digested the PCR products used in this study in order to generate 
fragnlents of less than 200 base pairs. 18 Moreover, a nonnal TP53 mutation spectrum was 
obselved since, of all tumours studied, 46% showed a TPS3 alteration as determined by 
SSCP. A recent review by Shelling et al12 reported that 44% (46 out of lOS) ovarian 
tumours showed TP53 mutations, measured by SSCP. 
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A low frequency of CDKN2 gene alteration in tumours and a higher frequency in cell 
lines has also been described in tumours of the breastI7,22, head and neck2J,24, lung, 
bladder, kidney, brain and colon?O,25 In contrast, homozygous deletions and/or mutations 
occur more often in mesotheliomas26, melanomas27, non-small-cell lung carcinomas28, 
glioblastomas29 and several other tumours.l°,JI 
This study does not mle out a putative role of methylation of the CDKN2 gene in 
ovarian cancer. De 1101'0 methylation of the 5'CpG island of CDKN2 is a frequent 
abnormality in non-small-cell lung cancer, gliomas, head and neck squamous cell 
carcinoma, breast and colon cancer32.3J This methylation could lead to lack of expression 
of CDKN2 protein causing loss of cell cycle control. This will be a subject for further 
study. 
In conclusion, alterations in the CDKN2 gene are infrequent in both primary and 
metastatic ovarian adenocarcinomas, suggesting that CDKN2 gene mutations play no 
significant role in the initiation or progression of ovarian cancer, A study on an 
association with prognosis is not attainable owing to the low prevalence of CDKN2 
mutations. Since LOH at 9p21 has been reported in up to 50% of primmy epithelial 
ovarian tumours34,J5, one or more other tumour-suppressor genes may be present in the 
region of9p21. 
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Summary 
As in many human malignancies, TP53 mutations are the most common genetic 
alterations in malignant human ovarian tumours. An approach often used in the 
determination of TP53 status is immunohistochemical staining of the protein. Non-
missense mutations, especially those of the null type, causing premature termination 
codons and resulting in tnmcated proteins, may often not . be detectable by 
immunohistochemistty. Therefore, current estimates of TP53 alterations in ovarian 
cancer may be inaccurate. By using polymerase chain reaction-single strand 
conformation polymorphism analysis and sequencing techniques, we have found a 
high prevalence of TP53 non-missense mutations in exons 5-8 in ovarian tumour 
specimens from patients from the southwestern pali of The Netherlands. Twenty-nine 
of 64 tumours showed mutations, of which 10 were non-missense mutations. The 
majority (9 of 10) of these non-missense mutations, including 7 nonsense mutations 
and 2 frameshift deletions, were null type mutations and could not be detected by 
inununohistochemical staining. Five of the 7 nonsense mutations were mutations at 
codon 213 (Arg~Stop). The nature of the high prevalence of this nonsense mutation 
in our series of ovarian carcinomas remains unknown. In addition to the 9 null type 
mutations, a splice junction mutation was encountered. In conclusion, we have 
observed a high prevalence (13%) of ovarian tumours with null type mutations in 
exons 5-8 that did not result in inununostaining. Our data suggest that, especially in 
ovarian cancer, immunological assessment of TP53 is not an adequate tool to study 
TP53 alteration. A frequent nonsense mutation at codon 213 in 5 (8%) out of 64 
tumour specimens represents an important finding. 
Introduction 
Mutation of the tumour suppressor gene TP53, also named as P53, is the most 
common single gene alteration identified thus far in many human cancers. The 
majority of abnormalities (78%) are missense point mutations within the sequence-
specific DNA binding domain encompassing exons 5-8 (for reviews see Greenblatt ef 
at and Harris). 1,2 Missense point mutations give rise to the production of proteins with 
increased stability. The prolonged half-lives of these mutant proteins cause an 
accumulation, mainly in the nucleus, that can be detected immunohistochemically in 
contrast to wild type TP53 protein that cannot be detected immunohistochemically 
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due to its shOl1 half-life.) Immunohistochemishy has therefore become an important 
tool in the assessment of TP53 status. 
Mutations, however, may not invariably agree with immunohistochemical staining 
of the TP53 protein since positive TP53 staining can result from mechanisms other 
than TP53 mutation such as binding of TP53 to viral or cellular proteins, thus causing 
stable complexes with these proteins. In addition, null type mutations such as 
nonsense mutations, insertions and deletions resulting in frameshift errors and some 
splice junction mutations may result in truncated protein products that cannot be 
detected by immunohistochemical techniques.4 
Human ovarian cancer, being the most significant cause of gynaecological deaths 
in the western world, is also frequently associated with TP53 mutation. TP53 gene 
mutation and/or overexpression occurs in approximately 50% of malignant ovarian 
cancers (for review see Shelling ef al).5 Missense point mutations account for more 
than 85% of all TP53 gene abnormalities reported in ovarian cancer.6 
High frequencies of non-missense mutations have been reported in ovarian cancers 
from U.S. women.7,8 In these American studies, analyzing the entire open reading 
frame of TP53, deletions OCCUlTed at high frequency (15%). 
In our studies on TP53 alterations and protein expression in ovarian carcinomas 
from women from the southwestern Netherlands, we have also encountered a high 
occurrence rate of nOllumissense mutations within exons 5-8. However, instead of 
deletions, we observed that nonsense mutations, particularly a nonsense mutation in 
exon 6 (codon 213A,g.-,sIOP), were prevalent. Since these mutations were not detectable 
by immunohistochemistry, we recommend careful interpretation of 
inm1Ul1ohistochemically obtained data for screening, diagnosis, prognosis and 
treatment strategies of human ovarian cancel'. 
Materials and Methods 
Tumour specimens 
Tumour specimens, obtained from 64 women with primary epithelial ovarian 
cancer living in the southwestern part of The Netherlands, were snap-frozen at the 
time of surgery in liquid nitrogen and stored at -80°C until processing. According to 
the World Health Organization criteria9, 30 adenocarcinomas were classified as 
serous, 9 as mucinous, 13 as endometrioid, 4 as clear cell, 3 as mixed and 5 as poorly 
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differentiated carcinomas. Tumour stage was determined according to the criteria of 
the International Federation of Gynaecology and Obstetrics (FIGO)IO Twenty-five 
tumours were stage I or II and 39 tumours were stage III or IV. The median age of the 
patients was 51 years (range 28 - 82). 
DNA isolalioll alld PCR-SSCP 
High m.w. chromosomal DNA was prepared from frozen tissue samples by 
proteinase-K digestion and phenol/chloroform extraction according to standard 
procedures. II Exons 5-8 of the TP53 gene were amplified using intronic primer pairs 
as previously described. 12 
For SSCP analysis 32P-Iabelled PCR products were diluted with milliQ-H20 (I :4). 
To obtain a false-negative rate below 10%, products smaller than 200 bp were 
generated 13 . To this end, TP53 PCR products were digested with Hinfl (in case of 
exon 5), HaeIlI (exon 6) and BsrI (exon 8). SSCP analysis was performed using a 
non-denaturing 8% polyacrylamide gel containing 10% (v/v) glycerol. Gels were 11m 
with Ix Tris-Borate-EDTA buffer at 30 W for 6 hI' at room temperature. Breast cancer 
cell lines were used as controls: ZR75-1 as a negative control and SK-BR-3 (mutated 
in codon 175, exon 5), T-47D (codon 194, exon 6), EVSA-T (codon 241, exon 7) and 
MDA-MB-231 (codon 280, exon 8) or the colon cancer cell line HT-29 (codon 273, 
exon 8) as positive controls. PCR products showing an altered electrophoretic 
mobility were analyzed again. Since a base change in codon 213 destroys a naturally 
occurring TaqI restriction site, samples with a nonsense mutation at codon 213 were 
reanalyzed to confirm the mutation by digestion of exon 6 PCR product or fragment II 
RT-PCR product with the restriction enzyme TaqJ. 
RT-PCR 
Total RNA was isolated /i'oin 7 3D-ron thick cryostat sections using RNAzolB 
(Teltest, Friendswood, TX) as described by the manufacturer. Total RNA was reverse 
transcribed to cDNA by using superscriptII RNase H-reverse transcriptase (Gibco 
BRL, Breda, The Netherlands) and random hexamers and oligo d(T) as primers. 
Subsequently, the resulting cDNA was used for PCR analysis. Two fragments were 
amplified covering codons 93-209 (fragment I, exons 4-6) and 188-393 (fragment II, 
exons 6-11). 
75 
TP53 CODON 213 MUTATIONS IN OVARIAN CANCER 
Primers used for generating fragment I are: 
5'-CTGTCATCTTCTGTCCCTTCCCA-3' (sense) and 
5'-TCTGTCATCCAAA TACTCCACACG-3' (antisense). 
Primers used for generating fragment II are: 
5'-CTGGCCCCTCCTCAGCATCTTAT-3' (sense) and 
5'-TCAGTCTGAGTCAGGCCCTTCTGT -3' (antisense). 
PCR reactions consisted of 0.8 rnM dNTP, I 11M of each primer, 1.5 mM MgC\z, 50 
mM KCI, 10 mM Tris-HCI, 0.1 % Triton X-IOO, 0.2 U Taql DNA polymerase and 
approximately one-tenth of cDNA in a total reaction volume of 25 III covered with a 
drop of mineral oil. PCR cycling conditions included an initial 2 min denaturation 
step at 940 C followed by 35 cycles at 940 C for I min, 600 C for I min, and noc for 2 
min, and finally a telminal extension at 72°C for 7 min. 
SlIbclollillg alld seqllellcillg 
PCR products showing an altered SSCP migration pattern were either sequenced 
using an AmpliCycle sequencing kit (Perkin ElmerlRoche Molecular Systems, Nutley, 
NJ) or, when SSCP band shifts were indicative of a deletion, were subcloned using a 
TA cloning kit (Invitrogen, Leek, The Netherlands). RT-PCR product I of one tumour 
sample (919) was also subcloned. Individual clones were sequenced using a T7 
sequencing kit (Pharmacia, Uppsala, Sweden). Electrophoresis was performed using a 
6% polyacrylamide gel containing 8 M urea in Ix Tris-Borate-EDTA buffer at 60 W. 
Fragment II RT-PCR product of a tumour sample (696) with two nonsense 
mutations at codon 213 and codon 306 was digested with Taql. A 380 bp Taql 
fragment was isolated (QIAquick gel extraction kit, QIAgen, Santa Clarita, CAl and 
cloned in a pBluescript SK-vector linearized with Cia 1. Individual clones were 
sequenced using a T7 sequencing kit (Phatmacia). 
[III III 1111011 iSlocllelllical slaill illg 
Immunohistochemical staining for TP53 was performed by a peroxidase-labelled 
streptavidin-biotin-complex technique. Five-micron-thick cryostat sections were fixed 
in acetone and preincubated with 5% BSA-PBS. Endogenous biotin was blocked with 
avidin and biotin (avidin-biotin blocking kit, Vector, Burlingame, CAl for 10 min, 
respectively. Sections were subsequently incubated with DO-I (diluted I :200, clone 
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SC-126, Santa Cmz Biotechnology, CAl for one hr. After washing with PBS, 
biotinylated rabbit anti-mouse Ig (diluted 1:200, Dako, Glostmp, Denmark) in PBS 
containing 2% normal human sennn was applied for 30 min followed by an 
incubation with peroxidase-labelled streptavidin-biotin complex (Vecta Stain Elite 
Peroxidase kit, Vector) for 30 min. Visualization of the antibodies was performed by 
incubating the sections with diaminobenzidine (Fluka, Buchs, Switzerland) in the 
presence of hydrogen peroxide for 10 min. All reactions were performed at room 
temperature. Sections were finally counterstained with Harris haematoxylin, 
dehydrated and mounted with Pel1ex. Breast carcinoma tissues with known TP53 
overexpression served as positive controls. In the negative controls primary antibody 
was omitted. Sections were evaluated by 2 observers and were considered positive for 
TP53 when a distinct nuclear staining was seen in greater than 10% of tumour cells.8 
Results 
Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) 
of exons 5-8 of the TP53 gene in 64 primaty epithelial ovarian tumours revealed 30 
band shifts in 29 tumours (45%), which were confirmed in independent experiments. 
The samples showing altered migration patterns, indicative of a mutation, were 
sequenced to study the nature and the location of the mutations. Twenty-nine 
mutations (45%) and two (3%) neutral polymorphisms (2 I 3A,.-.Mg) were encountered. 
Table 1: Mutations leading to premature termination oftlte protein in Ituman 
ovarian cancers 
# Histology FIGO % me Exon Codon Mutation Effect Type 
no. stage tUl110r 
cells 
620 endometrioid 2C 25-50 ncg 5 136 CAA~TAA Gln--.-)Stop nonsense 
1214 poorly cliff. 4 >75 neg 6 196 CGA~CA Stop 150 bp frameshift 
downstream del 
1017 scrous 3C >75 neg 6 206 TIGGATG Stop framcshift 
A--.-)TGA del 
591 serous 3 <25 neg 6 213 CGA-)TGA Arg-)Stop nonsense 
616 scrous 3 25·50 neg 6 213 CGA--.-)TGA Arg-)Stop nonsense 
697 serous 3B >75 ncg 6 213 CGA--.-)TGA Arg--.-)Slop nonsense 
793 endometrioid 2C 25·50 neg 6 213 CGA-)TGA Arg--.-)Stop nonsense 
696 poorly diff. 3 >75 neg 6 213 CGA-»TGA Arg--.-)Stop nonsense 
8 306 CGA.--)TGA Arg--}Stop nonsense 
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Eighteen tumour specimens were found to have missense mutations and 17 of 
these specimens showed positive immunostaining with the monoclonal antibody DO-I 
(data not shown). One tumour specimen showed a silent mutation and negative 
immunostaining. Moreover, lOnon-missense mutations were encountered in 9 tumour 
samples. Nine of the lOnon-missense mutations, including 7 nonsense mutations (all 
C-t T transitions) and 2 frameshift deletions, were null type mutations causing 
premature termination codons and as a result showed negative immunostaining (Table 
I). The other non-missense mutation was a splice junction mutation resulting in a 
strong nuclear staining (80% of the nuclei). At the genomic level this splice junction 
mutation consisted of a deletion of the final 5 bp (tacag) of the intron between exon 4 
and 5, thus including the 5'-splice acceptor site (Figure I). To investigate this 
specimen in more detail, RT-PCR was performed. 
Cloning of the RT-PCR product (fragment I) and sequencing revealed an in-frame 
21 bp deletion (codons 126-132, Figure I). Hence, the cell's splicing machinery used a 
cryptic splice site (nucleotides 395-396) within exon 5, thereby causing an in-frame 
deletion of the first 7 codons of ex on 5. 
Seven of the 9 non-missense mutations were encountered in exon 6. Five 
mutations were nonsense mutations at codon 213 (213M g-,slop; Table I). To rule out 
the possibility that these nonsense mutations could be due to cross-contamination of 
DNA, we have performed RT-PCR using fresh cryostat sections. In this way, 3 
tumour specimens were indeed confirmed to have nonsense mutations at codon 213. 
No frozen tumour specimens were available for the other 2 tumours with a codon 213 
nonsense mutation. The non-invasive borderline component, however, was available 
from I of these 2 tumours. This sample (591) did not show the nonsense mutation that 
was seen in the invasive tumour component, implying that, at least in this case, the 
mutation is not germ line based. 
One of the tumour specimens with a nonsense mutation at codon 213 was found to 
have an additional mutation in exon 8 (696; Table I and Figure 2). To investigate 
whether the two mutations were located on the same allele, this specimen was 
analyzed in more detail. To this end, RT-PCR product (fragment II) was digested with 
TaqI restriction enzyme. Only DNA carrying the wild type sequence at codon 213 will 
yield a 380 bp product after this digestion. Subcloning of this 380 bp fragment and 
subsequent sequencing demonstrated the presence of the mutation at codon 306. This 
shows that the two mutations are not located on the same allele. 
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(bottom) to 3' (lOP). Exol/ sequences are showII in capitals alld illll'OI1 sequences ill lower 
case. 
Discussion 
The prognosis and treatment strategies of ovarian carcinoma remain to a large degree 
based on patient and tumour characteristics and (histo)pathological features (typing, 
grading, staging). There is, however, a desire to find a prognostic factor in ovarian 
cancer to individualize treatment protocols. The TP53 tumour suppressor gene 
is the most commonly altered gene in human ovarian cancer. Nevertheless, the 
prognostic value of TP53 abnormalities remains obscure. Different techniques are 
used to determine TP53 status of which immunohistochemistlY is most commonly 
used. Since not all mutations can be detected by immunohistochemistty, 
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A: B: 
EXON6 EXON8 
codon 213 T C G A codon 306 T C G 
A 
A G 
G T<-C-
T<-C-
Figure 2: Sequence allalysis o/tulllour sample 696 with two IIOllsense I1Il1tatiolls. 
(a) Nonsense mutation ill eXOf/ 6, codoll 2 J JArg---+5top, 
(b) Nonsense mutation in exoJ/ 8, codoll 306Arg---;Stop, 
A 
discrepancies may exist between inul1unohistochemical data and genetic analysis. An 
interesting finding in our studies on TP53 in ovarian cancer is that we observed a high 
prevalence of tumours with non-missense mutations. Mutations were detected in 29 of 
64 (45%) ovarian tumours. Nine tumour specimens (14%) showed 10 non-missense 
mutations. These non-missense mutations showed a poor concordance with 
immunohistochemical data. Only I of 9 tumour specimens with non-missense 
mutations showed positive inul1unostaining. 
The occurrence of tumours with non-missense mutations (31 % of the tumours with 
mutations) in exons 5-8 in this study is high. According to a database containing 
infol111ation on 333 ovarian cancer mutations (database update 1997: 
http://sunsite.unc.edu/dnam/mainpage.html)6, only 15% of the mutations in exons 5-8 
are non-missense mutations. A high prevalence of non-missense mutations has also 
been repOlted by Skilling et a1 7. Among 64 ovarian carcinomas from midwestern U.S. 
women, screened for TP53 dysfunction over the entire open reading frame, 39 (61 %) 
mutations were detected. Fourteen of these mutations (36%) were null mutations 
(defined as frameshift inseltions and deletions, nonsense and splice junction 
mutations) and the majority (9 of 14) were deletions. Ten null mutations (26%), 
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including 8 deletions, I insertion and I splice junction mutation, were located within 
exons 5-8. [n a larger study Casey et alB have reported similar findings. Of 108 
ovarian tumours from midwestern U.S. women 62 (57%) cases showed mutations in 
exons 2-11. Twenty-two tumours showed either deletions, insertions, nonsense or 
splice junction mutations. Twelve of these 22 non-missense mutations, including 8 
deletions, 2 insertions, I splice junction and I cryptic splice mutation, were located 
within exons 5-8. Thus, in these American women the majority of non-missense 
mutations in exons 5-8 are deletions whereas in our study nonsense mutations (7 out 
of 10) predominate with a nonsense mutation in exon 6 (213A<g->sIoP) being most 
prevalent (5 out of 7). This C:G to T:A transition has been described in I ovarian 
tumour thus far. 14 Nevertheless, codon 213 is a more frequent target for nonsense 
mutations in other human cancers like colorectal (41 % of all nonsense mutations), 
gastric (33%) and breast (21 %) carcinoma.6 A codon 213 nonsense mutation has also 
been described as a gernlline mutation in a Japanese family with Li-Fraumeni like 
syndrome lS and recently, this mutation was detected in a German family with Li-
Fraumeni syndrome. 16 Furthermore, codon 213 has also been described as a neutral 
polymorphic site with a silent mutation in the third position of the codon, occurring in 
3-10% of the n0I11131 population. 17 As expected, we also observed 2 neutral 
polymorphisms at codon 213, concordant with these published data. 
Both exogenous carcinogens and endogenous biological processes are known to 
cause mutations I and may contribute to ovarian carcinogenesis to different extents in 
different populations. Since codon 213 consists of a CpG dinucleotide, which is a 
target for cytosine methylation, the nonsense mutation at codon 213 could be the 
result of endogenous deamination of 5-methylcytosine to thymine. Denissenko et al 18 
have suggested that methylated CpG dinucleotides, in addition to being an 
endogenous promutagenic- factor, may represent a preferential target for exogenous 
chemical carcinogens. Thus, perhaps a combination of endogenous alteration and 
exogenous carcinogen could be responsible for the high prevalence of the nonsense 
mutation at codon 213 in this study. All patients with codon 213A<g-.Stop nonsense 
mutations were Caucasian and were living in the same area. However, no overall 
increase in mutations at other CpG dinucleotide sites in the TP53 gene was observed 
compared with TP53 mutation databases (update 1997: hllp'Usullsite UIlC cdul 
dnam/mainpage.html).1.6 
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In addition to the null type mutations, a splice junction mutation was observed. 
This splice junction mutation deletes the final 5 bases at the intron-exon junction of 
exon 5. This results in the use of an alternative splice acceptor in exon 5 causing a 21 
bp deletion spanning codons 126-132 in the messenger RNA. Casey et a18, using only 
mRNA to study TP53 mutation, have also described this 21 bp deletion. Since they 
did not investigate the genomic structure, it is tempting to speculate that this 21 bp 
deletion starting at codon 126 is also the consequence of a splice junction mutation. 
Another intriguing sample was a tumour in which 2 nonsense mutations were 
encountered and no itrnllunohistochemical staining was observed. These mutations 
were demonstrated not to be assigned t.o the same allele. Since published data have 
shown that ovarian carcinoma is mainly of unifocal origin 19.20, we speculate that the 
mutations are located on both alleles. Interestingly, this patient had a disease free 
survival of only 2 months. 
In summary, we have encountered a high prevalence (9 of 64) of tumours with 
non-missense mutations in exons 5-8 of the TP53 gene in ovarian cancers from the 
southwestern part of The Netherlands. The majority (9 of 10) of non-missense 
mutations were null type mutations leading to tnmcated proteins. All tumour 
specimens with null type mutations did not show detectable innllunohistochemical 
staining. We thus conclude that immunohistochemistry misses a subsk1ntial number of 
mutations in ovarian cancer and this may have severe impact on protein-based studies 
on the prognostic significance of TP53. Furthermore, a frequent nonsense mutation 
(codon 213 Arg~Stop) in TP53 in 5 of 64 (8%) tumour specimens is an important 
finding. The nature of the high prevalence of this mutation is unknown. Molecular 
epidemiological studies, including patient characteristics, ethnicity, place of 
residence, clinical course and mutagen exposure will be necessary to better 
understand the high prevalence of the nonsense mutation at codon 213. Studies on 
larger series of ovarian tumours are needed to elucidate whether this clustering is 
typical for the southwestern part of The Netherlands or also occurs in ovarian tumours 
from other parts of The Netherlands. 
Acknowledgements 
The authors thank Ms. 1.L. Van Staveren and Ms. 1. Verwaard for technical assistance. 
We are grateful for the suppDl1 of the Dutch Cancer Society (grant DDHK 94-840). 
82 
CHAPTER 3 
References 
I. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor 
gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-78, 1994 
2, Harris CC: The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: 
insights from the mutational analysis of the p53 tumour-suppressor gene. Bf J Cancer 
73:261-9, 1996 
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-6, 
1991 
4. Wynford-Thomas 0: P53 in tumour pathology: can we !nlsl immunocytochemistry? J 
Pathol 166:329-30, 1992 
5. Shelling AN, Cooke IE, Ganesan TS: The genetic analysis of ovarian cancer. Bf J Cancer 
72:521-7, 1995 
6, Cariello NF, Cui L, Berond C, et al: Database and software for the analysis of mutations in 
the human p53 gene. Cancer Res 54:4454-60,1994 
7. Skilling JS, Sood A, Niemann T, et al: An abundance of 1'53 null mutations in ovarian 
carcinoma. Oncogene 13:117 M 23, 1996 
8. Casey G, Lopez ME, Ramos JC, et al: DNA sequence analysis of exons 2 through 11 and 
immunohistochemical staining are required to detect all known 1'53 alterations in human 
malignancies. Oncogene 13:1971 M 81, 1996 
9. World Health Organization: WHO handbook for reporting results of cancer treatments. 
Geneva, World Health Organization offset publication, 1979 
10. Kottmeier HL: Presentation of therapeutic results in carcinoma of the female pelvis: 
experience of the Annual Report on the Results of Treatment in Carcinoma of the Utems, 
Vagina, and Ovary. Gynecol OncoI4:13-9, 1976 
11. Sambrook J, Fritsch E, Maniatis T: Molecular Cloning. A Laboratory Manual (ed 2). New 
York, Cold Spring Harbor, 1989 
12. Berns EM, Klijn JG, Smid M, et al: TP53 and MYC gene alterations independently predict 
poor prognosis in breast cancer patients. Genes Chromosomes Cancer 16: 170-9, 1996 
13. Hayashi K, Yandell DW: How sensitive is PCR-SSCP? Hum Mutat 2:338-46, 1993 
14. Milner BJ, Allan LA, Eccles DM, et al: p53 mutation is a common genetic event in 
ovarian carcinoma. Cancer Res 53:2128-32,1993 
15. Horio Y, Suzuki H, Ueda R, et al: Predominantly tumor-limited expression of a mutant 
allele in a Japanese family carrying a gennline p53 mutation. Oncogene 9: 1231-5, 1994 
16. Dockhom-Dwomiczak B, Wolff J, Poremba C, et al: A new gennline TP53 gene mutation 
83 
TP53 CODON 213 MUTATIONS IN OVARIAN CANCER 
in a family with Li-Fraumeni syndrome. Eur J Cancer 32A: 1359w 65, 1996 
17, Carbone D, Chiba I, Mitsudomi T: Polymorphism at codon 213 within the p53 gene. 
Oncogene 6:1691-2,1991 
18. Denissenko MF, Chen JX, Tang MS, et al: Cytosine methylation determines hot spots of 
DNA damage in the human P53 gene. Proc Nat! Acad Sci USA 94:3893-8, 1997 
19. Tsao S\V, Mok CH, Knapp Re, et al: Molecular genetic evidence of a unifocal origin for 
human serous ovarian carcinomas. Gynecoi OncoI48:5-10, 1993 
20. Abeln Ee, Kuipers-Dijkshoom NJ, Berns EM, et al: Molecular genetic evidence for 
unifocal origin of advanced epithelial ovarian cancer and for minor clonal divergence. Bf J 
Cancer 72: 1330-6, 1995 
84 
CHAPTER 4 
REDUCED EXPRESSION OF SAX IS ASSOCIATED 
WITH POOR PROGNOSIS IN PATIENTS WITH 
EPITHELIAL OVARIAN CANCER 
A MULTIFACTORIAL ANALYSIS OF TP53, p21, 
SAX AND SCL-2 
M Schuyer, MEL van der Burg, SC Henzen-Logmans, JH Fieret, 
JGM Klijn, MP Look, JA Foekens, G Stoter and EMJJ Berns 
submitted 
86 
CHAPTER 4 
Summary 
Purpose: Traditional clinicopathological features do not predict which patients 
with ovarian cancer will develop chemotherapy resistance. The TP53 gene is 
frequently mutated andlor overexpressed in ovarian cancer but its prognostic 
implications are controversial. Furthermore, little is known on the impact of TP53-
downstream genes on prognosis. Therefore we analyzed TP53 mutation and protein 
expression as well as the expression of the TP53-downstream genes p21, BAX and 
BCL-2 in ovarian tumor tissues and evaluated the results in relation to clinico-
pathological parameters, clinical outcome and response to platinum-based 
chemotherapy. Methods: Expression of TP53, p21, BAX and BCL-2 was studied 
using inul1unohistochemical analysis. TP53 mutation status was studied using SSCP 
and sequencing. Associations of tested factors with patient and tumor characteristics 
were studied by Spearman rank correlation and Pearsons X' test. The Cox proportional 
hazard model was used for univariate and multivariate analysis. The associations of 
tested factors with response were tested using logistic regression analysis. Results: 
TP53 mutation, p21 and BCL-2 expression were not associated with increased rates of 
progression and death. Expression of TP53 was associated with a shmier overall 
survival only (relative hazard rate [RHR], 2.01; P = .03). Interestingly, when 
combining TP53 mutation and expression data, this resulted in an increased 
association with overall survival (P = .008). BAX expression was found to be 
associated with both a longer progression-free (RHR, 0.44; P = .05) and overall 
survival (RHR, 0.42; P = .03). Those patients whose tumors simultaneously expressed 
BAX and BCL-2 had a longer progression-free and overall survival compared to 
patients whose tumOl'S did not express BCL-2 (P = .05 and .015 respectively). No 
relations were observed between tested factors and response to platinum-based 
chemotherapy. Conclusiou: We conclude that BAX expression may represent a novel 
prognostic factor for patients with ovarian cancel'. The combined evaluation of BAX 
and BCL-2 may provide additional prognostic significance. 
Introduction 
Epithelial ovarian cancer is the most lethal gynecologic malignancy in Western 
countries. About 70% of the patients present with an advanced stage meaning that 
widespread intraperitoneal metastasis has already occurred. Despite a high overall 
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clinical response rate to modern treatment, including debulking surgelY and platinum-
based chemotherapy, reported 5-year survival rates for women with advanced ovarian 
cancer are still less than 25%,1 Although the majority of patients initially respond to 
chemotherapy, two thirds of the patients will die due to progressive disease that has 
become refractoty to chemotherapy. I The prognostic characterization of ovarian 
cancer patients is currently routinely based on c1inico-pathological criteria. These 
features, however, have been proven insufficient to define prognostic subgroups and 
to accurately predict response to chemotherapy. Identification of new prognostic 
factors to select patients with good or bad outcome might help to improve treatment. 
The resistance of tumors to platinum-containing chemotherapy has been a matter 
of great interest during the past decade. The cytotoxic effect of cisplatin and its 
analogues is mediated through the interaction with DNA and formation of a variety of 
DNA adducts, followed by the induction of programmed cell death (apoptosis) and/or 
other mechanisms of cell death,2.3 It has been suggested that defects in the apoptotic 
pathway can result in chemotherapy resistance.4 Many genes that either positively or 
negatively influence apoptosis have been identified among which are members of the 
BCL-2 gene family. The BCL-2 protein has been related to the inhibition of apoptosis 
and also to prolonged cell survival following DNA-damage.5•6 On the other hand, the 
BAX protein, another member of the BCL-2 family, accelerates apoptosis and 
antagonizes the anti-apoptotic function of BCL-2. 7 BAX has been shown to 
homodimerize as well as to heterodimerize with BCL-2, and the balance between 
BAX and BCL-2 is crucial for survival following an apoptotic stimulus'? In addition, 
recent studies have demonstrated that BCL-2 and BAX regulate not only apoptosis 
but also the cell cycle. Interestingly, the tumor suppressor gene TP53, which is 
mutated frequently (up to 50%) in epithelial ovarian tumors8, has besides cell cycle 
arrest, senescence and DNA repair, also been implicated in apoptosis. 
Several authors have reported that TP53 mutations, estimated by TP53 protein 
accumulation might be of clinical significance in ovarian cancer. However, the 
prognostic value of TP53 is still controversial.9 Tumor heterogeneity, small numbers 
of tumors and different techniques used for studying TP53 may be responsible for the 
repotied inconsistencies about the prognostic value of TP53. Moreover, it is not 
known how and to what extent TP53 mutation affects the function of the protein. 
More insight could come from the study of "downstream genes" of TP53. To date, 
genes considered to be target genes of TP53 include BCL-2, BAX, topoisomerase II, 
multidrug resistance gene I (MDR1), insulin like growth factor binding protein-3 
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(IGFBP3), vascular endothelial growth factor (VEGF) and the cell cycle inhibitor 
p2llWAFllelPl. 
For the present study, we used immunohistochemistry (IHC) to assess the 
expression of TP53, p21, BAX and BCL-2 in epithelial ovarian tumors. In addition, 
polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) 
and sequence analysis was applied to determine TP53 mutation status. Our aim was to 
analyze whether and which protein levels and/or mutational status are significantly 
related to patient characteristics, disease outcome and response to platinum-based 
chemotherapy. None of the factors investigated showed a clear association with 
response to platinum-based chemotherapy. However, we found that high BAX 
expression is a favorable prognosticator in univariate analysis. Our results suggest that 
BAX expression may be a novel prognostic factor for patients with ovarian cancer. 
Patients and Methods 
Patiellts alld tisslles 
In the present study 102 tumor tissue specimens from patients who underwent 
prim31Y surgery for ovarian cancer between 1988 and 1993 in hospitals in the 
southwestern p311 of the Netherlands were included. The median age of the patients at 
the time of surgely was 56 years (range 27-86). The disease was staged according to 
the International Federation of Gynecology and Obstetrics (FIGO).IO Tissue biopsies 
were placed on ice inmJediately following surgely and stored in liquid nitrogen. 
Ninety-one samples were resected from the tumor within the OV31Y whereas eleven 
samples were obtained from the tumor extension to the omentum. Histological typing 
and grading were assessed on paraffin-embedded tissue specimens according to the 
classification of the World Health Organization (WHO). All tissue samples were 
reviewed by the same pathologist (SH-L). A detailed description of patient and tumor 
characteristics is listed in Table I. Three patients received radiation and 81 patients 
were treated with post-operative chemotherapy. Platinum-containing therapy was 
given to 75 patients (71x cyclophosphamide/cisplatin; 3x cyclophosphamide/ 
carboplatin and Ix taxollcisplatin). The remaining six patients received 
cyclophosphamide (2x) or melphalan (3x) and in one patient treatment was not 
specified. Clinical response was assessed according to the standard WHO response 
criteria. I I In brief, complete response (CR) was defined as the disappearance of all 
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clinically measurable tumor lesions. Partial response (PR) was defined as a 50% or 
more decrease in size of all lesions. Stable disease (SO) was either a decrease in size 
of less than 50% or an increase in size of less than 25% of one or more measured 
tumor lesions. Progressive disease (PO) was either a 25% or more increase in size of 
one or more clinically measured lesions or the appearance of new disease 
manifestations. Twenty-one patients had a complete response, six in whom the CR 
was confirmed by second-look laparotomy: in three patients a pathologic CR and in 
the other three patients microscopic residual disease was observed. Response was not 
assessable in 40 patients, of whom 27 had no macroscopic residual tumor after 
surgery and 13 had residual tumor less than I COl. The median follow-up for patients 
still alive was 78 months (range 2-120 months). 
Table 1: Patient and tumor characteristics 
Patient and tumor No. of patients Patient and tUlllor No. of patients 
characteristics characteristics 
All 102 Residual disease 
FIGD stage None 42 
early (I-IIA) 34 ~ lern 28 
advanced (liB-IV) 68 > I em 32 
Histologic type Ascites 
serous 51 Present 55 
mucinous 13 Absent 46 
endometrioid 17 Unknown 
clear cell 6 Response to chemotherapy'" 
mixed 7 Complete 21 
poorly differentiated 8 Pmiial 4 
Tumor grade stable disease 
I 16 progressive disease II 
2 36 not assessable 40 
3 42 unknown 4 
unknown 8 
>I< For 81 patients who received posl-operative chemotherapy 
11/11/1111/ 0" i sf 0 C" e 1/1 i sf 1')' 
Immunohistochemical staining was performed by a peroxidase labeled 
streptavidin-biotin-complex technique on 90 tumor samples. Five micron thick 
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cryostat sections were fixed in 4% buffered formalin in case of TP53 and p21 or in 
acetone in case of BAX and BCL-2 and preincubated with 5% BSA-PBS for 5 
minutes. Endogenous biotin was blocked with avidin and biotin (Avidin-biotin 
blocking kit, Vector Laboratories, Burlingame, CA, USA) for 10 minutes 
respectively. Sections were subsequently incubated with the appropriate mouse 
monoclonal for one hour, i.e. for TP53 clone DO-I (I :200, Santa Cl1IZ Biotechnology, 
Santa Cl1IZ, CA, USA) and DO-7 (1:100, Dako, Glostl1lp, Denmark); for p21 clone 
2GI2 (1:100, Phanningen, San Diego, USA); for BAX clone 4FII (I mg/ml, 1:100; 
Beckman Coulter BV, Mijdrecht, The Netherlands); for BCL-2 clone 124 (I: 100, 
Dako, Glostrup, Denmark). After washing with PBS (2x 5 minutes), biotinylated 
rabbit anti mouse Ig (diluted 1:200, Dako) in PBS containing 2% normal human 
serum, was applied for 30 minutes followed by an incubation with peroxidase labeled 
streptavidin-biotin-complex (Vecta Stain Elite Peroxidase kit, Vector Laboratories, 
Burlingame, CA, USA) for 30 minutes. Visualization of the antibodies was performed 
by incubating the sections with diaminobenzidine tetra hydrochloride (Fluka Chemie, 
Buchs, Switzerland) in the presence of 3% hydrogen peroxide for 10 minutes. All 
reactions were performed at room temperature. Sections were finally counterstained 
with Harris haematoxylin, dehydrated and mounted with Pertex. Positive and negative 
controls were included. Sections were evaluated by two observers (SH-L and JHF). 
When possible, dependent on the amount of tumor tissue, 300 epithelial tumor cells 
were counted and results were given as the percentage positive tumor cells. 
Expression data were divided into two categories: low (,; 10% tumor cells) and high 
(> I 0% tumor cells) TP53 expression'lO (79 samples evaluable); no p21 (no staining in 
any of the tumor cells) and p21 (>0% tUlllor cells) expression (69 samples evaluable); 
low (,; 75% tumor cells) and high (>75% tumor cells) BAX expression, as determined 
by isotonic regression analysis l3 (52 samples evaluable); low (,; 40% tumor cells) and 
high (>40% tumor cells) BCL-2 expression l4 (88 samples evaluable). 
TP53 expression was the only marker studied using two different (DO I and D07) 
antibodies, which recognize overlapping epitopes. Staining results for both antibodies 
were similar in 65 tumors. However, a low level of staining (range 12-35%) was 
observed with D07 antibody in eight tumors that were inununonegative « 10% tumor 
cells) with DO I antibody. With respect to clinical correlations. only results with DO I 
~ntibody are shown. 
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DNA iso/atioll, PCR-SSCP alld seqllellcillg 
The tumor tissue was pulverized in the frozen state to a fine powder and 
homogenized in phosphate buffer according to the EORTC procedure. IS High 
molecular weight chromosomal DNA was isolated from 82 tumor specimens, of 
which 70 were also available for our immunohistochemical studies. DNA was isolated 
from an aliquot of the total tissue homogenate according to standard procedures. 16 
Exons 5-8 of the TP53 gene were subsequently analyzed by single-strand 
conformation polymorphism (SSCP).17 Following SSCP, products with an altered 
electrophoretic mobility were analyzed again. PCR products were then either 
subcloned into a TA-cloning vector (TA-cloning kit, Invitrogen BV, Groningen, The 
Netherlands) and sequenced (T7 sequencing kit, Pharmacia Biotech, Uppsala, 
Sweden) or were directly sequenced (AmpliCycle sequencing kit, Perkin Elmer Cetus, 
Norwalk, CT, USA). Electrophoresis was performed using a 6% denaturing 
polyacrylamide gel containing 8 M urea. Sequencing gels were autoradiographed 
without intensifying screens. 
Statistics 
The strength of the associations between TP53, p21, BAX and BCL-2 as 
continuous variables was tested by Speal111an rank con-elation. Pearson's x2-test was 
used for categorical variables. To test whether staining percentages for TP53 differed 
in tumor specimens with and without a mutation the Mann-Whitney test was used. A 
cut-off point for BAX expression was determined using isotonic regression analysis. I) 
The relationship between patient and tumor characteristics and TP53, p21, BAX and 
BCL-2 as categorical variables was tested using Pearson's x'-test. Overall and 
progression-free survival probabilities were calculated by the actuarial method of 
Kaplan and Meierls and the log-rank test was used to test for differences between 
groups. The Cox proportional hazard model was used for univariate and multivariate 
survival analysis. To evaluate whether factors contribute to the prognostic value of the 
classical prognostic factors in a multivariate analysis for progression-free and overall 
survival, patients were stratified by age, FIGO stage, residual tumor rest and the 
presence of ascites. The likelihood ratio test was used to test between models with 
variables in- and excluded. The association of variables with response to 
chemotherapy was tested using logistic regression analysis. All statistical analyses 
were performed with STATA statistical software (release 6.0 College Station, TX: 
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Stata Corporation). Two-sided P-values less than .05 were considered statistically 
significant. 
Results 
fllIIlI II110slaill illg 
The expression of TP53, p21, BAX and BCL-2 was studied by 
immunohistochemishy in primaIY ovarian tumors. Table 2 shows the imlllunostaining 
results for each marker. Seventy-nine tumors were evaluable for TP53 
inm1Unostaining with DO I antibody. In 31 specimens (39%) no nuclear 
inm1Unoreactivity was detected. For the other 48 samples, 13 tumor specimens (16%) 
showed TP53 staining in less than 10% of tumor cells and staining in over 10% of 
tumor cells was observed in 35 (44%) tumors. These latter specimens were considered 
positive using the cut-off point of 10% positive cells. Nuclear p21 expression was 
evaluated in 69 ovarian tumors. Nineteen specimens (28%) demonstrated p21 
imlllunoreactivity and were defined as positive. BAX inm1Unostaining was evaluable 
in only 52 tumors. Cytoplasmic BAX staining was observed in 45 tumors and 
according to the cut-off point of 75% tumor cells, 40 tumors (77%) were positive for 
BAX. Cytoplasmic BCL-2 inununostaining was evaluable in 88 tumors. Using the 
cut-off point of 40% positive tumor cells, 29 (33%) tumors were considered positive. 
No significant relationships were observed between TP53, p21, BAX or BCL-2 
expression. 
Table 2: Immllnostaining results 
TP53 p21 BAX BCL-2 
Neva!uablc 79 69 52 88 
Tumors with staining 48 *t 19 *1 45§ 48§ 
Range of staining 1-100 1-36 25-100 1-100 
Median staining 74 4 100 78 
Cut-off point >10 >0 >75 >40 
Positive tumors (%) 35 (44) 19 (28) 40 (77) 29 (33) 
>I< Only nuclear staining was considered. t Cytoplasmic staining was observed in 16 (20%) hlmor 
.specimens of which 15 also had nuclear staining. :j: Cytoplasmic staining was observed in 15 (22%) 
hllUor specimens of which 5 also had nuclear staining, § Cytoplasmic staining was considered. 
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TP53 gelle aiteratiolls alld relatiollship with iJlIlII/II/Ostaillillg 
Eighty-two epithelial ovarian tumor specimens were studied for TP53 mutations 
by PCR-SSCP analysis (exons 5-8) and sequencing. Among 36 (44%) tumor samples 
with altered migration patterns, 37 sequence alterations were detected. These included 
22 (65%) missense point mutations resulting in an amino acid substitution, 7 nonsense 
mutations (in 6 tumors) and 2 frameshift deletions, leading to premature termination 
of the protein (24%) and a splice junction mutation leading to an altered transcription 
product. Two neutral mutations and three neutral polymorph isms at codon 213, which 
generally occur in 3-10% of the normal population l9 , were not scored as mutations 
since these sequence alterations do not alter the amino acid. 
A significant correlation was observed between TP53 mutation and 
inul1unohistochemical status (P < .001). As expected, especially the missense 
mutations correlated with positive inul1unostaining. Of the 20 tumor specimens with 
missense mutations that were both analyzed by sequencing and 
inul1unohistochemistry, 19 specimens were found to be immunopositive (> 1 0% 
positive tumor cells). However, of the 7 tumor specimens with non-missense 
mutations that were also analyzed by inul1unohistochemistly, only the sample with a 
splice site mutation showed nuclear accumulation of the TP53 protein. FUl1hernlore, 9 
out of 36 mutation-negative specimens, which were analyzed for TP53 expression, 
demonstrated inul1unopositivity although the level of expression was lower (median: 
37%; range 15-90%) than that in illul1unopositive tumor specimens with a confirmed 
TP53 mutation (median: 90%, range 47-100%; P = .0001). 
Relatiollsllips with patiellt alld tlllllor characteristics 
A significant correlation was observed between TP53 mutation or overexpression 
and advanced FIOO stage (P = .008 and .02 respectively) and between TP53 
expression and the size of residual tumor after SurgClY, i.e. in tumors with a residual 
tumor rest larger than 1 cm TP53 expression was found more frequently (P = .004; 
Table 3). Furthermore, TP53 mutation and TP53 and BCL-2 expression were less 
frequently observed in more differentiated tumors, although these differences were 
not significant. Staining for p21 was more often observed in tumors of patients with 
residual tumor lesions larger than 1 cm (P = .04). No other relations were found 
between patient and tumor characteristics and p21, BAX or BCL-2. 
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Table 3: Relationships of TP53 mutation and TP53, p21, BAX and BCL-2 expression with patient and tumor 
characteristics 
Gene mutation Protein eXEression 
. __ .. _---
Factor TPS3 TP53 221 EAX ECL-2 
0 positive P-vaIue n positive p- o positive p- o positive p- positive p-n 
(%) (%) 
value (%) value (%) value (%) value 
All 80 31 (39) 79 35 (44) 69 19 (28) 52 42 (81) 88 29 (33) 
Age 
:s median 44 16 (36) 42 17(40) 37 8 (22) 25 18 (72) 46 16 (35) 
>median 36 15 (42) .63 37 18 (49) .47 32 11 (34) .24 27 22 (81) .42 42 13(31) .70 
FIGO-stage 
=ly 27 5 (I9) 27 7 (26) 22 4 (I 8) 16 13 (81) 29 11 (38) 
advanced 53 26 (49) .008 52 28 (54) .02 47 15 (32) .23 36 27 (75) .62 59 18(31) .49 
Tumor rest 
::; 1 em 53 17 (32) 54 18 (33) 46 9 (20) 34 28 (82) 59 20 (34) 
> I em 27 14 (52) .09 25 17 (68) .004 23 10(43) .04 18 12 (67) .20 29 9 (31) .79 
Ascites 
absent 37 13 (35) 36 13 (36) 31 7 (23) 24 19 (79) 37 10 (27) 
present 42 17 (40) .63 42 22 (52) .15 37 11 (30) .51 28 21 (75) .72 50 19 (38) .28 
Histology 
serous 38 18 (47) 39 21 (54) 35 10 (29) 27 19 (70) 45 18 (40) 
nOD-Serous 42 13(31) .13 40 14 (35) .09 34 9 (26) .85 25 21 (84) .24 43 11 (26) .15 
Grode 
1 11 2 (I 8) 10 3 (30) 7 2 (29) 9 6 (67) 12 2 (17) 
2 30 12 (40) 28 8 (29) 26 7 (27) 14 13 (93) 31 13 (42) 
3 33 IS (45) .27 35 19.(54) .O~ 32_ 8.1;!5) _ .~ _ 27_ I2J101_ 2L_ ~ 12 (32) .28 
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Progressioll-free alld overall survival 
In Cox univariate regres'sion analysis, older age, advanced FIGO-stage, larger 
tumor rest and ascites at presentation were significantly associated with a short 
progression-free and overall survival (Table 4). Patients with grade 3 tumors had an 
early progression compared to patients with grade I tumors. No association was 
observed between p21 or BCL-2 expression and progression-free or overall survival 
in univariate analysis. Patients with BCL-2 positive tumors, however, appeared to 
have a longer progression-free survival (median: 36 months) and overall survival 
(median: 59 months) compared to patients with BCL-2 negative tumors (median PFS: 
27 and os: 34 months) but the differences were not statistically significant (Kaplan-
Meier curves not shown). TP53 protein expression was found to be associated with a 
pOOl' overall survival (Table 4). As shown in Figure IB, patients with TP53 
immunopositive tumors experienced an earlier death (P ~ .03) compared to patients 
with TP53 negative tumors. Although there was a trend toward a poor progression-
free survival in patients with TP53 immunopositive tumors, this difference was not 
statistically significant (Figure IA). Patients whose tumors showed TP53 mutations 
also tended to have a worse progression-free and overall survival compared to patients 
whose tumors exhibited no mutations. However, these differences were not 
statistically significant (Figure IC and 0). Categorizing TP53 mutation to missense 
mutations, which generally lead to immunocxpression, and non-missense mutations, 
did not result in a relation between mutation and prognosis either (Table 4). Next we 
combined the results of the genetic and immunohistochemical TP53 analysis. Patients 
whose tumors demonstrated a mutation and/or itmnunopositivity had a similar 
progression-free and overall survival and were thus combined ("TP53 rest"). Patients 
with both mutation negative and immunonegative tumors, however, had a better 
progression-free (P ~ .07) and overall survival (P ~ .008) compared to patients with 
either one or both parameters positive (Figure I E and F). 
Figure 1 (II ext page): Progressioll·free allli overall survival as a filllctioll of TP53 
illlllllllloitistocitemical (A alld B), mlltatlollal (C alld D) allli immlllloitistocltemical alld 
IIll1tatiollal statlls combilled (E alld F). The resl grollp illeludes paliellis with mllialioll 
negalil'elimmulloposWve, mutation positive/immuflonegative and mutation positivel 
immulloposilive IU1110rs, The cut-off point Ilsed Jor TP53 e.\pressioll was 10% positive 
IUllIor ceils. NlImber ill parelliheses illdicale IIl1mber of relapses or deaths/lotal ill each 
grollI'. 
96 
A 
,.00- r Progression~free survival 
'" i~ t 0.80-;  
~ 0.60 - ~ ~ TP53low (21/42) 
:2 0.40 - "-" TP53 high (20132) 
£ ,.><>-
P~.18 
0·00 -
RHR (95% ell: 1.53 (0.82·2.83) 
, , 0 
" 
,. 
'" 
.". 
" "-TP:'.'_ ., 
" 
~ 
" Tr:;Jh.p l2 
" " " 
. . 
C 'OO-i~ 
~ 0.60-1 ~;~~~ '"" 124/46) ~ ~~ 8~n 
'0 - TP53 m'tatioo (1 
~ 0.60 _ 
~ OAO-
D 
£ ,.><> -
p= .10 
I RHR (95% ell: 1.69 (0.91-3.13) 
0.00 - , I I I I 
(I 12 ~ ~ _ .~ 
~'­Tn)m""''''. 
E (/) '.oo-~ 
& 0.80-1 ~~ 
'0 
~ 0.60-
:5 
J'l '.<0-
£ ,.><> -
p= .07 
~ 
TP53 mutation negative 
and immunonegative (12/25) 
TP53 rest (21134) 
I RHR (95% CI): 1.93 (0.94-3.94) 
0.00 - I I I , 
'"""'''''nI'mm_''''''''· .... ". 
TP5h"" "" 
12 ~ ~ q 00 
" 
" 
Months 
B Overall survival 
1.00 -
'" 
0.80 -
0 
'0 000-
~. 
rc~ ~ T!'.$>-.I'_w-D_~ ,  ~-
~~) :5 m 0.40 -
D 
£ ,.><> -
p= .03 
0.00 -
RHR (95% ell: 2.01 (1.08-3.74) 
, 0 
" 
,. 
'" 
.". 
" TP5.'""", " " " Tf>5.' to",_ "" 
" " " " 
D "OO-'~~~ ~ ,-,,-' ~ -~WildJM~) 
'0 0.60 - "-----~ -P~53 mutallon (19/30) ~ l...k;-~-'-'L-:g 0.40-
e 
~ ,.><> -
P"'.10 
0.00 -
RHR (95";;' ell: 1.66 (0.91-3.05) 
, , 0 
" 
,. 
'" 
.". Jo 
"-
" " " 
... ,I~ 'YP< .~ ~ ~ TP~J m"""oo" 30 
" 
(f) --,-- TP53 mutation negative 
o 0.80 - '--. ~'"L, L-..,_<lD!:Um!D.u.I).9.Qegative (19f30) F "00-
1 '0 '------L (9127) >- 0.60-: '3 ~ 0.40- ~_3_~5) £ 0.20 -
p; .008 
0.00 _ I RHR (95% CO: 2.85 (1.31-620) 
o 
""-
mUb"""'""",.""",,, '" T""~ "'" " 
" ~ 
" 
,. 
" 
" 
Months 
'" 
." Jo 
MULTlFACTORIAL ANALYSIS OF TP53, p21, BAX AND BCL-2 
High BAX expression was associated with a favorable progression-fi'ee (P = .05) 
and overall survival (P = .03; Table 4 and Figure 2A and B). The median progression-
free and overall survival of patients in the high BAX group was 27 and 54 months 
respectively compared to II and 18 months in the low BAX group. In an exploratory 
subgroup analysis in patients with advanced disease (n = 32 for PFS; n = 35 for OS), 
BAX expression was also significantly associated with a longer progression-free 
(RHR, 0.40; 95% CI, 0.17 to 0.95; P = .04) and overall survival (RHR, 0.43; 95% CI, 
0.19 to 0.97; P = .04). Since BAX and BCL-2 are antagonists and known to form 
heterodimers, we studied whether the combined evaluation of BAX and BCL-2 
expression provided additional information on overall or progression-free survival. 
All patients with a low expression ofBAX in their tumors had a similar poor survival, 
irrespective of BCL-2 status. However, of the patients with BAX positive tumors, 
those simultaneously expressing BCL-2 showed a significantly longer progression-
free and overall survival compared to patients whose tumors did not express BCL-2 
(Figure 2C and 0). 
MlIltivariale Allal),sis for Progressioll-ji'ee alld Overall SlIrvival 
A possible independent prognostic significance of BAX or TP53 expression was 
examined by Cox multivariate analysis for progression-free and overall survival. 
Univariate analysis (Table 4) showed that age, FIOO stage, residual tumor rest after 
cytoreductive surgelY, and the presence of ascites are factors that strongly predict 
disease outcome and survival. Van del' Burg el al and Neijt el al have also described 
this.20,21 In multivariate analyses patients were stratified by these factors. BAX 
expression and grade, both significantly related with progression-free survival in 
univariate analysis, were included in the model. Only BAX expression tended to 
predict progression (RHR, 0.35; CI, 0.11 to 1.11; P = .075). In the multivariate 
analysis for overall survival, BAX or TP53 expression was tested but neither was 
found to be independently associated with survival. 
Figllre 2 (lIexl page): Progressioll-free alld overall sllrvival as a jilllclioll of BAX 
illllllUllOflislocflemical staills (A alld B) alld BAX alld BCL-2 illlllllllloflislocflemical 
slaills com billed (C alld D), The Clll-oj)'poillillsed for BAX expressioll was 75% alld for 
BCL-2 expressioll 40% positive 11111101' cells. Nlllllber ill parelllheses illdicale IIlImber of 
relapses 01' dealhs/lolal ill each grollp. 
98 
A '00 _ Progression-free survival 
& oao-It>_,-
'0 I . '->. 0.60 - , ~ L ~-~-----, Sax high (20137) 
2 0.40-: 
~ I ~ Baxlow (8/11) 
....... 0.20-
P=.OS 
0.00 _ ; RHR (95% ell: 0.44 (0.19-1.01) 
&Xn,gh 
~ .. 
6 
" ~
c '.00 - ~U--, 
,. 
,; -, ~ '" , '. 
, 
- " 
~ 080-\~~ ~ MO-' l ~Baxh;9hfBd-2h;9~(5111) 
:2 0.40 - tBa:< high/ 8cJ-2 Jow (15125) 
o 
ct 0.20 _ P = .05 "'Sax low (8/11) 
; t vs· RHR (95% GIl: 0.33 (0.11-1.00) 
0.00 _ I :l:vs· RHR (95% CO: 0.52 (0.22-125) 
, , , 
o 12 24 
--B:c< hJghl!kI-~ high " Sax h,gl"Bd-~ 1_ 2:> 
Bax low " '.  
Months 
'6 
-
'0 
B '00 _ Overall survival 
(/J oao-~ ~ I ~ ~ ~ 060- ~ ~9~9) 
~o40-1  
a.. 0.20- Sax low (9/12) 
, P=.03 I RHR (95% Gil: 0.42 (0.19-0.93) 
0.00 - "-"========'--------~ 
I I I I I I 
o ,. _ _ _ M 
Sa>; high 
&xl_ --" 
, 
~ ~ 
, 
" 
o ,oo-~ _ 
;3 0.80 -! ~ ~9hf Bd-2 h;gh (4112) 
, 
" 
~ o.M-1 ~ L- L ~ 0.40 - ~ ~tBax high/ Bd-2 Jow 
-g I --
ct 0.20 _ ~p = .015 1"'Bax low (9/12) 
t vs • RHR (95% Gil: 0.25 (0.08-0.80) 
0.00 _ tvs" RHR (95% ell: 0.54 (0.24-124), 
au htgl\lBcl-2 ",gh 
Bax "'I;I\IBd-2 1_ 
~,~ 
6 
--
" ~
" 
, ,. 
, 
~ 
" 
2' 
-
Months 
..a , 60 
(16126) 
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Table 4: Cox univariate analysis of progression-free aud overall survival 
Factor* Progression-free survival O\'erall survival 
P-value RHR (95% CIlt P-value RHR (95% CI)t 
Age (continuous) .03 1.02 (1.00-1.04) .004 1.03 (1.01-1.05) 
>56 vs. s 56 year .02 1.94 (1.l2-3.35) .001 2.68 (1.53-4.69) 
FIGO-stage 
advanced vs. early <.001 8.80 (3.72-20.82) <.001 24.95 (6.05-102.88) 
Tumor rest 
>lcmvs. s tCIll <.001 5.53 (3.08-9.94) <.001 6.01 (3.40-10.64) 
FIGO-stage(ful11or rest 
advanced! s I em vs, early <.001 6.33 (2.57-15.61) <.001 17.77 (4.19-75.37) 
advanced! > I em YS. early 18.17 (7.10-46.48) 42.71 (10.02-182.06) 
Ascites 
present vs. absent .01 2.11 (1.20-3.72) <.001 3.05 (1.68-5.56) 
Histology 
non-serous VS. serous .21 0.71 (0.41-1.21) .24 0.73 (0.43-1.24) 
Grade 
grade 2 vs. grade I .03 1.95 (0.66-5.80) .18 1.27 (0.50-3.21) 
grade 3 VS, grade 1 3.27 (1.l4-9.36) 1.96 (0.81-4.75) 
TP53 mutation 
mutation vs. no mutation .10 1.69 (0.91-3.13) .10 1.66 (0.91-3.05) 
missense vs, no mutation .25 1.77 (0.90-3.50) .27 1.69 (0.87-3.28) 
non-missense vs. no mutation 1.50 (0.57-3.95) 1.60 (0.61-4.21) 
TP53 expression 
>1O%vs.s 10% .18 1.53 (0.82-2.83) .03 2.01( 1.08-3.74) 
p2 t expression 
>0% VS. 0% .32 1.40 (0.73-2.68) .49 1.26 (0.65-2.47) 
BCL-2 expression 
>40%V5.540% .37 0.75 (0.39-1.42) .31 0.72 (0.38-1.37) 
BAX expression 
>75 %V5. <75 % .05 0.44(0.19-1.01) .03 0.42 (0.19-0.93) 
• PFS (OS): n ~ 94 (n = 101) for clinico-pathological variables except for ascites and grade 
(I respectively 8 missing values); n ~ 48 (n ~ 51) for BAX expression; n ~ 82 (n ~ 87) for BCL-2 
expression; n = 65 (n = 68 ) for p21 expression; n = 74 (n = 78 ) for TP53 expression; n = 73 
(n = 79) for TP53 mutation. t RHR: relative hazard rate with 95% confidence interval (el). 
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Respollse to platillum-based chemotherapy ill advallced disease 
Of the 68 patients with advanced stage disease, 58 patients received platinum 
containing first-line chemotherapy. For three patients response was unknown and for 
21 patients response was not assessable due to no or small residual tumor rest after 
surgery. The overall clinical response rate was 68% (23/34), i.e. 19 patients achieved 
a complete response and four a pat1ial response. One patient had stable disease and 10 
patients experienced progressive disease. In an exploratory analysis we studied the 
association of the markers investigated with response to platinum-containing 
combination therapy in advanced stage disease. There was no significant association 
between response to chemotherapy (complete or patiial response versus stable or 
progressive disease) and p21, BAX, BCL-2 and TP53 expression or TP53 mutation. 
Discussion 
Besides the classical prognostic factors, it would be beneficial for patients with 
ovarian cancer if there were additional tumor-associated markers that could more 
reliably predict the rate of progression and/or the efficacy of response to 
chemotherapy. In the present study we determined the relationship between TP53 
mutation and expression and the expression of its downstream genes (i.e. the cell 
cycle inhibitor p21, the cell death agonist BAX and its antagonist BCL-2) and 
evaluated the outcome in relation to patient and tumor characteristics, survival and 
response to platinum-containing chemotherapy in patients with ovarian cancer. 
There is clear experimental evidence that TP53 aberrations playa critical role in 
the development and progression of ovarian cancer. However, the prognostic and 
predictive significance of TP53 aberrations (i.e. overexpression and gene mutation) is 
still unclear.9,12,22-38 The lack of unanimity may be due to the heterogeneous 
population of ovarian cancer patients as well as to methodological differences. 
FUl1hermore, miscellaneous chemotherapeutic regimens and different definitions of 
response make it difficult to evaluate the predictive value of response to 
chemotherapy. Since there still is a controversy with respect to the value of 
immunohistochemical or molecular based techniques39-41 , we have chosen to utilize 
both approaches to study the clinical relevance of TP53. In the present study we have 
found TP53 expression but not TP53 mutation to be of prognostic value. In univariate 
analysis, TP53 expression was found to be significantly associated with a poor overall 
survival (P ~ .03). However, as shown in multivariate analysis, TP53 expression was 
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not independently associated with survival. Interestingly, when combining TP53 
mutation and expression data, this resulted in an increased association with overall 
survival (P = ,008) whereas the association with progression-free survival was 
borderline significant (P = ,07), Patients whose tumors were both mutation- and 
immunonegative had a clear survival advantage compared to patients whose tumors 
had either a mutation andlor TP53 overexpression (RHR, 2.85; P = .006). Wen el a(l2 
have recently reported that the combination of both TP53 expression and mutation 
data results in a stronger prediction of outcome as well. However, more studies are 
needed to verify the prognostic value of the combined expression and mutation data. 
With respect to treatment, no association between TP53 expression or mutation and 
response to platinum-based chemotherapy was found in this relatively small group of 
advanced ovarian cancer patients. This is in agreement with data from previous 
immunohistochemical-based studies26•3o,34,42 but in contrast to other studies using 
either immunological9,24 or molecular-based techniques.27,28 
The presence of a TP53 aberration is not informative for the biological function of 
TP53. Additional information could be provided by the study of downstream genes of 
TP53, i.e. the cell cycle inhibitor p21, the apoptosis-related BAX and its antagonist 
BCL-2. Although TP53 regulates the expression of these genes ;11 1';1/,043 -46, we could 
not confirm any correlation between TP53 mutation or expression and expression of 
p21, BCL-2 or BAX in ovarian tumor specimens. This is consistent with findings 
from several other studies29,42,47-49 although an inverse correlation between TP53 and 
BCL-2 and between TP53 and p2l has also been reported in ovarian tumor 
tissues. 50,5 I The lack of a correlation between TP53 and its downstream genes may 
reflect the fact that expression of these genes can also be regulated by TP53-
independent pathways. 
Expression of p2l was only associated with tumor rest and not with any of the 
other patient and tumor characteristics studied. Furthermore, p2l expression was 
neither associated with clinical outcome or with response to platinum-containing 
chemotherapy. This is in agreement with a recent report that also failed to find an 
association between p21 expression and prognosis or response to platinum-based 
chemotherapy in 185 paraffin-embedded tumor specimens from stage III ovarian 
cancer patients. 47 However, in contrast to these findings and using a polyclonal 
antibody in 295 paraffin-embedded ovarian tumor specimens, Anttila el at reported 
that low p21 expression is a marker of poor overall survival.51 
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No statistically significant association between BCL-2 expression and survival 
was found. However, patients with increased BCL-2 expression tended to have a 
better progression-free and overall survival compared to patients with low BCL-2 
expression in their tumors. Several studies have correlated BCL-2 with a survival 
advantage in ovarian cancer29,42,48.50 but failed to find an association with overall 
response to chemotherapy.42.48 In contrast, BCL-2 expression has also been reported 
to be associated with a poor prognosis and resistance to chemotherapy.52.53 Since 
BCL-2 is thought to function as an anti-apoptotic protein, a correlation between BCL-
2 expression and a favorable outcome may seem paradoxical. This inhibition of tumor 
cell growth by BCL-2 has also been observed in certain solid tumor cell lines and in 
breast cancer as well.54,55 Furthermore, it has been suggested that BCL-2 plays a role 
in the suppression of angiogenesis.56 Thus BCL-2 may have different functions in 
normal differentiated and in cancer cells. Moreover, there is also evidence that BCL-2 
functions as a pro-apoptotic protein in some circumstances since overexpression of 
the BCL-2 protein has been shown to increase the half-life of the BAX protein.57 
We have demonstrated the clinical relevance of BAX protein expression. High 
expression levels of BAX were found to be associated with an improved progression-
free and overall survival in univariate analysis. When corrected for classical factors, 
BAX expression tended to be an independent factor in multivariate analysis for 
progression-free survival. The clinical relevance of BAX expression has also been 
demonstrated by Tai el al. 58 In a comparable group of 45 ovarian cancer patients these 
authors showed that high BAX levels were associated with improved disease-free 
survival only. BAX expression was found not to be associated with overall survival, 
probably reflecting the short follow-up (median: 21 months) of the patients. In 
contrast, another study in 215 ovarian cancer patients described that BAX expression 
was correlated with a poor clinical outcome. 59 
Since BCL-2 is a critical factor for susceptibility to an apoptotic stimulus, the ratio 
of BCL-2 to BAX may be even of greater imp0l1ance.60 Surprisingly, in this study we 
observed that the combination of BAX and BCL-2 expression was a stronger 
predictor of outcome than BAX expression alone. Patients with both BAX and BCL-2 
positive tumors showed a better survival compared to patients with BAX 
positive/BCL-2 negative tumors. BCL-2 status did not add on the prognosis of 
patients with BAX-negative tumors. 
H has been suggested that BAX may be involved in the development of cisplatin 
resistance.61 A cisplatin-resistant ovarian cancer cell line was found to have reduced 
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BAX mRNA levels, which is consistent with the loss ofTP53'sabilitytotransactivate 
BAX as a consequence of TP 5 3 mutation. As in the present study, BAX levels did not 
significantly correlate with response to platinum-containing chemotherapy. An 
association between high BAX levels and improved response to combination therapy 
consisting of paclitaxel and cisplatin in a small group of 26 patients was observed by 
Tai et al.58 A relation between BAX and paclitaxel responsiveness has further been 
suggested by ill vitro studies showing that BAX could preferentially sensitize ovarian 
cancer cells to the effects of paclitaxel and vincristine, as opposed to carboplatin or 
ionizing radiation.62-64 The relation between BAX expression and response to 
paclitaxel needs further investigation. 
In conclusion, TP53 expression but not TP53 mutation was found to predict 
overall survival in ovarian cancer patients. The combined evaluation of TP53 
mutation and protein expression provides additional infol1nation, especially in those 
patients whose tumors are negative for both expression and mutation. Furthermore, 
high BAX expression was found to be associated with a favorable outcome in 
univariate analysis. The simultaneous evaluation of BAX and BCL-2 expression 
provides additional prognostic information when compared to BAX alone. Future 
studies should therefore focus on the ratio of BCL-2 to BAX in relation to clinical 
outcome. 
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Summary 
Borderline ovarian tumors are intermediate in their clinical behavior between 
benign adenomas and malignant neoplasms, and are associated with overall IO-year 
survival rates in excess of 90%. It is unclear whether borderline tumors represent a 
biological continuum of stepwise progression toward invasive carcinoma or whether 
they are distinct entities, each arising de novo. The characterization of oncogenes and 
tumor suppressor genes, such as K-RAS and TP53 may give insight into the biology of 
borderline tumors and/or may also serve as markers associated with prognosis. We 
observed that TP53 mutation is infrequent in borderline tumors. In contrast, K-RAS 
mutations are more common, having been found in 27% of borderline tumors. 
Interestingly, these mutations are strongly associated with the mucinous cell type. 
Introduction 
As early as 1929 Taylor l reported a series of patients with semi-malignant tumors 
of the ovary. However, it was not until 1973 that this group of tumors was formally 
recognized by the World Health Organization (WHO) and the International 
Federation of Gynecology and Obstetrics (FIGO) as a distinct categOlY with the 
interchangeable ten]]s cystadenomas of borderline malignancy and carcinomas of low 
malignant potential.2•J Ovarian borderline tumors constitute approximately 15% of 
ovarian tumors. Patients with borderline tumors are usually older than patients with 
benign neoplasms and younger than women with frank malignancies. Although 
borderline tumors have some clinical and pathological features in common with 
ovarian carcinomas, they usually behave relatively benignly even in the presence of 
widespread abdominal disease. Most borderline tumors are of the serous (60%) or 
mucinous (34%) histological subtype, with endometrioid, clear cell, Brenner and 
mixed epithelial types making up the remaining 6%. The major histological feature 
used to separate ovarian borderline tumors from invasive carcinomas is destructive 
stromal invasion. The distinction between a pushing border versus destructive 
infiltrative growth is often the only feature that differentiates a borderline tumor from 
one that is fully malignant. This sometimes makes this tumor difficult to classify. 
The survival of patients with borderline tumors is superior to patients with 
epithelial ovarian cancer. The 5-year survival rate is about 95% and 20-year survival 
is 80%.4 Borderline ovarian tumors often present as early stage lesions. SurgelY is the 
113 
K-RAS AND TP53 MUTATIONS IN BORDERLlNETUMORS 
recommended treatment for early-stage tumors and patients with these tumors have an 
excellent prognosis and a nearly 100% survival. Approximately 15% to 20% of 
patients with borderline tumors present with advanced stage disease at the time of 
diagnosis.4•s Stage III patients typically have a 56-73% survival long term.6 The 
benefit of postsurgical therapy in patients with advanced stage borderline tumors has 
not been well established.7 
Molecular analyses of oncogenes and tumor suppressor genes have contributed to 
the debate as to whether benign and borderline tumors are part of a continuum in the 
transformation of epithelial cells to malignancy. A similar pattern of mutations in 
benign, borderline and malignant tumors would be consistent with a continuum 
hypothesis whereas a different pattern of alterations would support the hypothesis that 
they are different entities. Some investigators suspect that borderline tumors, as 
intermediate form of malignancy, may be a precursor of invasive carcinomas whereas 
others believe that borderline tumors are separate biological entities. Indeed, several 
studies showed that the incidence of K-RAS mutation in ovarian borderline tumors 
was much higher than in invasive carcinomasS-II , suggesting that they might occur 
through independent pathways8 Other evidence, however, suggests that malignant 
epithelial tumors may result from the progressive transformation of benign andlor 
borderline tumors. 12 For example, loss of heterozygosity analyses showed no distinct 
patterns of loss between borderline tumors and adenocarcinomas but loss of 
heterozygosity was observed at lower levels in borderline tumors. IO Furthermore, 
benign or borderline epithelium has been identified in some serous and mucinous 
carcinomas suggesting malignant progression from altered benign epithelium. 13 
The relationship between borderline ovarian tumors and invasive epithelial ovarian 
carcinoma will become more clear as more genes are studied. Furthermore, the 
discovery of markers that can predict a poor prognosis should aid the clinician in 
making decisions about the therapy for a particular patient with a borderline ovarian 
tumor. The characterization of oncogenes and tumor suppressor genes, such as K-RAS 
and TP53 may give insight into the biology of borderline tumors andlor may also 
serve as markers associated with prognosis. Whereas the TP53 gene is the most 
commonly mutated tumor suppressor gene in human cancer, the K-RAS gene has been 
implicated as the most conmlOnly mutated oncogene associated with human tumors, 
including ovarian malignancies. The K-RAS gene is a member of the RAS gene t:1mily 
consisting of the three members N-, H- and K-RAS, which code for highly homologous 
proteins with a molecular weight of21 kDa. K-RAS localizes to chromosome band 12pl2 
114 
CHAPTERS 
and encodes a small membrane bound GTP-binding protein that serves as a relay signal 
from receptor tyrosine kinases (e.g. EGF/PDGF) to the nucleus. 14 In the active GTP-
bound confollnation p21-RAS protein transmits a signal to an effector molecule. The 
stimulation of signal transduction cascades results in the synthesis or activation of specific 
transcription factors, thereby stimulating cell proliferation. The transforming potential of 
K-RAS has been related mainly to point mutations in codon 12 although, sometimes, 
base substitutions occur in codons 13 or 61. Surveys of tumor series show that K-RAS 
mutations are commonly present in human adenocarcinomas originating at several 
sites, including colon (up to 80% of colorectal carcinomas), lung (up to 50% of lung 
adenocarcinomas), and pancreas (up to 90% of pancreatic carcinomas). 15-17 
Interestingly, K-RAS mutations have been detected in benign lesions of the colonic 
epithelium that precede the development of malignant tumors. 18 Therefore, K-RAS 
mutations have been suggested to represent early genetic events in the process of 
carcinogenesis. 
To get more insight in the biology of ovarian borderline tumors we have studied 
K-RAS and TP53 mutations and TP53 expression in borderline tumors and in the 
borderline components of carcinomas. 
Materials and Methods 
TUlIlor specimens 
Tumor specimens were obtained /i'om 30 patients diagnosed with a borderline tumor. 
Histology was assessed on paraffin material according to the World Health Organization 
criteria. 19 Serous tumors were graded according to Burks et al.43 Briefly, nuclear atypia 
was graded on a three-tier scale. Grade I was characterized by predominantly round to 
oval nuclei with relatively fine chromatin and small nucleoli; grade 2 by moderately 
enlarged, oval to more rounded nuclei with less evenly dispersed clu'Omatin and more 
prominent nucleoli; grade 3 by markedly enlarged pleomorphic and vesicular nuclei with 
many nuclei displaying prominent eosinophilic nucleoli. The same criteria were used for 
mucinous tumors. In addition, serous tumors showing a pattern of highly complex 
micropapillae stmctures were noted.43 Sections were evaluated by one pathologist (S-
HL). Nineteen tumor specimens were classified as serous and II as mucinous. Sixteen 
specimens were grade I, 7 grade II, 4 grade III and for 3 specimens grade was not 
detennined. In addition, seven so-called borderline components were collected: initially, 
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frozen tumor sections were found to contain borderline tumor components but, following 
revision, invasive areas pointing to carcinoma were also observed in the paraffin sections 
(archive material) of these tumors. In one case, the transition fOlm carcinoma to the 
borderline component was observed in the paraffin section. Four of the borderline 
components had a serous and three had a mucinous histology. All borderline components 
were grade III. 
DNA isolalioll alld PCR-SSCP 
High molecular weight chromosomal DNA was isolated fi'Om frozen tumor tissue 
specimens according to standard procedures.2o Mutations in K-RAS (exon I, encoding 
mutational hotspots codons 12 and 13) and TP53 (exons 5-8) were studied using 
Polymerase Chain Reaction-Single Strand Conformation Polymorphism (PCR-SSCP) and 
sequencing. PCR-SSCP for TP53 was perfOlmed as previously described. 21 ,22 
Exon I of K-RAS was amplified using intronic primers: KRI (5'-TGATAGT 
GTATTAACCTTATG-3') and KR2 (5'- TTTATCTGTATCAAA GAATG-3'). Cycling 
parameters were 94° for 4 min, followed by 25 cycles of 94°C for I min, 50°C for 1.5 min 
and noc for 2 min, and tellllinated by noc for 7 min. PCR products were diluted with 
miIliQ-H20 (1:4) and checked on ethidium bromide-stained agarose gels (1.3%). To 
decrease the false negative rate, PCR products were subsequently digested with HiIlJl, 
resulting in fragments of 95 and 154 bp. SSCP analysis was performed using a non-
denattlling 8% polyacrylamide gel containing 10% (v/v) glycerol. Gels were lun with IX 
Tris-borate-EDTA buffer at 30W for 6 to 7 hI' at room temperature. The colon cancel' cell 
lines SW-480 (codon 12:GGL.,GTT) and SW-1398 (codon 12:GGT--+TGT) and the 
breast cancer cell line MDA-MB-231 (codonI3:GGC--+GAC) were used as positive 
controls. Samples showing an altered migration pattem were analyzed again and 
independent PCR products were sequenced using a T7 sequencing kit (Pharmacia, 
Uppsala, Sweden) following subcloning using a TA cloning kit (Invitrogen, Leek, The 
Netherlands). 
11/11/1 /11/0 iii sl oc It e 1/1 is 1 ry 
Immunohistochemical staining for TP53 was perfOlmed on frozen formalin-fixed 5 
micron thick sections using a peroxidase-labelled streptavidin-biotin-complex technique 
as previously described.21 The monoclonal DOl (Santa emz) and D07 (Dako) antibodies 
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were used. Sections were considered positive when 10% of tumor cells showed a clear 
I .. 23 nuc ear stammg. 
Results 
K-RAS altem/iolls ill borderlille /1II/lOrs 
Seven out of 26 (27%) borderline tumors, which were studied for K-RAS mutations 
were found to have mutations in codon 12 (Table I). Interestingly, 5 of8 (63%) mucinous 
borderline tumors specimens showed mutations (3x Glyl2Val, 2x Glyl2Asp) compared 
to only 2 of 18 (11%) serous tumors (both GlyI2Val). 
TCGA 
--. 
• • 1IiIIII.. 
.. -
Wild type 
Codon 12:Gly 
T", 
T/ 
G 
TCGA 
-
-I11III 
.... -
.... II 
- .. 
Mutant 
Codon 12:Asp 
TCGA 
-. 
--
'. 
'!II' -Mutant 
Codon 12:Val 
Figllre 1: K-RAS codoll 12 IIIlIlaliolls ill ovariall borderlille IlIlIIors 
TP53 altem/iolls it/ borderlille /lIl11ors 
Thirty tumor specimens were studied for TP53 mutations. Mutation of TP53 was 
observed in only one mucinous tumor (Thr284Ala). In addition, two tumor specimens 
showed a conunon neutral polymorphism (Gly213Gly). With respect to 
immunostaining, the percentage of positive tumor cells ranged from <I % to 55% with 
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Table 1: K-RAS and TP53 alterations in ovarian borderline tumors 
TPS3 expression 
K-RAS TP53 (% positive tumor cells) 
Hislology Grade Age mutation mutation DOl D07 
serous
l 62 n.d. n.d. 
scrous 34 <1% <1% 
serous 28 <1% <1% 
serous 40 9 <1% 
serous 47 5% 3% 
serous 87 3% 12% 
serous
2 59 28% 8% 
serous
3 81 Glyl2Vai 30% 2% 
serous 40 Glyl2Vai 55% 30% 
serous II 74 n.d. <1% <1% 
serous II 43 2% 3% 
serous II 27 4% 6% 
serous II 32 8% 3% 
serous II 32 12% 10% 
serous II 43 31% 30% 
serous II 47 Gly213Gly 17% 16% 
serous III' 52 9% <1% 
serous III 34 17% 5% 
serous n.d. 49 9% n.d. 
mucinous 53 n.d. 7% 15% 
mucinous 56 n.d, n.d. 
mucinous 72 <1% <1% 
mucinous 47 2% <1% 
mucinous 68 Gly 12Asp 2% <1% 
mucinous 43 Glyl2Asp 5% 10% 
mucinous 69 n,d. Gly213Gly <1% <1% 
nnlCinolis III 26 Glyl2Vai <1% <1% 
mucinous III 48 n.d, Thr284Ala <1% <1% 
mucinous n.d. 83 Glyl2Vai 12% 12% 
mucinous n.d. 27 Glyl2Vai <1% <1% 
(n.d).: 110t detelmined (~): no mutation 
K~RAS mutations: Glyl2Val: GGT-;qrr Glyl2Asp: GGT-;GAT 
TP53 mutations: Gly2J3Gly: CGA-;CGG Thr284Ala: ACA-;GCA 
I) left ovary; right ovaty contains carcinoma; 2) implant on diaphragm; 
3) also contains adenoma; 4) micropapillary paltem 
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a median of 6% for the DO I antibody and 3% for the D07 antibody. According to the 
10% cut-off point, which is commonly used for invasive carcinomas21 ,23, TP53 
immunostaining with at least one monoclonal antibody was observed in ten of 28 (36%) 
tumor specimens analyzed. Only four out of 27 (15%) tumor specimens showed 
inullunopositivity with both monoclonal antibodies. 
K-RAS allli TP53 afleraliolls ill borderlille compollellis 
In addition, seven borderline components were studied from tumors that included a 
carcinoma component. Four of these borderline components showed a K-RAS mutation. 
Two of these Illutations (both Glyl2Val) were obselved among the serous tumors 
whereas the other two (both Glyl2Asp) were found in mucinous tumors. One mucinous 
tumor without K-RAS mutation showed a TP53 mutation in exon 8 of the TP53 gene 
(Arg273His). The resuits are summarized in Table 2. 
Table 2: K-RAS and TP53 alterations in borderline components 
TP53 expression 
K-RAS TP53 (% positive tumor cells) 
Hislology Grade Age mutation mutation DOl D07 
serous III 62 <1% <1% 
serous III 76 Glyl2Vai 15% 12% 
serous JII 29 Glyl2Vai 20% 15% 
serous m' 33 <1% <1% 
mucinous III 68 Glyl2Asp 26% 30% 
mucinous III 73 Arg273His 58% 65% 
mucinous m '34 Glyl2Asp 60% 20% 
(n.d.): not determined (-): no mutation 
I) micropapillary pattem 
Discllssion 
Despite substantial advances in our understanding of other adenocarcinomas, 
particularly in the colon, very little is known about the molecular evolution of ovarian 
tumors. It is likely that, as in other solid tUlllors, multiple events including inactivation 
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of tumor suppressor genes and activation of cellular oncogenes are required for the 
transformation of normal ovarian epithelium to benign, borderline, malignant and 
metastatic tumors. The issue of whether or not borderline tumors progress to fi'ankly 
malignant ovarian adenocarcinomas is an important one in screening for ovarian cancer 
and in the treatment of borderline tumors. The relationship between borderline ovarian 
tumors and fi'ankly invasive adenocarcinomas is now beginning to be explored with the 
tools of epidemiology and molecular biology. 
In an exploratOlY study we have demonstrated K-RAS mutations in 27% (7 out of 26) 
borderline tumors. Interestingly, borderline components were found to have more 
K-RAS mutations (4 out of 6 or 67%), although the number is small. Furthermore, it 
should be noted that only exon I of the K-RAS gene, encoding codons 12 and 13, has 
been analyzed. Although K-RAS mutations can also occur at codon 61, these mutations 
are rather infi'equent and therefore the prevalence of K-RAS mutations is not expected to 
be highly underestimated. The fact that K-RAS mutations are commonly detected in 
ovarian borderline tumors suggests that these changes may represent an early genetic 
alteration. High incidences of K-RAS mutations have also been observed by others. 
However, data conceming K-RAS mutations in invasive carcinoma are conflicting. 
Sevcral authors reported higher K-RAS mutation fi'equencies in borderline tumors (30-
50%) compared to invasive carcinomas (4%).8-11 Based on these observations it has been 
suggested that borderline tumors and invasive carcinomas each may follow a different 
molecular developmental pathway and thus are separate biological entities.s However, we 
observed K-RAS mutations more frequently in mucinous tumors (63%) than in tumors 
with a serous histology (II %). Likewise, other authors have also reported an association 
of K-RAS mutation with mucinous differentiation in ovarian borderline tumors andior 
invasive carcinomas.9.24-26 Interestingly, mucinous tumors represent approximately 35% 
of borderline tumors compared to only 10% of ovarian carcinomas. This may explain why 
some have observed a higher incidence of K-RAS mutations in borderline tumors 
compared to invasive carcinomas. Interestingly, by investigating only tumors with a 
mucinous histology, even more K-RAS mutations (85%) have been found in 
adenocarcinomas compared to borderline tumors (73%)27, which supports the hypothesis 
that borderline tumors represent a pathological continuum between benign and frankly 
invasive neoplasms. Since the different histological distribution of borderline tumors and 
invasive carcinomas has not been considered, the conclusion that borderline tumors and 
carcinomas arise independently is therefore not justified 
Finally, the association of K-RAS mutation with mucinous borderline tumors suggests 
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that it may playa role in maintaining the mucinous differentiation pathway of ovarian 
epithelial cells. Moreover, K-RAS gene mutations have been associated with a mucinous 
subtype in other types of human cancers as well, including colon, pancreas and lung 
carcinomas.28-33 These studies all SUpp011 the idea that K-RAS activation plays a role in 
the cellular pathway of tumor differentiation. 
With respect to TP53 alterations, we showed that mutation of the TP53 gene is 
infi'equent in borderline tumors. This finding is consistent with that of previous 
studies.8,34-36 In addition, several studies have also shown that TP53 overexpression is 
rather unconnnon in borderline tumors, although reported percentages varied from 4 to 
24% (mean between 10 and 15%).9,31-40 However, it should be noted that different 
antibodies, different methods of scoring (e.g. intensity or percentage of stained tnmor 
cells) and cut-off points and finally different tumor material (paraffin-embedded or 
frozen) make it difficult to compare studies. In the present study we have obselved 
immunopositivity for TP53 (using the 10% cut-off point) with at least one monoclonal 
antibody in 10 of 28 (36%) borderline tumors and 5 of 7 (71%) borderline components. 
When both antibodies are evaluated, only 4 of 27 (15%) borderline tumor specimens are 
considered positive. Surprisingly, the percentages of stained tumor cells are much smaller 
than usually obselved in ovarian adenocarcinomas,41 Furthermore, carcinomas that do not 
stain often completely lack any staining for TP53. It remains unknown why in the absence 
of TP53 mutations some borderline tnmor specimens reveal TP53 immunostaining. TP53 
mutations may have been missed due to the fact that they are located outside exons 5-8, 
Otherwise, the cut-off point of 10% positive tumors cells perhaps needs to be adjusted in 
case of ovarian borderline tumors. For example, using a 20% cut-off point, which has also 
been used for ovarian carcinomas42, only 2 out of27 (7%) tumor specimens score positive 
with both antibodies. 
In conclusion, we have shown that K-RAS mutations occur frequently in mucinous 
borderline tumors, Conversely, TP53 mutations are uncommon in borderline tumors. 
The role of TP53 accumulation in borderline tumors needs to be further investigated, 
It remains controversial whether borderline tumors are capable of progression to 
invasive carcinoma or whether they represent different entities. Some ovarian 
epithelial neoplasms are heterogeneous and benign, borderline and malignant components 
may coexist within an individual tnmor. It has been postulated that the benign or 
borderline areas might have preceded the development of the malignant component. In 
the cunent stndy seven borderline components adjacent to an area of invasive tumor 
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cells were investigated. An increased incidence of K-RAS and TP53 mutation and 
accumulation was observed in these borderline components compared to pure 
borderline tumors, suggesting that these tumors indeed progress to the malignant 
invasive phenotype through an accumulation of genetic alterations. It would be 
interesting, especially in these tumors, to study both the borderline and the invasive 
component. Microdissection techniques, however, are a prerequisite. 
Recently, some investigators have proposed to abandon the borderline categOlY 
and retum to the old benign-malignant classification system. Mucinous borderline 
tumors have a good prognosis and can be treated as benign tumors with the exception 
of those tumors associated with pseudomyxoma peritonei. These latter tumors are 
thought to be secondary neoplasms of the appendix. With respect to serous borderline 
tumors, these can be unevenly divided into a larger group of atypical proliferative 
epithelial cystadenomas and a smaller category of recently described noninvasive 
carcinomas, designated micropapillary serous carcinoma (MPSC).43,44 These latter 
neoplasms have a complex micropapillary architecture and often lack destructive 
infiltrative growth but appear to behave as low-grade invasive carcinoma. They are 
often associated with invasive implants that in turn are associated with recurrences 
and a poor prognosis. Therefore these tumors should be classified and treated as 
carcinoma.43.44 However, this class of tumors is not well characterized and currently 
there are no molecular markers available that distinguish between these tumors and 
the benign ones with a more favorable prognosis. Since TP53 alterations are common 
in serolls ovarian carcinomas and, additionally, predict a poor prognosis in ovarian 
carcinoma, TP53 mutation or overexpression could represent a suitable marker. 
However, only two tumor specimens in this study met the pathological criteria of a 
micropapillary serous tumor44 and no TP53 alteration was found in these tumors. One 
other studl5 also reported absence of TP53 mutations in micropapillary serous 
ovarian carcinoma. Interestingly, the latter study rep0l1ed a moderately intense TP53 
staining in these tumors. 
Further analysis of genetic abnormalities in larger tumor sets and in patients with 
follow-up may delineate the relationship between borderline ovarian tumors and 
epithelial ovarian carcinomas better, and will hopefully lead to a unifying hypothesis 
as to the origin of these important ovarian lesions. 
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Summary 
The identification of the breast/ovarian susceptibility genes, BRCAI and BRCA2 
was an important advancement in the field of breast and ovarian cancer research. 
About 40-50% of site specific hereditaIY breast cancers and up to 80% of hereditaIY 
breast-ovarian cancers result from mutations in the BRCAI gene. Although BRCA I 
mediates multiple functions in the cell, including a role in DNA damage repair and 
gene transcription, the role of BRCA I has not completely been elucidated yet. It has 
been suggested that mutational inactivation of TP53 may be required for BRCA 1-
associated tumorigenesis. Several studies have shown that TP53 is more frequently 
inactivated in BRCAI-associated tumors than in sporadic breast or ovarian cancer. Up 
to 90% of BRCAI-associated tumors harbor either a TP53 mutation and/or TP53 
protein accumulation. The remaining tumors may well have other alterations affecting 
the cell cycle checkpoint. Loss of this checkpoint may be obligatory for BRCA 1-
tumorigenesis. In this review, we discuss recent advances in BRCA I-research and 
stress the pivotal role TP53 may play in BRCAI-associated carcinogenesis. 
Introduction 
Since its identification in 1994, the human breast and ovarian cancer susceptibility 
gene (BRCAI) on chromosome 17q21 i has proven to be a gene of great interest. 
Inherited mutations in the BRCA 1 gene predispose women to breast and ovarian 
cancer and account for nearly half of familial breast cancers and for up to 80% of 
families with both breast and ovarian cancer.2 In addition, germ-line mutations of the 
BRCAI gene confer a substantially increased risk for prostate cancer in male 
probands.3 Moreover, a role for BRCAI as a potential human prostate tumor 
suppressor has been proposed.4 
Carriers of a BRCAI germ-line mutation have a 90% life-time risk to develop 
either breast or ovarian cancer2 although certain BRCAI mutations have been 
associated with a considerable lower penetrance.5 Compared to non-familial 
(sporadic) breast and ovarian cancel', BRCAI-associated tumors occur at younger age, 
are more frequently bilateral, are of higher histological grade, show an increased 
proliferative capacity (as demonstrated by higher S-phase fractions and higher mitotic 
index) and are more often aneuploid.6.9 Interestingly, the total number of 
chromosomal gains and losses, estimated by comparative genomic hybridization, has 
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been found to be twice as high in BRCAI-linked breast cancers than in sporadic breast 
cancers.
IO In contrast with sporadic breast cancer, tumors from BRCA 1 germ-line 
carriers are more frequently estrogen receptor (ER), progesterone receptor (PgR) and 
HER2/neu negative9,11 and demonstrate more TP53 alterations, The latter alterations 
are also more prevalent in BRCA I-associated tumors from ovarian cancer patients but 
alterations in the oncogenes K-RAS, ERBB-2 (HER2/lIell), c-MYC alld AKT2, all 
known to play a limited role in sporadic ovarian tumorigenesis, have not been 
reported. 12 
Whether the prognosis of BRCA1-related breast and ovarian cancer differs fi'om their 
sporadic counterparts is still a matter of debate. The prognosis for women with BRCA 1-
related breast or ovarian cancer has been rep0l1ed to be similar8,9,13-15 or worse l6,17 than 
that for age-matched breast or ovarian cancer patients without BRCAl mutations, In 
contrast with these studies, caniers with ovarian cancer have been reported to have a more 
favorable outcome thannon-caniers. 18 
The majority (86%) of BRCAI mutations that have been described are frameshift, 
nonsense or splice-site Illutations that generate a tnmcated BRCAI protein. 19 A genotype-
phenotype correlation has been suggested by Gayther et al20 who obsClved that mutations 
in the 3' third of the genc are associated with a lower proportion of ovarian cancer. 
Furthermore, mutations in either the amino or the carboxyl termini are conelated with 
highly proliferating breast cancers,21 Tumors fi'om BRCA1-germ line caIriers show loss of 
heterozygosity (LOH) around the BRCAIlocus at 17q21 which invariably involves loss 
of the wild-type allele,22-26 This implies that BRCA 1 may fimction as a tumor suppressor 
gene, The tumor suppressive function of BRCA 1 is fill1her sUPP0l1ed by experimental 
studies which show that antisense oligonucleotides accelerate the growth of normal 
and malignant mammaIY epithelial cell lines,27 Moreover, introduction of the wild-
type BRCAI gene inhibits growth of breast and ovarian cancer cell lines.28 
Interestingly, loss of heterozygosity at the BRCAIlocus also frequently occurs in sporadic 
b 29-32 d . . 3133-35 H . BJ'CA1' I reast an ova nan carcinomas.' owever, somatic \ mutations are rare y 
obselved in these tumors. 31 ,36.38 The reduction in BRCAI mRNA levels obselved in 
invasive breast tumors relative to the normal breast epithelium and carcinoma ill silll 
suggests a role for BRCA I in sporadic breast cancer?7 The reduced BRCA I levels in 
these tumors may result fi'om alterations other than coding-region mutations including 
LOH or deletion, preferential alellic expressionJ9 or hypermethylation of the promoter 
region,40,41 . 
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Both hereditary and sporadic cancer are thought to arise from an accumulation of gene 
defects. In addition to the germ line inheritance of a mutant BRCAI allele, not only the 
wild-type BRCA I allele has to be inactivated but other acquired somatic alterations must 
be involved in the development of a BRCA I-associated tumor as well. Recent studies 
suggest that the TP53 gene is a key factor in BRCAI-associated carcinogenesis. Besides 
an overview of BRCAI, this paper will focus on the proposed prominent role ofTP53 in 
BRCA I-associated carcinogenesis. 
BRCAI structure and function 
The BRCA 1 gene consists of 24 exons, spanning a 100 kb region on chromosomal 
band 17q21. The gene encodes a 1863 amino acid nuclear protein which is expressed 
in a variety of adult human tissues including breast, ovary, testis and thymus. I BRCA I 
expression is relatively high in tissues undergoing rapid growth and differentiation 
and has been shown to be regulated by the steroid hormones estrogen and 
progesterone42•43 The induction of BRCA 1 transcription by steroid hormones may 
however be indirect and rather be the result of the mitogenic activity of these 
hormones.44 Several reports have shown that the BReA I protein is expressed and 
phosphorylated in a cell-cycle dependent fashion, with levels increasing in late G I 
and maximum expression and phosphOlylation during the S- and M_phases.45•48 In 
cell lines several naturally occurring splice variants of BReA I have been 
identified.49,5o The subcellular localization remains controversial. BReA I has been 
localized to the nucleus51 but others have shown that BReAI localizes to the 
cytoplasm 52 
Functiollal domaills 
Molecular features of the BReA I protein reveal several characteristic domains 
(Figure I). Two putative nuclear localization signals (NLS I &2) are located in exon 
II but only NLS I is required for nuclear localization. 53 Based on sequence homology, 
BReAI exhibits a granin consensus sequence in exon 11.52 Granins are proteins 
localized to secretory vesicles and expressed in neuroendocrine tissues but their 
function is not clear. The N-terminal region of BReA I contains a RING finger 
domain. This zinc-binding cysteine rich sequence is also found in other proteins 
which mediate their function through protein-DNA or protein-protein interactions. 54 
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Furthermore, the C-terminal region of BRCA I includes an excess of negatively 
charged residues, correlated with a transcriptional activation function of BRCA1.55,56 
Apart from this trans activation domain (TAD), the C-terminal region encompasses 
two copies of a BRCAI C-tenninal (BRCT) domain, a newly recognized amino acid 
motif of approximately 95 amino acid residues, 57 These BRCT domains are thought to 
mediate protein-protein interactions and have been found in a large number of 
proteins involved in cell cycle checkpoint functions responsive to DNA damage 
including a TP53-binding protein (53BP I), DNA repair protein XRCC I, the 
Schizosaccharomyces pOll/be protein Rad4 and the Saccharomyces cerevisiae protein 
Rad9.58 
Illteractillg proteills alld trallscriptioll 
Reccntly, several newly discovered proteins have been shown to associate with 
BRCAI (Figure I), Using the yeast two-hybrid system Wu et al 59 identified a protein 
that binds to the RING finger domain of BRCAI. Interestingly, this BRCAI-
Associated RING Domain (BARD I) protein resembles BRCA I in that it contains an 
N-terminal RING domain and the C-terminal BRCT domains. BRCA I missense 
mutatiolls in the RING finger domain disl11pt the interaction with BARD I, implying 
that complex formation with BARDI may be essential in BRCA!-mediated tumor 
suppression. 59 Although infrequently, both germ-line and somatically acquired 
mutations of BARD! have been observed in breast, ovarian and uterine cancers, 
suggesting a role for BARDI in the development of these tumors,60 A second protein 
identified by means of a yeast two-hybrid screen for BRCA I RING finger interacting 
proteins, is the recently discovered BAP I (BRCA I-Associated Protein I), This 
protein is a nuclear-localized ubiquitin carboxy-terminal hydrolase that enhances 
BRCA I-mediated suppression of cell growth in colony formation assays,61 
Several lines of evidence suggest that BRCA I functions as a regulator of 
transcription, The transcriptional activation function of the C-terminal region of 
BRCAI was demonstrated by fusion to the DNA-binding domain of the GAL4 
protein,55,56 Recently, a C-terminal Interacting Protein (CUP, Figure I) has been 
described that specifically interacts with this transactivation domain of BRCA 1.62 
Although the function of CUP is unknown, the reported association of CUP with a 
transcriptional repressor (CtBP) points to a role in transcription. Furthermore, BRCAI 
binds to c-MYC ill vitro in both yeast and mammmalian cells and represses MYC-
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mediated transcription.63 Since c-MYC acts as a transcription factor promoting cell 
proliferation, this underscores the link between BRCA I, tumor suppression and 
transcriptional regulation. Additional evidence for the role of BRCA I in 
transcriptional activation is provided by the identification of BRCAI as a component 
of RNA polymerase II holoenzyme.64 The BRCAI protein is linked to the 
holoenzyme complex via RNA helicase A.65 Moreover, BRCA I interacts with CREB-
Binding Protein (CBP), also a component of RNA polymerase II holoenzyme with 
histone acetyl transferase (HAT) activity, suggesting that one of the mechanisms by 
which BRCAI functions is through recruitment ofCBP-associated HATIFAT activity 
'fi 66 to spec I IC promoters. 
Interacting proteins 
c-MYC 
RING finger domain NLS I NLS2 Granin motif 
Functional domains 
TP53 interaction 
domain II 
1863 
BRCT BRCT 
TAD 
Figure 1,' The lower part of the figure shows fimetional domains of BRCA I,' the RING finger 
domain (amino acids 21-67), two nnc/ear localization sequences (NLS1 & 2, amino acids 500-
508 & 609-615), a graninmotif (amino acids 1214-1223) and a transaetivation domain (TAD, 
amino acids 1528-1863) encompassing two BRCA1 C-terminal domains (BRCT). 171e upper 
part shows BRCA I-interacting proteins. BARD 1 and BAP I both bind to the RING finger 
domain of BRCA I. c-MYC can bind at two BRCA I-binding sites. ClIP binds to the 
transaetivation domain of BRCA1. TP53 also associates with the transactivation domain and 
ill addition interacts with a more N-Iermillal parI of the protein. hRAD5! associates with bill 
may not bind directly to BRCA I as indicated by dolted lines. 
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BRCAI alld TP53 
Further evidence for the role of BRCA 1 in transcriptional regulation was provided 
by Somasundaram et al67 who demonstrated that BRCA I transfected into mammalian 
cells trans activates expression of the cyclin-dependent kinase inhibitor p21IVAF/CIPI in 
a p53-independent manner and in this way contributes to cell cycle arrest. In addition, 
Ouchi et a168, using artificial and genomic promoter constmcts containing p53-
responsive elements showed that BRCAI could enhance TP53-dependent gene 
expression by acting as a coactivator. Mutant forms of BRCA I lacking the second 
BRCT domain showed reduced TP53-mediated transcriptional activation. Other data 
have shown that BRCAI and TP53 physically associate both ill vitro and ill vivo.69 
The interacting regions map to the N-terminal region (amino acids 224-500) of 
BRCA I (TP53 interaction domain I, see Figure I) and the C-tenninal domain of 
TP53. Recently, the second BRCT domain (amino acids 1760-1863) of BRCA I has 
also been shown to interact with TP53 (TP53 interaction domain II) and to stimulate 
TP53-dependent transcription from the p21IVAFI/CIPI promoter. 70 
In addition to a role in transcription regulation, studies with knockout mice have 
linked BRCAI to DNA damage response pathways. Mntant mouse embryos lacking 
Brcal function die early in development, between 6 and 13 days of gestation. 71 •n 
Smprisingly, these embryos show a decreased expression of the tp53 inhibitor mdm-2 
and an increased expression of the cyclin-dependent kinase inhibitor p21, the latter 
being a target for tp53 transcriptional activation.72•74 The increased p21 levels cause a 
G 1 cell cycle arrest which leads to reduced cellular proliferation in these mouse 
embryos. The early embryonic lethality in Brcal-deficient mice can be partially 
rescued by tp53 or p21 null mutation. 74•75 Double mutant embryos survive an 
additional 1-2 days of gestation which can be partially explained by the abrogation of 
the cell cycle arrest. 
BRCAI alld DNA repair 
COlToborating evidence that BRCA 1 is involved in DNA damage response pathways 
comes fi'om the observation that BRCA I associates with human RAD51 (hRAD51), a 
homolog of the bacterial RecA protein that is required for mitotic and meiotic 
recombination and for repair of double strand DNA breaks in the yeast S. cerevisiae.76 
Interestingly, TP53 has also been linked to homologous recombination processes via 
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interaction with hRAD51. 77,78 Whereas hRAD51 stimulates homologous 
recombination, TP53 has been shown to suppress homologous recombination 
processes. 79,80 
In mitotic S-phase cells BRCA I and hRAD51 colocalize to discrete subcellular 
nuclear foci (BRCAI nuclear dots)81 The second hereditaty breast cancer gene 
product BRCA2, which interacts directly with hRAD51 82,s3, and BARD I also localize 
to these nuclear bodies during the S-phase of the cell cycle.84,85 When S-phase cells 
sustain DNA damage, BRCA I becomes hyperphosphOlylated, disperses from dot 
structures and then accumulates together with BRCA2, hRAD51 and BARD at 
proliferating cell nuclear antigen (PCNA)-containing replication stmctures, implying 
an interaction of the multiprotein complex with damaged replicating DNA,48,85 These 
observations suggest that BRCA I, in cooperation with BRCA2, RAD51 and BARD I, 
responds to DNA damage and pat1icipates in a replication checkpoint response. The 
fact that mouse embryonic stem cells deficient in Brcal are defective in the ability to 
carry out transcription-coupled repair of oxidative DNA damage and their 
hypersensitivity to ionizing radiation86 underscores the role of BRCA I in repair. 
Moreover, mouse embryos lacking MmRad51 demonstrate reduced cellular 
proliferation and show an early embryonic lethality at the same stage as Brca I null 
embryos. Once again, emblyonic lethality can be suppressed in a p53 null 
background.87 
Based on these observations, Bmgarolas and Jacks88 suggested that mutational 
TP53 inactivation may be required for BRCA1-associated tumorigenesis, At least 
during early mouse embryogenesis, absence of Brca I function results in a failure to 
repair damaged DNA and activates a tp53-dependent cell cycle arrest. This cell cycle 
arrest can be overcome by elimination of tp53 or p21 function, which allows cells to 
proliferate as shown in Figure 2 (which represents an update of the model proposed 
Brugarolas and Jacks),88 The view of BRCAI acting as a protein to maintain genomic 
stability, coincides with the definition of caretaker genes as proposed by Kinzler and 
Vogelstein.89 'Caretaker' genes maintain the integrity of the genome, whereas 
'gatekeeper' genes regulate cellular proliferation and differentiation. Inactivation of a 
caretaker gene may cause genetic instability resulting in an increased mutation rate 
and initiation of a tumor, but only when a gatekeeper gene becomes inactivated, this 
process may progress rapidly. Thus, BRCAl may be included in the family of 
caretaker genes, whereas TP53 seems to fit the gatekeeper class more explicitly, 
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I Caretaker and gatekeeper roles of BRCAI and TP53 
WTBRCAI: 
DNA REPAIR 
DNA 
damage 
cyetin D 
eye lin E 
cyclin A 
cyclin B 
l 
NON FUNCTIONAL BRCA I: 
FAILED DNA REPAIR 
CHECKPOINT ACTIVATION 
WT TP53 A NON FUNCTIONAL TP53 
/' ,"OR P2I 
IMDM21-i~ .j. 
.j. PROLIFERATION 
cdk4/6 ~ G;] cdk2 cdk2 
.j. 
cdc2 CELL CYCLE 
ARREST 
Figure 2: The upper parirepresellis Ihe carelaker /tIllClioll of BRCAI. The 1II0dei suggesls 
Ihal RAD5I alld BRCAI alld BRCA2 logelher acl as a complex 10 repair damaged DNA. 
BRCAI lIIulalioll lIIay lead 10 acculllulatioll of DNA dalllage. Subsequent aclivation of a 
checkpoilll mechallism resulls ill activatioll of TP53 alld Ihe upregulatioll of p2I. This latter 
proleill illhibits cyclill-depelldelll killases which are respollsible for progressioll of Ihe cell 
cycle, Ihus resultillg ill cell cycle arresl (galekeeper /tll/ctioll of TP53 as represellied ill Ihe 
lower pari oflhejigure). Cells call escape lhis cell cycle arresl by Ihe illactivatioll ofTP53 or 
p2I. Sillce Ihe activity ofTP53 is lIegatively regllialed by MDM2, loss ofMDM2/tll/ctiollmay 
also be respollsible for the escape of cells /t'om the collsiraillis oflhe cell cycle. WT, wild-Iype 
TP53 alterations ill BRCA1-associated tumol'S 
Although the previous section predicts an almost all-important role of TP53 in 
BRCAI-associated tumorigenesis and BRCAI-associated tumors might be expected to 
exhibit loss of TP53 function, the final proof of which role TP53 really plays in 
BRCA I-associated tumorigenesis must come from tumors. In early studies, before the 
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discovery of the BRCA1 gene, immunohistochemically detected TP53 protein 
accumulation was seen more often in tumors from patients with familial breast (34%) 
or familial breast and ovarian cancer syndrome (52%) than in sporadic breast (22%) 
carcinomas.9o In addition, Glebov et al91 found a four times higher incidence of TP53 
mutation (58%) in tumors of patients with a family histDlY of breast cancel' (of 
unknown BRCA status) compared to sporadic breast tumors (13%). Since the 
discovelY of the BRCA 1 gene, Crook et al92 showed that eight tumor specimens from 
affected BRCA1 carriers all had TP53 mutations (Table I). In a larger series of both 
BRCA 1- and BRCA2-associated breast tumors the same authors demonstrate that 68% 
(19/28) of BRCA1-associated breast cancers show TP53 mutation compared to 35% 
(7/20) of sporadic grade-matched breast tumors.93 In the same study positive TP53 
immunostaining was found in 77% (20126) of BRCA1-associated breast tumors (Table 
I) compared to 35% (25/72) of sporadic breast tumors. Others observed positive TP53 
staining in 41 % (12/29) of BRCA1-associated breast cancers versus 17.5% of sporadic 
breast cancers.94 Interestingly, these authors repDl1ed TP53 accumulation more 
consistently in tumors with mutations in the RING finger domain ofBRCAI, pointing 
to a possible correlation between the site of the BRCA1 germ-line mutation and the 
presence of TP53 alterations. Recently, Phillips et al95 detected TP53 mutations in 10 
of 13 (77%) breast tumors from Ashkenazi Jewish BRCA1mutation carriers versus 10 
of 33 breast tumors (30%) from non-carriers. A high incidence of TP53 mutation has 
also been observed in BRCA1-associated ovarian cancers. Rhei et al 12 observed TP53 
mutations in 24 out of 29 (83%) ovarian tumors from patients with BRCA1 mutant 
alleles whereas 72% (21129) of the tumors revealed immunohistochemically 
detectable TP53 protein expression. It should be noted that in the latter two studies 
85% and 76% of the mutations respectively are represented by the Jewish founder 
mutation 185deiAG which locates to the RING finger domain. In contrast to these 
high frequencies of TP53 mutation in BRCA1-associated tumors, Schlichtholz et al96 
repDl1ed a low incidence of TP53 mutations (23%) in II breast and three ovarian 
tumor specimens of patients with a BRCA1 germ-line mutation. However, this may be 
underestimated since only exons 4-9 of the TP53 gene were analyzed. 
An invariable problem with the analysis of TP53 is that incomplete gene analysis 
or a small percentage of tumor cells may underestimate the TP53 mutation frequency. 
On the other hand, not all mutations result in TP53 accumulation. Null mutations 
leading to a tnmcation of the protein do not result in immunostaining and may account 
for more than 20% of the TP53 mutations.97,98 Othelwise, mutations that may have 
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Sobol et al (1997)94 
9' Crook et al (I997) -
Crook et al (1998) 93 
Schlichtholz et aI 
(1998)96 
Rhei et al (1998)12 
. . 9)95 Phllhps et al (199 
overall inci.dence: 
Table 1: TP53 mutations and protein accllmruation inBRCAI-associated tumors 
Tumor TP53 mutation2 % 
breast 
breast 
ovarian 
breast 
breast 
ovarian 
ovarian 
breast 
N.D. 
m 
III 
19128 
3111 
0/3 
24129 
10113 
64192 
100 
68 
27 
83 
77 
70 
TP53 
accumulation3 
12129 
N.D. 
N.D. 
20126 
5111 
112 
21129 
N.D. 
59/97 
% 
41 
77 
45 
72 
61 
TP53 mutation and 
accumulation 
combined 
N.A. 
N.A. 
N.A. 
22/26 
6111 
112 
28/29 
N.A. 
57/68 
% Remarks 
Observed association between positive TPS3 staining 
and SRCA1 mutations in the RJN'G finger domain 
Type of BRCAI mutations not dcscnbed 
85 TP53 exons 2-11 analyzed 
55 TP53 exons 4-9 analyzed 
97 TP53 exons 2-11 analyzed~ 93% Ashkenazi Jewish 
BRCAJ founder mutations: 185dc1AG (76%), 
5382insC (l7%t 
84 
TP53 exons 4-10 analyzed All Ashkenazi Jewish 
BRCAI founder mutations: 185deIAG (85%). 
5382insC (15%) 
'Only those papers are listed that clearly define BRCAI mutations. 2A direct but rather tedious approach to examine TP53 dysfunction is mutation analysis 
of the gene. The majority of TP53 mutations localize to the sequence-specific DNA-binding region comprising exons 5-8, which often leads investigators 
to study only this part of the gene. A detailed database of TP53 mutations in all human cancers including sporadic breast and ovarian cancers can be 
found on the website http://perso.curie.frrrhierrv.soussi. 3 A rapid and simple approach to study the TP53 gene is to examine TP53 protein expression. 
In its wild-type fonn, TP53 has a very short half-life. The majority of TP53 mutations (approximately 80%) result in stabilization of the protein, which 
allows for immunological detection. 'also referred to as I 87delAG and 5385insC. A database of BRCAI mutations can be found on httpll:www.nhgri.nih.gov/ 
intI1lmural Jesearch! Lab _ transferlbiciindex.htrnl; N.D.= not determined; N.A . = not applicable 
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been missed using mutational analysis may be detected using immunohistochemistry. 
In addition to mutation, dysregulation of normal TP53 protein may also cause TP53 
immunostaining. Binding of TP53 to the product of the MDM2 gene, for example, 
may result in TP53 protein accumulation. Therefore, the combined mutation and 
immunohistochemical data will give a better estimate of the actual incidence of TP53 
aben·ations. As expected, this gives a higher prevalence of TP53 alterations with all 
overall incidence of84% TP53 alterations in BRCA1-associated tumors (Table I). 
In conclusion, TP53 aberrations in BRCA1-associated tumors are two to three 
times as frequent (84%) as in sporadic breast and ovarian cancer. This suggests that 
loss of TP53 function may be an elemental step in the transfOlUlation of cells with a 
BRCAl mutation. 
Is TP53 dysfunction required for BReAl-associated tUlllorigenesis? 
Although the inheritance of a BRCAl germ-line mutation subsequently followed 
by loss of the wild-type allele are initiating events in the development of a BRCA1-
associated tumor, additional somatic mutations in oncogenes and tumor suppressor 
genes are required. Data from mouse models suggest that loss of TP53 function may 
be a critical event in BRCA1-related pathogenesis. Indeed, the data summarized in the 
previous section demonstrate that there is an indisputable increase in the frequency of 
TP53 abeITations in BRCAI-associated tumors compared to sporadic breast or ovarian 
tumors. However, the comparison of TP53 alterations in BRCA I -associated and 
sporadic tumors may be biased. Heterogeneity in histology could create a bias. For 
example, medullalY breast carcinomas are more common among BRCAI-associated 
breast cancer as compared to sporadic breast cancer. Furthermore, BRCA I alterations 
themselves may create a bias. The Jewish founder mutation 185delAG represents a 
large proportion of the BRCAI mutations studied so far. Approximately 90% of the 
BRCA1-associated tumors involve loss of heterozygosity. Therefore, in addition to the 
mutant germ-line BRCAI-allele these tumors may have an intact BRCAI-allele, 
allowing those tumors to develop through a different pathway that may not involve 
TP53-inactivation. Finally, the number of tumors investigated is still small and larger 
sample sizes are required for a better estimate of the TP53 mutation frequency. 
As yet, no other mutations have been reported in BRCAI-associated tumors. 
Although the incidence of TP53 abnormalities in BRCAI-associated tumors is high 
(84%, Table I), not all BRCA1-associated tumors seem to harbor a TP53 aberration. 
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Although the question "Is TP53 dysfunction required for BRCAi-associated 
tumorigenesis?" cannot be answered with affirmative "yes", the prerequisite of TP53 
dysfunction for progression of a tumor that is initiated by BRCAI is not yet 
disproven. In addition to an underestimation of TP53 aberrations due to technical 
difficulties, TP53 function may be eliminated through other mechanisms, such as 
hypennethylation or mutation of the TP53 promoter region or large chromosomal 
deletions involving the TP53 locus. If not TP53 itself, one or another component of 
the TP53-dependent cell cycle control checkpoint may be altered (Figure 2). Since 
both TP53 and BRCAI regulate p21, this p2iCipllWa!1 gene would be a likely 
candidate. Although intragenic mutations in p2iCipllWa!1 are absent in human 
malignancies99, downregulation of p21 expression by other means could result in an 
escape from the checkpoint control mechanism. During the preparation of this 
manuscript Li et al loo published that binding of CtIP to the BRCT repeats of BRCAI 
is abrogated upon DNA damage and that expression of exogenous CtIP diminishes the 
transactivation of the p21 promoter. Since both TP53 and CtIP bind BRCA 1 at the 
same position, this suggests that their binding may be mutually exclusive and that 
only binding of TP53 may transactivate the p21 promoter. Consequently, mutations 
resulting in a relative overexpression of CtIP protein may cause the inability to 
transcriptionally activate p21. Furthermore, alterations in cell cycle proteins as for 
example amplification of the cyclin Dl gene or the cyclin-dependent kinase 4 (CDK4) 
gene, known to be involved in a subset of breast cancers lOI ,I02 could also be involved 
in BRCAi-mediated carcinogenesis. 
In conclusion, this review has indicated that TP53 alterations indisputably occur 
more often in BRCA i-associated tumors than in sporadic breast or ovarian tumors. 
This implies that loss of TP53 function is a critical event in the molecular 
pathogenesis of BRCAi-associated tumors. However, since TP53 alterations have not 
been found in all BRCA i-associated tumors, we speculate that other genes, most likely 
involving the TP53 checkpoint mechanism, might be involved, 
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Introduction 
Hereditaty ovarian cancer, which comprises approximately 10% of epithelial ovarian 
cancers, has been described in association with three autosomal dominant syndromes: 
hereditmy breast and ovarian cancer (HBOC), hereditmy site-specific ovarian cancer 
(HOC), and the hereditmy nonpolyposis colon cancer syndrome (HNPCC). In 80% of 
families with inherited breast and ovarian cancer and in nearly half of familial breast 
cancers linkage to the BRCAl gene exists. The majority of repotted BRCAl gene 
mutations are frameshift or nonsense mutations that result in premature tlUncation of the 
encoded protein. 
Recent data have shown that BRCAI and TP53 physically associate and that BRCAI 
enhances TP53-dependent gene expression by acting as a co-activator, whereas mutant 
fon1ls of BRCA I lacking the second BRCA I C-temunal (BRCT) domain show reduced 
TP53-mediated transcriptional activation. 1,2 The cooperative action of BRCA I and TP53 
is fllliher strengthened by the observation that early emblyonic lethality of brcal deficient 
nuce could be partially rescued by Ip53 01' p21 nullmutations.3 Mutations in the TP53 
gene are the most common somatic changes found in sporadic breast and ovarian cancers 
but no data are available on TP53 in hereditary ovarian cancers. We investigated the 
prevalence of TP53 gene alterations in BRCA1-associated heredita.y ovarian cancers. 
Patients and Methods 
TP53 gene mutations were studied using polymerase chain reaction-single strand 
conformation polymorphism analysis and subsequent sequence analysis 4 on genomic 
DNA isolated fi'om seven fi'ozen ovarian tumor specimens from individuals of six 
consecutive families with distinct BRCA 1 gel1ll-line mutations, which previously had 
been identified by the Depmiment of Clinical Genetics (Erasmus University Rotterdam). 
Two tumors were recognized as a primalY peritoneal carcinoma with papillary serous 
histology.5 One woman (fanuly I) was diagnosed with this condition 17 months after 
prophylactic oophorectomy. 
Results and Discussion 
In all seven hereditary tumor specimens analyzed acquired TP53 mutations (Table I) 
were identified (P<.OI, tested against 27 TP53 gene mutations observed by us in 62 
unselected ovarian tumor specimens). These mutations localized to the DNA binding 
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Table 1: TP53 mutations in BRCAl-associated ovarian rumors 
BRCAI mutations C1inico-pathologicai characteristics TP53 mutations 
Family Designation Predicted Age Histology Research FlGO- Codon N "deotide Amino 
effect material stage acid 
1411insT F 61 serous PSCP mc 179 CAT---,>CGT His-}Arg 
2 lVS12-1643de13835 F 37 serous primary tumor mc 242 TGC---7TCC CyS---7Ser 
F 57 serous primary tumor mc 281 GAC---,>GAG Asp---,>Glu 
3 lVS12-1643de13835 F 64 serous PSCP 174 CGC---7CAC Arg---,>His 
4 E908X N 51 serous peritoneal mc 273 CGT---,>CAT Arg---,>His 
metastasis 
5 5396+1G>A S 37 poorly diff. prima.ry tumor mc 275 TGT---,>TAT CYS---7Tyr 
6 lVS22+5G>A S 49 endometrioid primary tumor mc 237 ATG---,>ATA Met---,>ile 
PSCP: papillary serous carcinoma of the peritoneum. F: frameshift; N: nonsense; S: splice-site mutation (as described in BIC, breast cancer information 
core). FIGO: International Federation of Gynaecology and Obstetrics. - : unknown. 
CHAPTER6B 
domain of TP53, which has been shown to be essential for its tnmor suppressive function. 
One of the mutations (codon 273) affects direct DNA binding, whereas four other 
mutations (codons 174; 179; 237; 242) are localized to the Zn-binding domains. Crook et 
al6 recently repolied similar findings for seven BRCAJ-associated fhmilial breast cancers. 
Whereas all but one of the mutations in their stndy localized to exon 5 of TP53, the 
mutations reported here were equally distributed over exons 5, 7, and 8 of the gene. 
What then could be the role of TP53 in BRCA J-associated ovarian cancer? Our data 
and those of Crook et al6 suggest that for BRCAJ-associated breast and ovarian tumori-
genesis acquired somatic mutation of the TP53 gene is essential. TP53 and BRCA I are 
both involved in cellular proliferation and interact directly with RAD51, a DNA repair 
protein. Kinzler and Vogelstein theorized that "caretakers" maintain the integrity of the 
genome whereas "gatekeepers" regulate cellular proliferation and differentiation.? Thus, 
inactivation of a caretaker gene causes genetic instability that results in an increased 
mutation rate, but only when a gatekeeper becomes inactivated, neoplasia can occur. We 
have provided evidence that llJutation of the TP53 gene could be a necessary step in 
BRCAJ-associated ovarian cancer. Based on these observations we would like to propose 
a role for BRCAJ as a caretaker whereas TP53 appears to fit the gatekeeper class more 
explicitly in BRCAJ-associated ovarian cancer. 
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Ovarian cancer may be regarded as a potentially curable disease for which a variety of anticancer dlllgs alone or in combination produce durable remissions. 
Further progress in the treatment of this disease depends on: 
I) refinements of the prognostic groups based on the classical FIOO stage criteria 
either by incorporation of morphological attributes including grade, morphomehy, 
ploidy, molecular markers of proliferation, germ-line genotyping, genetic 
polymorph isms, membrane-linked growth factor levels 01' cell cycle checkpoints 
control genes 
2) identification of subgroups which may respond to certain dlllgs, either related to 
expression of dlllg resistance proteins, presence of repair enzymes or expression of 
proteins related to drug-related apoptosis. 
Many observations indicate that cancer susceptibility is under complex 
multigenetic influences. The pI6'NK4'/RB and the pl4ARF/TP53 pathways have been 
shown to playa central role. Multiple cross talks are known to exist between these 
two pathways. Both pathways can be deregulated by homozygous deletions of the 
INK4alARF locus. 1 With respect to the pl6'NK4aIMTSI gene, cha[lter 2 describes a 
low prevalence of pI 6'NK4a mutations in a set of 32 ovarian tumor specimens. Other 
authors have also reported a low prevalence of pI6'NK4a1MTSI mutations.2. lo The 
method we used to study pldNK4alMTSI mutations, i.e. PCR-SSCP, is not sensitive 
enough to detect homozygous deletions unambiguously. Homozygous deletion has 
been shown to be an infrequent way of p 16'NK4a/MTS I inactivation in ovarian 
cancer.2.4,6.12 In chapter 2 we have suggested that methylation may cause p16'NK4a 
inactivation. However, more recent reports have shown that methylation inactivation 
of p161NK4a does not play an important role in ovarian carcinogenesis.4,6,8,13.15 
Whether the lack of homozygous deletions and hypermethyation of p 16'NK4a is 
inherent to the methodology used remains an intriguing question, Future studies 
dealing with tumor specimens should therefore utilize microdissection techniques for 
the enrichment of tumor cells prior to studying genes. Alternatively, the use of 
xenografts, for example, may be useful to demystify the role ofpl6'NK4a inactivation. 
Despite the absence of mutations and homozygous deletions of the pI 6JNK4alMTS I 
gene in ovarian tumor specimens, these alterations have been observed more often in 
"ell lines,16 Since loss of heterozygosity (LOH) at 9p21 occurs in 50-65% of human 
epithelial ovarian tumors3,IO and alterations of pl6'NK4a seem to be a rare event in 
ovarian carcinogenesis, this raises the possibility that another gene, located in the 
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same region, is implicated. The p15INK4bIMTS2 gene is another member of the INK4 
family. This family consists of p 16INK4" p ISINK4b, pISINK4, and p 19INK4d, which are all 
inhibitors of CDK4 and CDK6. In contrast to pI6INK4" which is activated by 
oncogenic stresses, the expression of piSINK4b is upregulated by the negative growth 
factor TGFp.'7 The p 15INK4b gene is also located on 9p21, immediately upstream of 
p161NK4a. In this view,pl5lNK4b might be a plausible candidate. Only few studies have 
addressed the role of piSINK4b in ovarian cancer. Homozygous deletions of piSINK4b 
have been reported to occur in 1-33% of ovarian tumor specimens whereas mutations 
are rare.4,5,9 Perhaps, an even more interesting candidate is the p14ARF gene. Recently, 
the genetic locus encoding pl6 INK4'/MTS has regained interest because it also encodes 
the unrelated pl4ARF protein (or murine homologue pI9ARF), which arises from an 
alternative reading frame of the pl6INK4a gene l8 (see Introduction). The p14ARF protein 
has turned out to be a negative regulator of the TPS3-destabilizing oncogene MDM2. 
Therefore, in view of its capacity to induce cell cycle arrest in cell lines, pl4ARF is 
likely to be a good candidate as a target for inactivation. It has been shown that, when 
overexpressed, the amino-terminal moiety of ARF (amino acids 1-64), encoded 
entirely by exon I p, is sufficient for the induction of cell cycle arrest. 19,20 So far, 
however, no tumor-specific point mutations in exon I p have been detected in a variety 
of human tumors21 •22 and those found in the exon 2 pmi conunon to both proteins do 
not appear to be deleterious for p 14ARF activity while inactivating p 16 INK4'.19 
Neveliheless, in small cell lung cancer ARF expression was found to be lost in 6S% 
oftumors.23 It is also interesting to mention that haploinsuffieiency by itself may have 
strong effects on tumorigenesis?4 Different cell types may have different sensitivities 
to changes in the genetic dose of INK4aIARF. 
In conclusion, although at the time of its discoveIY the pl61NK4alMTSI gene raised 
high expectations as the candidate tumor suppressor gene that could explain the high 
rate of LOH at 9p21 observed in multiple cancers including ovarian cancer, it now 
becomes clear that the pl6INK4a gene may not be the target. Since the pl4ARF protein 
provides a link between the p 16INK4'/RB and the TPS3/RB pathway, inactivation of 
the INK4alARF locus could provide a mechanism to interfere with both pathways. 
With respect to inactivation of the TPS3 pathway, the high rate of LOH on 
chromosome 17p 13 observed in ovarian cancer can be attributed to the inactivation of 
the TP53 gene25.27 
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In recent years numerous reports have appeared on the relation between TP53 
status and (progression-free or overall) survival, and conflicting conclusions have 
been reached on the prognostic value of TP53 in ovarian cancer. The lack of 
unanimity between authors may be explained by: (a) differences in techniques used 
for the analyses of TP53 status; (b) tumor heterogeneity; (c) patient sample size; (d) 
subset analyses; (e) retrospective nature of the studies; (f) different treatments of 
patient population; (g) different prognostic covariates used in the multivariate 
analyses; (iI) the subjectivity inherent to some approaches and (i) publication bias. 
Some of these items have been addressed in this thesis and will be discussed below. 
With respect to differences in techniques used for the analyses of TP53 status, 
many studies have used immunohistochemistry to determine TP53 status. This 
approach, however, can give false negative results in the case of stop codons, 
frameshift and destabilizing mutations. In contrast to TP53 accumulation that is 
indicative for the presence of missense mutations, nonsense and frame shift mutations, 
both causing premature termination codons and leading to truncated proteins, do not 
cause TP53 accumulation. Heterogeneity also results from the use of different 
antibodies, different techniques to prepare sections and different criteria for scoring 
positives. Chapter 3 describes a relatively high prevalence (in 8% of the tumors) of a 
distinct nonsense mutation at codon 213 (Arg--}STOP) of the TP53 gene. In addition 
to common missense mutations (in 28% of the tumors), non-missense mutations, 
consisting of frameshift, nonsense and splice site mutations, were detected in 14% of 
the tumor specimens. The pattern of TP53 alterations within exons 5-8, i.e. the high 
prevalence of non-missense mutations and especially the high prevalence of the codon 
213 nonsense mutation, differs from that described in other studies of ovarian cancer 
patients from the western world. Future studies have to confirm the high prevalence of 
the codon 213 nonsense mutation and, in addition, epidemiological studies including 
patient characteristics, ethnicity, place of residence, clinical course and mutagen 
exposure will be necessary to understand the high prevalence of this mutation. In 
conclusion, chapter 3 as well as other studies28•29 have described a high prevalence of 
non-missense mutations in ovarian cancer. Since many studies have used 
immunohistochemistry to determine TP53 status, the actual TP53 mutation frequency 
in ovarian cancer is likely to be underestimated. 
Direct assessment of TP53 mutation avoids the uncertainties inherent in inferring 
TP53 status from TP53 protein levels. Techniques that detect small changes in DNA 
structure caused by mutations are often used as a first step. Although single strand 
159 
CONCLUSIONS AND PERSPECTIVES 
conformation polymorphism analysis (SSCP) is frequently used, other techniques 
such as dideoxyfingerprinting (ddF), denaturing gradient gel electrophoresis (DGGE) 
and constant denaturing gel electrophoresis (CDGE) have also been applied to 
determine TP53 status. Ultimately, sequencing is always necessaty to avoid false 
positives caused by known polymorph isms and silent mutations. Since the majority of 
TP53 mutations have been reported to be localized to the sequence-specific DNA-
binding domain and analysis of the complete coding region is time-consuming, most 
researchers have restricted their analysis to exons 5-8 of TP53. Only few studies have 
reported mutations outside exons 5-8 in ovarian cancer28,29 and the assumption that 
TP53 is frequently targeted by missense mutations in the DNA-binding domain may 
well be explained by the trivial fact that most published studies screened exons 5-8, 
Future studies should therefore analyze the complete coding region of TP53. An 
important advancement in cancer research is the enlly of the DNA chip technology, 
which makes it easier to screen the complete TP53 gene. In 1997 Affymetrix launched 
its GeneChip® p53 assay for research applications, The GeneChip p53 assay is the 
first conmlercially available DNA probe array-based product capable of analyzing the 
full-length coding sequence of the human TP53 tumor suppressor gene. This 
technology, however, requires diverse specialist equipment and, therefore, the assay is 
too expensive for general'laboratOlY use. The technique is limited because only point 
mutations and single base pair deletions can be detected but in case of ovarian cancer 
this limitation may not be problematic. 
With respect to heterogeneity, ovarian cancer represents a broad range of disease. 
Approximately 5-10% of ovarian tumors are familial and inherited mutations in the 
BRCA I gene account for up to 80% of families with both breast and ovarian cancer.30 
Chapter 6A reviews recent literature on BRCAI-fieldwork and stresses the almost all-
important role ofTP53 in BRCAI-associated tumorigenesis. The pivotal role ofTP53 
is illustrated in chapter 6B by our own findings in a small set of BRCA I-associated 
ovarian and peritoneal tumors. The significantly increased frequency of TP53 
aberrations in BRCA I-associated tumors needs to be fill,ther investigated in larger sets 
of defined tumors. In addition, it is imp0l1ant to unravel whether TP53 is involved in 
the development or in the progression of BRCA I-associated tumors, Furthermore, the 
interaction between BRCA I, BRCA2, RAD51 and other proteins needs to be further 
investigated, especially in relation to their role in repair. To uncover why TP53 is 
such an important player in the development of BIICA I-associated tumors may not 
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only give us a better understanding of BRCA I-associated tumorigenesis but may also 
provide new tools to improve treatment strategies for hereditaty ovarian cancer. 
Finally, the question remains whether there are other genes involved in BRCAI-
associated (and naturally also in BRCAI-independent) hereditary ovarian cancer. 
The majority of epithelial ovarian tumors are, however, sporadic. They can be 
benign (adenomas), intermediate malignant (borderline tumors) or simply malignant 
(carcinomas). Ovarian tumors are characterized by differences in the prevalence of 
TP53 mutations. Whereas TP53 inactivation may be a prerequisite for the 
development of hereditaIY BRCAI-associated tumors (chapter 6), TP53 alterations 
have been found in approximately half of the sporadic carcinomas (chapters 3 and 4). 
With respect to borderline tumors, chapter 5 discusses the prevalence of TP53 
mutations and relative protein overexpression in these tumors. It was shown that TP53 
alterations are infrequent in ovarian borderline tumors. However, borderline tumors 
have a relative high incidence (27%) of K-RAS mutations. Interestingly, K-RAS 
mutations were observed more often among borderline tumors with a mucinous 
histology (67%) compared to tumors with a serous histology (11%). Since the 
mucinous histology is more conunon among borderline tumors (approximately 35%) 
than among carcinomas (approximately 10%), this may explain the reported higher 
overall prevalence of K-RAS mutations among borderline tumors compared to 
carcinomas. Finally, the total number of genetic alterations (both K-RAS and TP53 
alterations) seems to be increased in borderline components that are adjacent to 
infiltrative components. 
There is clear experimental evidence that TP53 aberrations playa critical role in 
the development and progression of ovarian carcinomas but the prognostic and 
predictive significance of TP53 aberrations is still unclear. Moreover, it is not known 
how and to what extent TP53 mutation affects the function of the protein. More 
insight could come from the study of downstream genes of TP53. To date, genes 
considered to be target genes ofTP53 include the cell cycle inhibitorp2J1WAFJlCIPI 
and the apoptosis-associated genes BAX and BCL-2. Our findings on the clinical 
relevance of TP53 mutations and the expression of TP53 and its downstream genes 
are described in chapte,' 4. In conclusion, we showed that high expression of the 
apoptotic protein BAX predicts a favorable progression-free and overall survival in 
patients with epithelial ovarian carcinoma. Furthermore, we showed that the combined 
evaluation of BAX and BCL-2 expression results in a more pronounced significance 
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of these apoptosis-related proteins: high BCL-2 expression superimposing on the 
favorable effect of high BAX expression. The prognostic role of BAX expression has 
not been thoroughly studied yet, except for one study by Tai et al. 31 They found high 
BAX levels to be associated with improved disease-free survival but not with overall 
survival in a similar group of tumors from patients with a shorter follow-up compared 
to our study. In the second place, chapter 4 describes that high TP53 expression in 
tumors is associated with an unfavorable overall survival. The favorable effect of no 
TP53 accumulation is strengthened by the absence of TP53 mutation. TP53 mutation 
by itself was not found to be associated with a poor outcome of disease and in 
multivariate analyses TP53 expression was not independently associated with 
survival. Since TP53 has such an important function in diverse cellular functions (see 
Introduction), the lack of an independent correlation between TP53 status and disease 
outcome may seem surprising but is consistent with the overall conclusions from 
many other studies.32-50 As described above, underestimation of the frequency of 
TP53 mutations, small numbers of patients, subset analyses and different prognostic 
covariates used in the multivariate analyses make it difficult to compare results. 
Although there appear to be numerous databases on TP53 mutations, to our 
knowledge, no large multi-centered study or meta-analysis has been published with 
respect to the prognostic role of TP53 in ovarian cancer so far and the time is ready 
for such an analysis to be carried out. 
It is beyond the scope of this thesis to discuss dmg resistance in any detail (for 
review see Nooter and Stoter).51 This is an impOliant area of research and the ability 
to accurately predict chemosensitivity/chemoresistance would be of major prognostic 
interest and an impOliant advance. Recently, using a yeast system, genes (PDE2, 
ZDS2) have been identified which confer cellular resistance to cisplatin when 
overexpressed. 52 With respect to ovarian cancer and therapy resistance, most of the 
studies that have been published have been small and inconclusive. However, there 
are data to suggest that GSTpi expression5J, TP53 expression54, BCL-2 expression54, 
LRP55, MRP56, MDR]57, excision repair58, HER2/neu (cERBB2)59 and laminin 
expression58 correlate with response to chemotherapy in ovarian cancer, but they all 
deserve more detailed study before they are considered of clinical value. We could not 
demonstrate an association between response to platin-based chemotherapy and TP53 
alterations or BAX expression (chapter 4). With respect to the latter, an association 
was suggested between reduced BAX expression as a consequence of TP53 mutation 
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and cisplatin resistance in cisplatin resistant variants of the ovarian cancer cell line 
IOROV-1.6o However, i1l vivo a tumor cell is part of the complete architecture of the 
tumor. In cell lines, however, no tumor-stromal interaction exists and it is especially 
this interaction, which may be underestimated in many studies. Interestingly, BAX 
expression has been associated with a complete response to pac lit axel containing first-
line chemotherapy.31 Since nearly all patients received plat in-containing 
chemotherapy, we could not investigate the relationship between BAX expression and 
response to taxol-containing chemotherapy. Thus, not only the prognostic but also the 
predictive role of BAX expression in tumors needs fUliher investigation. 
With respect to the techniques used, a fundamentally different technique to study 
the biological effect of TP53 mutation is the yeast assay. Since this assay tests the 
critical biological function targeted by TP53 mutation in tumors, namely the ability of 
TP53 to activate transcription, this technique may even provide a better tool to study 
TP53 dysfunction, when possible in combination with sequence analysis. However, 
by using such a technique the emphasis is placed on one gene rather than on a series 
of genes or gene products. This study is not the first and will not be the last to suggest 
that more reliable prognostic infolmation can be obtained from an analysis of multiple 
genes associated with one biological pathway. Furthermore, it is likely that TP53 may 
be dysfunctional in many of the specimens despite the absence of mutations. If TP53 
is directly targeted in >50% of human malignancies, then TP53 negative tumors have 
likely sustained epistatic mutations such as MDM2 amplification or ARF loss. It may 
thus well be naive to think that a single gene mutation, even one as critical as TP53, 
can predict prognosis. After all, carcinogenesis is a complex process, with multiple 
genetic lesions and gene product interactions. 
GENERAL 
There is obvious merit in being able to accurately predict clinical outcome and 
tailor treatment according to individual risk and potential benefit for patients with 
epithelial ovarian cancer.61 There has been and there continues to be a lot of effOli in 
identifying new prognostic and predictive factors. A number of rapidly emerging 
technologies including comparative genomic hybridization (COH), multiplexed loss 
of heterozygosity analysis, differential display and suppressed subtractive 
hybridization are beginning to allow analysis of global genetic changes in an 
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individual tumor. Moreover, the past few years it has been shown that an enormous 
amount of information can be obtained through large-scale gene expression analyses. 
Gene expression profiling with techniques such as eDNA microarrays, serial analysis 
of gene expression (SAGE) and proteomics (MALDI) are novel techniques with 
heavy reliance on bioinformatics, which give relative expression levels of known and 
unknown genes. These new techniques provide the opportunity for new tumor 
classification and possible response to treatment.62-67 It is anticipated that this will be 
an area that will rapidly evolve and possibly alter our current approach of classifying 
ovarian tumors and predicting response to therapy and patient outcome. 
The search for new prognostic factors and testing is thus rapidly evolving with an 
increased understanding of the molecular basis for ovarian carcinogenesis and 
progression coupled with technological advances such as DNA arrays and 
bioinformatics. We are at the threshold of developing a new and more objective as 
well as rational approach to predict prognosis and response to therapy. However, 
before new prognostic factors find their clinical application, they should be subjected 
to rigorous testing and evaluation. Multinational prospective studies will obtain more 
generalizable results than small studies. Meta-analysis may also play an important role 
to interpret the enormous amount of information. Since we all seek the same goal of 
further exploring the biology of ovarian cancer and improving therapies for and 
survival of ovarian cancel' patients, working in concert seems an obvious way to 
proceed. It therefore is extremely important to stimulate communication between 
researcher, pathologist, oncologist and anyone else involved. Finally, it should be 
remembered that although from the researcher's point of view the aim is to achieve 
the maximum quantity of life, an increasing emphasis also has to be placed on the 
quality of life. 
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Ovarian cancer is the most deadly gynecological disease. Lethality is high due to 
the insidious onset of the disease and the development of chemotherapy resistance. As 
other cancers, ovarian cancer arises through the accumulation of genetic alterations. 
Little is known about the underlying genetic mechanisms responsible for the 
development of this biologically aggressive malignancy. The only way to develop 
new, effective therapies for epithelial ovarian cancer patients is to improve our 
understanding of and ability to identify the genetic changes leading to initiation and 
progression of ovarian cancer and to sensitivity and resistance to chemotherapy. This 
thesis describes genetic alterations in ovarian cancer and, if possible, their relationship 
with clinico-pathological parameters, clinical outcome and response to platinum-based 
chemotherapy. 
Chapter 2 describes the prevalence of MTSJ/CDKN21p161NK4a alterations in 
ovarian carcinomas and in ovarian cancer cell lines. Initial studies with cell lines 
showed that this tumor suppressor gene is homozygously deleted or mutated in many 
human cancer cell lines. It therefore was suggested to be an important player in a 
variety of human cancers including ovarian cancer. However, no somatic mutations 
were detected in ovarian tumor tissue specimens. In contrast, the TP53 tumor 
suppressor gene is frequently mutated in ovarian cancer and chapter 3 describes the 
prevalence of TP53 mutations in ovarian tumors. Interestingly, a nonsense mutation at 
codon 213, was seen in 8% of the tumor specimens. In addition, several other 
nonsense and frameshift deletions were encountered, all resulting in tnmcated TP53 
proteins. These so-called null type non-missense mutations (in 13% of the tumor 
specimens) cannot be dete.cted using immunohistochemishY. This in contrast to the 
more common missense mutations, which result in stabilization of the TP53 protein 
and thus a relative overxepression, that is measurable by immunohistochemishy. We 
therefore concluded that it is important not to restrict to one technique when studying 
TP53. After all, neither immunohistochemical nor genetic analyses are infallible at 
mutation detection. Most studies, however, have utilized only one approach, mainly 
immunohistochemishy, to study TP53 status. This may explain why the prognostic 
and predictive significance of TP53 aberrations in ovarian cancer is still under debate. 
Chapter 4 describes the prognostic significance of both TP53 mutation and TP53 
protein expression in ovarian cancer, and also of the combination of these data. Since 
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it is not known how and to what extent TP53 mutations affect the function of the 
protein, chapter 4 also describes the expression of certain downstream genes of TP53, 
including the cell cycle inhibitor p211W AFI/CIPI and the apoptosis-related proteins 
BAX and BCL-2. Data were evaluated in relation to clinical outcome. Interestingly, 
Bax expression was found to be a favorable indicator for both progression-free and 
overall survival. Although Bcl-2 was not significantly associated with prognosis, those 
patients whose tumors simultaneously expressed high levels ofBAX and BCL-2 had a 
longer progression-free and overall survival compared to patients whose tumors did 
not express BCL-2. With respect to TP53, only TP53 expression was associated with a 
poor overall survival. Combining mutation and expression data resulted in an 
increased association with overall survival. No relations were observed between tested 
factors and response to platinum-based chemotherapy. 
Although chapters 3 and 4 showed that the TP53 gene is frequently altered or 
overexpressed in malignant ovarian tumors, chapter 5 demonstrates that TP53 
alterations play no major role in the tumorigenesis of ovarian borderline tumors. In 
contrast, mutation of the proto-oncogene K-RAS is frequently (27%) observed in 
borderline tumors. Further analysis showed that mutations are strongly associated with 
the mucinous cell type, implying that K-RAS mutational activation is linked to 
mucinous differentiation. Interestingly, there are more mucinous borderline tumors 
than mucinous carcinomas and this may explain the reported higher frequencies of 
K-RAS mutations in borderline tumors compared to carcinomas. 
Chapter 6a covers a review on the breast cancer susceptibility gene I (BRCAJ). 
Inherited mutations in the BRCAJ gene are responsible for up to 80% of families with 
both breast and ovarian cancer. We hypothesized that TP53 dysfunction may be 
required for BRCA J -associated ovarian tumorigenesis. This hypothesis is strengthened 
by the observation that a small number of BRCA J -associated ovarian tumors studied 
all demonstrated TP53 alterations (chapter 6b). 
Finally, chapter 7 critically evaluates the results of the studies described in this 
thesis and discusses recently developed technologies. Moreover some ideas are 
suggested that may help to improve ovarian cancer research. 
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Ovariumkanker is een ziekte die zieh bij I op de 70 vrouwen manifesteert. Deze 
ziekte wordt pas vaak in een laat stadium ontdekt. Naast het operatief vetwijderen van de 
tumor worden de meeste patienten behandeld met een zogenaamde platinum-bevattende 
ehemotherapie. Vaak eehter wordt er resistentie tegen ehemotherapie ontwikkeld. 
Ovariumkanker kent dan ook vaak een dodelijke afloop. Bekend is dat katlker in het 
algemeen ontstaat door een opeenstapeling van hoofdzakelijk genetisehe defeeten. Er is 
eehter nog weinig bekend over de genetisehe defeeten die ten grondslag liggen laan 
. , 
ovadtunkanker. Voor de ontwikkeling van nieuwe effeetieve therapieen is tfteer 
genetisehe ketmis nodig omtrent het ontstaan en de progt'essie van ovariunlkanker en de 
ontwikkeling van ehemotllerapie resistentie. Het in dit proefsehrift besehreven onderzoek 
was erop gerieht om I) meer inzieht te krijgen in genetisehe veranderingen betrokken bij 
ovadumkanker en om 2) prognostisehe en predictieve markers te vinden die het beloop 
van de ziekte en de respons op ehemotherapie ktumen voorspellen. De aehtergt'ond van 
oval'iunlkanker en de daarbij betrokken genen zijn besehreven in de het inleidende 
hoofdstuk 1 van dit proefsehrift. 
Hoofdstuk 2 besehrijft het voorkomen van M7S1ICDKN2Ip16INK4a mutaties in 
oval'iumtllmoren en in ovariumtumor cellijnen. Eerdere studies hadden aangetoond dat dit 
tumor suppressor gen vaak gemllteerd of gedeleteerd is in cellijnen afkomstig van veel 
verschillende tumoren, inclusief ovarium tumor cellijnen. Aangezien er in 
ovariumtumoren vaak verlies van heterozygotie op 9p21, het MTSJlp161NK4a locus, was 
waargenomen, werd gespeculeerd dat het MTS1/p16INK4a gen een belangt'ijke rol zou 
ktmnen spelen bij de ontwikkeling of progt'essie van ovariumkanker. Het in hoofdstuk 2 
besclu'even onderzoek toont echter aan dat mutaties in dit gen niet voorkomen bij 
ovariumtumoren. 
In tegenstelling tot het MTS1/p16INK4a gen is het TP53 tumor suppressor gen weI vaak 
gemuteerd in ovariumtumoren, hetgeen besclu'even is in hoofdstuk 3. Alhoewel de 
aanwezigheid van mutaties doorgaans wordt onderzocht door rechtstreeks het DNA te 
bestuderen, wordt bij TP53 vaak het eiwit onderzocht met bijvoorbeeld 
imnmnohistochemie. Immers, de meeste TP53 mutaties leiden tot stabilisatie van het 
eiwit. Somnlige TP53 mutaties eehter leiden niet tot een gestabiliseerd eiwit maar juist tot 
het verdwijnen van het eiwit. Dergelijke mutaties zullen dus onopgemerkt blijven 
wanneer TP53 aileen met immunohistochenlie bestudeerd wordt. Hoofdstuk 3 beschrijft 
een relatief hoog percentage (13%) van deze zogenaamde non-nlissense mutaties in een 
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set ovariumtumoren afkomslig van patienten uit het zuidwestelijke deel van Nederland. 
Opvallend hierbij was dat een bepaalde mutatie in codon 213 voorkwam in 8% van de 
onderzc.chte tumoren. Vanwege het feit dat ongeveer een kwart van de mutaties niet leidt 
tot stabilisatie van het eiwit dient het aanbeveling om zich niet aileen te beperken tot 
il11mu",ohistochemie bij het bestuderen van TP53 in ovariumtumoren. 
Het feit dat de meeste studies zich wei beperkt hebben tot immunohistoehemie zou 
kUlmen verklaren waarom de prognostische en predictieve waarde van TP53 
veranderingen bij ovariumkanker nog steeds tel' discussie staat. In hoofdstuk 4 is getmcht 
het. klinisch belang van zowel TP53 mutaties als ook van TP53 eiwitexpressie te 
onderzoeken. Het TP53 eiwit fhnctioneert als een transcriptiefaetor betrokken bij onder 
andere de controle van de celcyclus en bij geprogrammeerde celdood (of apoptose). 
Omdat niet bekend is of en hoe verschillende TP53 mutaties effect hebben op de functie 
van het eiwit, is in hoofdstuk 4 tevens de expressie van zogenoemde "downstream" genen 
van TP53 onderzocht, namelijk van de celeyclus remmer p21/wAFI/CIPI en de 
apoptose gerelateerde eiwitten BAX en BCL-2. Verhoogde BAX expressie bleek een 
indicator te zijn voor een gunstige progressie-vrije en totale overleving, terwijl verhoogde 
BCL-2 expressie niet bijdroeg tot een significant veranderde overleving. Onverwacht 
echter toonde de combinatie van BAX en BCL-2 expressie aan dat patienten met zowel 
hoge BAX als hoge BCL-2 expressiepatronen in hun tumoren een betere overleving 
hadden dan patienten met hoge BAX en lage BCL-2 expressie. Met betrekking tot TP53 
werd gevonden dat verhoogde expressie geassocieerd is met een slechtere totale 
overleving. Het combineren van de TP53 mutatie- en expressiegegevens toonde aan dat 
patienten met tumoren zonder mutatie en negatief voor TP53 expressie de meest gunstige 
overleving tonen. VerdeI' zijn geen associaties waargenomen tussen de geteste factoren en 
respons op platinum bevattende chemotherapie. 
Alhoewel TP53 veranderingen vaak voorkomen bij maligne ovariumtumoren, laat 
hoofdstuk 5 zien dat deze veranderingen niet fi'equent voorkomen bij de zogenaamde 
borderline tumoren. Deze tumoren vormen een intermediair tussen de maligne 
carcinomen en benigne adenomen. Het is vooralsnog onduidelijk of borderline tumoren 
kUlmen ontaarden in maligne carcinomen of dat deze tumoren een aparte groep yO/men. 
Alhoewel TP53 mutaties niet vaak voorkomen in borderline tumoren, beschrijft 
hoofdstuk 5 dat mutatie van het proto-oncogen K-RAS relatief vaak voorkomt, namelijk 
in ongeveer 30% van de tumoren. Nader onderzoek toonde dat de K-RAS mutaties met 
name voorkomen in borderline tumoren met een mucineuze histologie. Tumoren met een 
mucineuze histologie komen vaker voor bij borderline tumoren dan bij carcinomen, 
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hetgeen zou kunnen verklaren waarom K-RAS mutalies vaker in borderline tumorCH 
gerapporteerd zijn dan in de meer kwaadaardige carcinomen. 
In tegenstelling tot sporadische tumoren ":'?\'~\ \J,U nf(llU,kl'l \lunoren een genetisch 
qere,! qvergeerfd. J-lierdoor is pe ~~n~ p,p, hl'! o.nl\Vikl<el~n van een tumor gedurende het 
I~ven *r~ vergrpqt. Itet BR{::;J J !len i& cen !\~n dat vank bctrokken is bij erfelijke 
VonJJCI1 ¥an IlPf&l, ell qY~ri\lmk~nl\"r. MutatioB In dlt gen zijn verantwoordelijk voor 
ongeveer 50% van de vrouwen met erfelijke borstkanker en voor 80% van de vroUWei1 
met zowel borst- als ovariumkanker. Hoofdstul< 6 geeft een ove17ich\ Y~n de interactie 
Vall !3RCA,1 met TP53. Naar aanleidinlo\ Y~n l'\'l1litem\\I\trqw~ioht van TP53 mutaties in 
BRDA I-geassociecrcl\l tnn19rcn Wor"\ ge hypotlwse ge~teld dot TP53 dysfunctie een 
vereiste zou kurmen ziJn voor het ontwikkelen van een BRCA !-geassocieerde 
ovariumrumor. In het tweede deel van hoofdstuk 6 wordt deze theorie luacht bijgezet met 
behulp van de eigen resultaten, namelijk dat in een kleine set van exfelUke 
ovariumtumoren met een bevestigde BRCA! mutatie TP~3, \11l1tft\i(l§ ftan!jetro(fcn zijn in . 
aile zeven rumoren. 
Hoofds!ul< 7 eValtleer! de resuita\en Peschr@y@n in dit proefschrift, bediscllssieert 
enkele recent QI]!wil¢elge tedmologleen en oppert enkele ideeen, die zouden kllnnen 
bijdragen om het ovarillmkanker onderzoek te verbeteren. 
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De schrijver van dit proefschrift werd op 8 oktober 1966 in Rotterdam geboren. In 
1986 behaalde zij het diploma gymnasium Il aan de Hugo de Groot 
scholengemeenschap te Rotterdam. In hetzelfde jaar begon zij aan een aJ.18listen 
opleiding aan het van Leeuwenhoek lnstituut in Delft (later Hogeschool Rottr)rdam & 
Omstreken, Polytechnische faculteit). Het daaropvolgende jaar koos zij voor de 
richting Biotechnologie. Van september 1989 tot mei 1990 liep zij sta,ge bij het 
Unilever Research Laboratorium in Vlaardingen op de afdeling Gene Te,c'fillology and 
Fermentation en in datzelfde jaar sloot zij haar opleiding met grJed gevolg af, 
Aansluitend bleef ze nog een jaar werkzaam als analiste bij Unilewer waarna zij in 
1991 begon met een verkorte opleiding Biologie (differentiatie P!iochemie) aan de 
Rijksuniversiteit Leiden, Tijdens deze studie werd door haar onderz(Jek ven'icht bij d" 
afdeling Moleculaire Plantkunde van de Rijksuniversiteit Leiden en bij de Afdeling 
"Reproductive Physiology and Endocrinology" aan Kent State; University (Kent, 
USA), In 1994 behaalde zij het doctoraalexamen, Van novembe,r 1994 tot december 
1998 was zij werkzaam als assistent in opleiding op de afdeling, Tumorendocrinologie 
van de Daniel den Hoed Kliniek in Rotterdam (vanaf 1998 ge',estigd in het Josephine 
NeIkens Instituut) op een door de Nederlandse Kankerbestrijd.ing gefinancierd project. 
Het onderzoek werd uitgevoerd onder begeleiding van d,r. Els Berns, De in dit 
proefschrift beschreven resultaten zijn tijdens deze perio.de gegenereerd, Vanaf I 
augustus 2000 is zij werkzaam als clinical research assodate bij Cardialysis B.V, te 
Rotterdam, 
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Na een boek vol wetenschappelijke bevindillgetl \fool' sommigen en abracadabra 
voor anderen, is dit stllkje het laatste dfit overblijft van mijn promotieperiode en het 
eerste dat iedereen leest bij het ultreiken van het boekje. Hoewel slechts mijn naam op 
de oms lag staat, kon dit proefschrif! aileen maar gerealiseerd worden door de inzet, 
belangstelling en hlllp van vele anderen. Langs deze weg wil ik dan ook iedereen 
bedanken die direct of indirect een bijdrage hebben gel~verd aan dit proef'schriit. Eell 
Mntal personen wil ik hier op chrollologische volgorde van betrokkenheid bl] ,lii 
boekje no em en. 
Alhoewel het dunkwoord meestal wordt afgegl\l\en met het bedanken van de 
partner, wil ik het omdraaien en hiennee beginnen. Ron, jij was (en bent nog steeds) 
mijn rots in de branding. Jouw mstige en relativerende instelling heef! mij er lettetHJk 
doorheen gesleept en ik hoop dat wij de komende jaren wat meer Ittgt "lIne\! vimle\l: tk 
wil je bedanken Voor alles, en dat is heel vee!. 
Iris vOnllde de overgang tnssen werk ell IlI'l~. iris, ik ken je al vanaf het HLO. 
Via jou ben ik bij de Daniel den Hoed kllniek terechtgekomen als AIO. Naast vriendin 
werd jij toen ook collega en uiteindelijk paranimf. lk wil je bedanken voor je labhulp 
maar ook voor al je sleun en opbeurende woorden. Wij zetten ol\ze vrlettdsdmll vodl1 
en hopelijk belevcn we nog vele aerobic uren. 
De eerste kennismaking op de Daniel den Hoad KII\II"k was met Els Berns, mijn 
copromotor. Els, jouw openheid en vriel\delijkheid maakte direct ind11lk op mij. Je 
bleek ook nog eens een kei van een co-promotor te zijn. Zonder jou was dit boekje er 
echt niet geweest. Bedankt voor al je steun en begeleiding en veel geluk Ydbl' In de 
toekomst. 
Samen met Silvia begon ik als AIO. Sil, onze vriendsehllpis III de Ilfgelb\leh Jareh 
echt gegroeid. Vooral tijdens het schrijven van dit boekje was jij, .iltheU hlet Marijke, 
mijn uitlaatklep en heb ik vee I steun bij jullie kUlmen vimlelt III het lot verbonden, af 
en toe in wk en as, maar het is ons tach maar mool gelukt. Ik wens jou en Marijke 
veel geluk I:oe. 
Ad, Maxime en Marion waren mijn eerste kamergenoten en al was ik een vreemde 
eend in de bijt, we konden hel al snel (te) goed met elkanr vinden. Ad, ik zal je humor 
miss',,1. Maxime, jou wil ik niet aileen bedanken voor de statistische bewcrking Vall de 
resultaten, maar ook voor je vriendschap. Uiteindelijk bleken we veel 
gemeenschappelijke interesses te hebben en onze poezengekte op het laatst heef! bij 
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ons momenteel voor gezinsuitbreiding gezorgd. Ik wens je een goede tUd toe in 
Amerika, Frankrijk, Amsterdam, ofwaar dan ook! 
Uiteraard wil ik ook mijn beide promotoren, professor Stoter en profesBor Klijn, 
bedanken voor hun interesse en bijdrage aan dit proefschrift. Daarbij zek,,, niet te 
vergeten de leden van de kleine promotiecommissie voor het kritisch lezel1 van het 
manuscript. Tevens wil ik Maria van del' Burg bed an ken voor haar aanzienlijke 
bijdrage aan de totstandkoming van dit boekje. Sonja Henzen-Logmans ben ik dank 
verschuldigd voor het begeleiden en het scoren van de immunohistochemische 
analyses en Vaal' de werkbesprekingen. Elly Fieret, jou wil ik bedanben voor de 
uitvoering van de imm\lIlohistochemie en voor aile andere taken die jij op je nam. Ik 
vind het leuk dat je mijn paranimf wil zijn. 
De bijdragen van de doctoraalstudent Jessica Verwaard en HLO-stagiai re Caroline 
Derksen wil ik niet ongenoemd laten. Caroline, ik vind het leuk dat wij nag steeds 
contact hebben en wens je vee I succes met je verdere carriere. 
Dan zijn er nag een aantal mensen van het au de "Biochemie" lab die ik ,graag wil 
noemen. John Foekens, bedankt dat ik op de afdeling in aile vrijheid het onderzoek 
heb mogen uitvoeren en oak bedankt Vaal' het kritisch lezen van manuscripten. Henk 
Portengen wil ik bedanken voor het bijhouden van de tumorbank en voor de aanvang 
van de statistische analyses. Hany bedankt voor al het "computergedoe" en Berthe, jij 
bedankt voor aile welwillende, 80ms overbodige, maar altijd gocd bedoelde hulp. 
Buddy was een aangename kamergenoot, waar ik vaak mee of 'am heb gelachen. 
Mieke Schutte wil ik bedanken voor de nodige inspirerende woorden. Dank is er oak 
voor de labbewoners: Anieta Sieuwerts, Cassandra, Erica, Joan, Clara, Anita Trapman 
en Mieke Timmermans, die altijd een goede labsfeer wisten te creeren. Uiteraard 
hebben oak aile andere medewerkers, ex-medewerkers, studenten en nieuwkomers 
van de afdelingen Moleculaire Biologie, LEPO en het secretari:aat hier enorm aan 
bijgedragen. Lambert, Jos (ik zal je oeverloze afwas- en andere Iliitheorieen missenl, 
Marcel S.(Fl, Lilian, Ton, Thecla, Ruud, Ad Gillis, Jessica de Bmin en al diegenen die 
ik niet genoemd heb, bedankt Vaal' de gezellige tijd. Apart noem ik nag even de 
meiden-Iabcollega's Erica, Lisbet, Anita Dekker, Lilian, Marjolein, Mirjam en 
Hannie, met wie ik veel 101 heb gehad. De meesten van ons zijn een andere weg 
ingeslagen maar ik hoop dat we nog eens een skate- of snowboarduitje zullen maken. 
En teuslotte, eindigend waar het allemaal begon, wil ik mijn vader en moeder 
bedanken, die mij door aile voor- en tegenspoed heen gesteund hebben en geen klap 
begrijpen van dit hele circus. Pa, ik vind het fijn dat je iedere week langskomt en ik 
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weet dat je ongelooflijk trots op me zult zijn als je dit boekje in handen krijgt. Lieve 
rna, het spijt me dat ik zo weinig tijd VOO! je heb maar ik weet dat je in goede handen 
bent. Bedankt voor jullie steun. 
:Monique 
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